![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
Kol Lebenslauf für Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Einflussstatistik
Concept | World rank |
---|---|
potential endophenotypes adhd | #1 |
9r allele | #1 |
anachronisms | #1 |
neuroleptic nonresponse | #1 |
qms adhd | #1 |
adhd community sample | #1 |
inattention adhd | #1 |
neuropsychological testing individuals | #1 |
adhd risk factors | #1 |
git1 adhd | #1 |
stress exposure connectivity | #1 |
scqscore | #1 |
sex bpi disorder | #1 |
deficit | #1 |
teacher report | #1 |
genomesignificance | #1 |
studies method | #1 |
linkage wave | #1 |
children bpi disorder | #1 |
etiology adhd | #1 |
rs1051312 | #1 |
african‐american pedigrees | #1 |
treatment mts | #1 |
vivo neuroreceptor imaging | #1 |
nonmental diseases | #1 |
disorder familial | #1 |
risk suds | #1 |
rs2272080 | #1 |
bpd anx bpd | #1 |
adhd proband | #1 |
distinct subtype | #1 |
pair health | #1 |
adhd children exposure | #1 |
hyperactivity female | #1 |
cortical networks attention | #1 |
comt odd | #1 |
2327t | #1 |
maf⩾1 | #1 |
rs3916970 | #1 |
risk opioid dependence | #1 |
diagnoses probands | #1 |
adhd aes | #1 |
genetic variation nr3c1 | #1 |
thermenos | #1 |
proband child | #1 |
exposure parental adhd | #1 |
siblings males | #1 |
male adolescents adhdct | #1 |
diagnoses valid | #1 |
laboratory driving simulation | #1 |
prodromal overt psychosis | #1 |
patterns psychiatric comorbidity | #1 |
criteria pdd | #1 |
nonaffected siblings children | #1 |
switches bipolar disorder | #1 |
cdbpd | #1 |
adhd module mwq | #1 |
adhd risk alleles | #1 |
subthreshold diagnoses valid | #1 |
association evidence | #1 |
hyperactivity disorder adults | #1 |
lateandmoderate | #1 |
adhd iiv | #1 |
odd control | #1 |
ldx size children | #1 |
persistence disorder | #1 |
molecular genetics network | #1 |
dao gene schizophrenia | #1 |
adolescents concurrent adhd | #1 |
intron8 | #1 |
risk adhd | #1 |
onset chronological age | #1 |
paternal overtransmission | #1 |
non‐adhd children | #1 |
genetic sexual dimorphism | #1 |
adhd haplotype block | #1 |
“forgetfulness | #1 |
adhd aud | #1 |
subjects adhd | #1 |
abstinence pharmacological treatment | #1 |
illness child comorbidity | #1 |
bpi disorder | #1 |
anxious depressed subscales | #1 |
adherence xr | #1 |
adolescence longitudinal analysis | #1 |
twin adoption | #1 |
noninhibited children | #1 |
prs rtv | #1 |
slc9a9 adhd | #1 |
cognitive endophenotypes adhd | #1 |
cardinal symptom mania | #1 |
n6979 | #1 |
adhd somatosensory functioning | #1 |
findings adhd | #1 |
gene interaction comt | #1 |
clinically diagnosed obesity | #1 |
adults stimulant sizes | #1 |
4‐year follow‐up study | #1 |
ldx sizes children | #1 |
genotype calling procedures | #1 |
drugplacebo | #1 |
rare protective allele | #1 |
experts abstinence | #1 |
insular lobule | #1 |
association tph2 | #1 |
emotional problems pmee | #1 |
genetic studies sud | #1 |
late onset adhd | #1 |
female humans inhibition | #1 |
latrophilin 3 gene | #1 |
educational failure | #1 |
48basepairrepeat | #1 |
adhdrs5 | #1 |
drd5 vntr | #1 |
aggressive symptoms risk | #1 |
child psychiatry referrals | #1 |
height ldx | #1 |
140 adhd probands | #1 |
adhd drd4 | #1 |
adhd switches | #1 |
relatives children | #1 |
paternal over‐transmission | #1 |
slc6a4 gene risk | #1 |
fidgety philipp | #1 |
anxiety disorders families | #1 |
common genetic risk | #1 |
stimulant treatment youth | #1 |
add antisocial disorders | #1 |
suggestive linkage signals | #1 |
stimulant therapy youths | #1 |
adhd degree relatives | #1 |
sp067 | #1 |
endosomal genes asds | #1 |
elaborative verbal encoding | #1 |
behavioral inhibition parents | #1 |
rels persons | #1 |
paliperidone monotherapy | #1 |
increased adhd symptoms | #1 |
nonmental diseases adhd | #1 |
familial moderators | #1 |
palau early | #1 |
ldx growth | #1 |
adhd predictors | #1 |
disorganized symptom dimensions | #1 |
impact tic disorders | #1 |
efs girls | #1 |
adhd adhd probands | #1 |
parents behavioral disinhibition | #1 |
years adhd | #1 |
girls learning disabilities | #1 |
adhd probands relatives | #1 |
smoking cessation controls | #1 |
families adhd | #1 |
rs1633445 | #1 |
druggable genome disorder | #1 |
disorder follow | #1 |
association syp | #1 |
h2053 | #1 |
bpi sza | #1 |
diagnostic efficiency analysis | #1 |
5ht1b receptor gene | #1 |
adhd symptoms crf | #1 |
psychopathology reward dysfunction | #1 |
adhd alcohol dependence | #1 |
scales risk | #1 |
pinslbl | #1 |
consensus statement combination | #1 |
manic symptoms vcfs | #1 |
adhd mdd prss | #1 |
efds youth | #1 |
groundskeeper | #1 |
schizophrenia familybased studies | #1 |
adhd female individuals | #1 |
psychiatric comorbidity md | #1 |
ldx expected height | #1 |
adhd adhdtd | #1 |
discordant twin study | #1 |
innovative sms intervention | #1 |
temperamental risk factor | #1 |
psud relatives | #1 |
taf9bp2 | #1 |
adhd children mania | #1 |
inflation personal satisfaction | #1 |
sud remittent adhd | #1 |
criteria age | #1 |
bpi disorder youth | #1 |
familial transmission adhd | #1 |
adhd adolescent patients | #1 |
adult samples model | #1 |
productivity adhd | #1 |
genetic correlations schizophrenia | #1 |
fam mothers | #1 |
896 cases | #1 |
mtbi adhd | #1 |
levels dysfunction | #1 |
chi28783 | #1 |
structured interview pdd | #1 |
relatives bipolar | #1 |
hamiltondepression | #1 |
pepple | #1 |
adolescent psychiatric cohort | #1 |
mania conduct disorder | #1 |
hyperactivity case | #1 |
subthreshold adhd | #1 |
add aff | #1 |
standardized manner | #1 |
adhd efficacy outcome | #1 |
adolescent follow youth | #1 |
neural network correlates | #1 |
disorder meta | #1 |
siblings antisocial families | #1 |
clock genes rorb | #1 |
placebo ldx treatment | #1 |
preschool comorbidity | #1 |
comorbidity conduct | #1 |
offspring parental adhd | #1 |
adhd educational deficits | #1 |
multi‐stage study | #1 |
subjects ldx | #1 |
onset distribution | #1 |
suds crosssectional studies | #1 |
quantitative analyses treatment | #1 |
adhd obesity overweight | #1 |
parents sud | #1 |
relatives wm performance | #1 |
nonreferred siblings | #1 |
onset distributions | #1 |
late‐onset adhd | #1 |
adhd neuropsychological | #1 |
rs7124601 | #1 |
persistence childhood adhd | #1 |
motor problems adhd | #1 |
gene studies | #1 |
adhd dbds | #1 |
siblings control probands | #1 |
bipolar disorders psud | #1 |
paediatric adhd | #1 |
lod213 | #1 |
quantitative phenotype snp | #1 |
adult persistence adhd | #1 |
treatment moderated | #1 |
adhdfamilies | #1 |
adhd income loss | #1 |
hyperactivity cross | #1 |
vcfs manic symptoms | #1 |
impulsiveness inattention | #1 |
male individuals adhd | #1 |
risk childhood onset | #1 |
cigarette smoking siblings | #1 |
adolescents genetic risk | #1 |
rs9325032 | #1 |
4q3121 | #1 |
volumes participants | #1 |
asd youth adhd | #1 |
relatives 1 probands | #1 |
dat1 untranslated regions | #1 |
population screen | #1 |
longitudinal outcome boys | #1 |
dna methylation adhd | #1 |
stimulant nonmedical | #1 |
dyscalculia adhd | #1 |
adhd females | #1 |
substance disorders relatives | #1 |
hyperactivity child humans | #1 |
adhd druggable genes | #1 |
antisocial disorder relatives | #1 |
co‐expression modules | #1 |
adhd oppositional | #1 |
marijuana cocaine crack | #1 |
genes association studies | #1 |
acting medications | #1 |
adhd sexes | #1 |
probands comorbidity | #1 |
aadhd cadhd | #1 |
adhd baseline assessment | #1 |
d10s2327 | #1 |
–rs2272080 | #1 |
depressed children depression | #1 |
elevated rates adhd | #1 |
adhd clinical characteristics | #1 |
cortical surface adhd | #1 |
subthreshold pediatric | #1 |
juvenile antisocial traits | #1 |
valid diagnosis | #1 |
association attention | #1 |
impulsive subtype | #1 |
probands rates | #1 |
persistence adhd | #1 |
relatives control | #1 |
hyperactivity disorder scores | #1 |
187 children | #1 |
p97e−03 | #1 |
rs552655 | #1 |
childhood adhd adulthood | #1 |
genetic correlation adhd | #1 |
35191 | #1 |
d10s195 | #1 |
sud adolescent | #1 |
gene attention | #1 |
genetic overlap adhd | #1 |
adhd prss | #1 |
pharmacological treatment adolescents | #1 |
bpi disorder adhd | #1 |
foursnp | #1 |
2064 trios | #1 |
youth adhd prss | #1 |
mph controls | #1 |
psychopathology implications | #1 |
bpprss | #1 |
adults diagnosis | #1 |
dat1 vntr | #1 |
ldx adult adhd | #1 |
addh dmi | #1 |
apol1 schizophrenia | #1 |
impulsive behavioral aggression | #1 |
bpi disorder relatives | #1 |
adhd psychiatric conditions | #1 |
stimulants abuse potential | #1 |
volume alterations | #1 |
haplotypes adhd | #1 |
disorders comorbid mania | #1 |
risk factors opd | #1 |
autism symptoms adhd | #1 |
13052159 | #1 |
suds nicotine dependence | #1 |
onset adult subjects | #1 |
9 nhe9 | #1 |
adhd methods | #1 |
specific psychopathology children | #1 |
pediatric panic disorder | #1 |
nmu oral | #1 |
familial risk gender | #1 |
drug dependence relatives | #1 |
clinical interview mania | #1 |
oih pain tolerance | #1 |
life adult adhd | #1 |
desr siblings | #1 |
c759t | #1 |
anxiety disorders baseline | #1 |
nonverbal social–emotional cues | #1 |
faraone | #1 |
studies attention | #1 |
addictive drugs dust | #1 |
mania manic features | #1 |
selfreport adhd | #1 |
familial links | #1 |
anxiety disorders twins | #1 |
children ermph | #1 |
adhd siblings | #1 |
administration marijuana | #1 |
rf025 | #1 |
comorbid oppositional | #1 |
23 candidate genes | #1 |
tomoxetine adult adhd | #1 |
add parent report | #1 |
adhd teenage parents | #1 |
association evidence schizophrenia | #1 |
dbds adhddbds | #1 |
aff add | #1 |
new psychometric definition | #1 |
bipolar disorder switches | #1 |
12allele | #1 |
transmission parents | #1 |
exposure clinical features | #1 |
hyperactivity databases | #1 |
mr005 | #1 |
adults cadhd | #1 |
parental bpd | #1 |
17year | #1 |
adhd probands adhd | #1 |
longacting medications | #1 |
efficacy adderall | #1 |
daonrg1 | #1 |
desr probands siblings | #1 |
disorder molecular | #1 |
disorders aa | #1 |
week treatment response | #1 |
bpi probands | #1 |
n55374 | #1 |
risk comt gene | #1 |
highiq adults adhd | #1 |
adhd desr probands | #1 |
sob sob association | #1 |
adolescent patients adhd | #1 |
maternal inattention anxiety | #1 |
druggable genome adhd | #1 |
twin adoption studies | #1 |
moderating effects patterns | #1 |
prss psychiatric disorders | #1 |
association maoa | #1 |
opd add opd | #1 |
falconer3 | #1 |
adult samples adhd | #1 |
persistent adhd adults | #1 |
gender adhd | #1 |
postmortem brain identifies | #1 |
valid disorder | #1 |
md parents | #1 |
2455 controls | #1 |
adhd specific | #1 |
relatives bpi probands | #1 |
hyperactivity child genome | #1 |
adhd prs gwas | #1 |
mania referred children | #1 |
74±77 | #1 |
aggregate cutoff score | #1 |
weaknesses comorbidity | #1 |
medications adhd | #1 |
adherence stimulant treatment | #1 |
cbclbp profile | #1 |
relatives adhd girls | #1 |
df39 | #1 |
youth adhd | #1 |
longitudinal analysis childhood | #1 |
rs916455 | #1 |
adhd girls | #1 |
age 7repeat allele | #1 |
efds bpi disorder | #1 |
adhd comorbid odd | #1 |
psychiatric comorbidities adhd | #1 |
pippi longstocking | #1 |
adults adhd subjects | #1 |
adhd antisocial comorbidity | #1 |
increased methylation genes | #1 |
pain tolerance fm | #1 |
cbclbp | #1 |
genes disorder | #1 |
proband youth bpd | #1 |
clinical features adhd | #1 |
hypothesized precursors | #1 |
suds adhd | #1 |
adult adhd treatment | #1 |
re‐review | #1 |
adhd community | #1 |
nasal nmu nmu | #1 |
familial disorders adhd | #1 |
odd relatives | #1 |
sbrv adhd | #1 |
nr3c1 stress exposure | #1 |
comparison subjects participants | #1 |
criteria☆ | #1 |
type attention | #1 |
adhd dsm | #1 |
p27e05 | #1 |
comt fsiq | #1 |
ainslbl | #1 |
psychiatric risk vcfs | #1 |
deficits time | #1 |
robust familiality | #1 |
qelbree | #1 |
subcortical structure volume | #1 |
dsmiiir dsmiv adhd | #1 |
validity adhd | #1 |
adhd 5 | #1 |
convergent functional genomic | #1 |
impulsive symptoms | #1 |
new diagnoses age | #1 |
asrs scores | #1 |
zmynd17 genes | #1 |
adhd responders | #1 |
hyperactivity comorbidity | #1 |
depressed children adhd | #1 |
adhd concurrent sud | #1 |
adhd familial disorder | #1 |
studies adhd | #1 |
adult adhd | #1 |
pdd subjects mania | #1 |
parental panic disorder | #1 |
maoa impulsivity | #1 |
rs3792452 | #1 |
n122 | #1 |
35191 controls | #1 |
familial subtype | #1 |
highiq youths adhd | #1 |
hartsough | #1 |
adhd children ld | #1 |
sud adolescent patients | #1 |
genetic risk severity | #1 |
orosmph adult adhd | #1 |
antisocial disorders risk | #1 |
association adhd | #1 |
dat1 adhd | #1 |
hyperactivity disorder | #1 |
tdt analysis | #1 |
adhd disorder | #1 |
adhd prs rtv | #1 |
adhd valid | #1 |
risk factor psud | #1 |
schizophrenia nonpsychotic relatives | #1 |
comorbid problems | #1 |
depression adhd child | #1 |
notch4 polymorphisms | #1 |
relatives default network | #1 |
probands adhd | #1 |
adhd scores | #1 |
genetic association rorb | #1 |
nonreferred samples | #1 |
familial risk analyses | #1 |
adhd adult disorder | #1 |
adhd cognition | #1 |
onset criterion adhd | #1 |
adult probands siblings | #1 |
adhd genetic variants | #1 |
parental adhd sud | #1 |
smd greater severity | #1 |
unipolar relatives bipolars | #1 |
authors adhd | #1 |
caregiver strain cgsq | #1 |
relatives adhd status | #1 |
psud controls | #1 |
risk female relatives | #1 |
distal genomic region | #1 |
mania criteria | #1 |
loci adhd | #1 |
tass adhdrs | #1 |
concurrent adhd sud | #1 |
trait educational attainment | #1 |
rorb bipolar disorder | #1 |
p902e−07 | #1 |
rs9627183 | #1 |
idir proteins siblings | #1 |
alcohol dependence relatives | #1 |
add pdics | #1 |
rtv adhd prs | #1 |
adhd alleles | #1 |
comorbid psychopathology childhood | #1 |
comorbidity major depression | #1 |
adhd candidate | #1 |
onset attention | #1 |
gsprss | #1 |
rs9610449 | #1 |
transmission adhd | #1 |
unexplored void | #1 |
oral methylphenidate treatment | #1 |
asds clinical scales | #1 |
followup assessment | #1 |
asthma motor preference | #1 |
pdics | #1 |
5‐generation | #1 |
relatives add probands | #1 |
association behavioral inhibition | #1 |
motor preference disability | #1 |
adhd follow | #1 |
genes sexdifferentiated effects | #1 |
40basepairrepeat | #1 |
offspring behavioral disinhibition | #1 |
adhd seconddegree relatives | #1 |
adhd neuropsychological impairments | #1 |
psud adhd probands | #1 |
relbps | #1 |
candidate genes adhd | #1 |
depression symptoms aggregation | #1 |
add opd | #1 |
adhd adverse impact | #1 |
adhd clinical | #1 |
diagnosis adhd | #1 |
familial vulnerability schizophrenia | #1 |
girls disorder | #1 |
adhd comorbid dbds | #1 |
learning disorders adhd | #1 |
dependence controls | #1 |
mania rates | #1 |
ldx sizes adults | #1 |
relatives adhd probands | #1 |
african children adhd | #1 |
sud nicotine dependence | #1 |
disorder schizotaxia | #1 |
familially | #1 |
adhd bpi disorder | #1 |
disorder relatives | #1 |
racial heterogeneity | #1 |
pdd pdd subjects | #1 |
youth informant source | #1 |
firstdegree relatives children | #1 |
higher adhd | #1 |
lifetime adhd | #1 |
24 gm day | #1 |
locus adhd | #1 |
valid psychiatric disorder | #1 |
neuroanatomic predictors | #1 |
adhd highly | #1 |
psychiatric conditions adults | #1 |
bpd parents | #1 |
oral nmu nmu | #1 |
paternal smoking conception | #1 |
fsiq comt | #1 |
rs41084 | #1 |
or133 | #1 |
s034 | #1 |
adhd genetic exome | #1 |
efficacy outcome week | #1 |
stimulant treatment risk | #1 |
attention deficit | #1 |
pdd mania mania | #1 |
increasing resource demand | #1 |
adhd higher | #1 |
children growth delays | #1 |
association dopamine receptors | #1 |
referred juveniles | #1 |
disorder boys | #1 |
children motor domain | #1 |
adhd brain alterations | #1 |
neurocognitive functions suds | #1 |
overweight obesity males | #1 |
20183 | #1 |
adhd conclusions | #1 |
smoking schizophrenia families | #1 |
pilot study adhd | #1 |
adhd baseline | #1 |
abnormalities adhd | #1 |
alcohol disorders offspring | #1 |
infas | #1 |
familiar disease | #1 |
actual motor performance | #1 |
stimulant treatment differences | #1 |
mp adhd | #1 |
expected growth children | #1 |
bmi mts | #1 |
adhd bipolar comorbidity | #1 |
biomarkers adhd | #1 |
personality traits adults | #1 |
patients adhdpi | #1 |
pdi impulsiveness | #1 |
treatment effects values | #1 |
adhd increased | #1 |
probands add | #1 |
adhd neuropsychological functioning | #1 |
manic symptoms disorder | #1 |
familial underpinnings | #1 |
adhd familial risk | #1 |
cacng2 genes schizophrenia | #1 |
motor skills attention | #1 |
chronic emotional dysregulation | #1 |
odd familial disorders | #1 |
daily parent rating | #1 |
antisocial families | #1 |
adhd antisocial | #1 |
molecular psychiatric genetics | #1 |
ldx growth delays | #1 |
fm pain tolerance | #1 |
rs2449340 | #1 |
dat110 6 | #1 |
comt maoa | #1 |
ptsd siblings | #1 |
subcortical volumes adhd | #1 |
ptsd adhd probands | #1 |
rs550818 | #1 |
adhd attention | #1 |
behavioral disinhibition offspring | #1 |
efds functional outcomes | #1 |
desr adult probands | #1 |
ptsd familial disorders | #1 |
schizotaxia schizophrenia | #1 |
83097 | #1 |
chronological age age | #1 |
nfspds | #1 |
adults neurodevelopmental disorder | #1 |
31item | #1 |
relatives control probands | #1 |
adhd children bpd | #1 |
peer environmental factors | #1 |
psychopharmacologic | #1 |
children behavioral inhibition | #1 |
adhd control probands | #1 |
relation stress exposure | #1 |
adhd candidate genes | #1 |
disorders parents | #1 |
affective psychosis hraff | #1 |
adhdrsivinv | #1 |
disorder hyperactivity | #1 |
adhd euphoria | #1 |
relatives greater activation | #1 |
inattention shr | #1 |
training raters | #1 |
adhd chinese population | #1 |
expected height weight | #1 |
adhd smoking | #1 |
mania clinical interview | #1 |
siblings adolescent | #1 |
motor preference adhd | #1 |
adhd long term | #1 |
p0499 | #1 |
1350t | #1 |
adhd prss adhd | #1 |
mania pdd | #1 |
hyperactivity cognition | #1 |
unique impairments | #1 |
reproducibility adolescent | #1 |
impactnl | #1 |
mitigates stimulant | #1 |
adhd disorders comorbidity | #1 |
rs6077690 | #1 |
2 familial factors | #1 |
morbidity bipolar disorder | #1 |
drug frequency variables | #1 |
genetic frontal schizophrenia | #1 |
18 items impairment | #1 |
clinical correlates ocd | #1 |
control probands | #1 |
relatives diagnoses | #1 |
efficacy outcome adhd | #1 |
genes hallucinations states | #1 |
bpd bpd anx | #1 |
braingenie | #1 |
ldx amses | #1 |
rate symptoms | #1 |
adhd reliability | #1 |
anxiety disorders findings | #1 |
risk subsequent substance | #1 |
sud adolescence | #1 |
prs58502974 | #1 |
variants aggressive behavior | #1 |
serotonin genetic | #1 |
rs12843268 | #1 |
akt1 snp markers | #1 |
“3 | #1 |
sud bpdsud | #1 |
adhd depressed children | #1 |
anxiousdepressed | #1 |
21 circadian genes | #1 |
np functioning chr | #1 |
pdag mdd mdd | #1 |
severe emotional dysregulation | #1 |
age1542 | #1 |
matching fallacy | #1 |
sodasmph | #1 |
differences medications | #1 |
adhd gwas | #1 |
pediatric bipolar spectrum | #1 |
patients adhdct | #1 |
pediatric bpi disorder | #1 |
time reproduction children | #1 |
95 hrr | #1 |
method authors | #1 |
adhddbds adhd | #1 |
ptsd bpi disorder | #1 |
1 relatives | #1 |
rationaleadhd | #1 |
asrs aisrs | #1 |
individuals adhd | #1 |
cases adhd | #1 |
hyperactivity body | #1 |
children mania diagnosis | #1 |
treatment stimulant | #1 |
adhdi prenatal exposure | #1 |
relatives bpi | #1 |
fiveminutespeechsample | #1 |
bpd girls | #1 |
shifting sands | #1 |
treatment bsd | #1 |
disorder adhd | #1 |
disorder attention | #1 |
p758e08 | #1 |
interaction adhd severity | #1 |
gsprs adhd | #1 |
expression adhd | #1 |
p647e07 | #1 |
fhrscz | #1 |
parents proband youth | #1 |
adhd children depression | #1 |
connectivity executive control | #1 |
palauans maps loci | #1 |
112 80 | #1 |
adhd gsprs | #1 |
regulation desr | #1 |
referred samples | #1 |
learning disabilities girls | #1 |
adhd personality traits | #1 |
schizotaxia negative symptoms | #1 |
growth deficits deficits | #1 |
kiaa1292 | #1 |
vntr haplotype | #1 |
suds genetic studies | #1 |
putamen volume alterations | #1 |
nimh genetics initiative | #1 |
palau scz | #1 |
relatives drug dependence | #1 |
adhd youth ld | #1 |
relatives alcohol dependence | #1 |
affective symptoms children | #1 |
mgh studies | #1 |
rs2469770 | #1 |
callingalgorithms | #1 |
ldx bmi | #1 |
parental sud sud | #1 |
add 73 probands | #1 |
adhd gene | #1 |
confusability analyses | #1 |
nonreferred siblings probands | #1 |
children motor competence | #1 |
pdd criteria | #1 |
growth delays weight | #1 |
chinese outpatient sample | #1 |
dopamine receptor polymorphism | #1 |
cortical thickness adhd | #1 |
rs11133767 | #1 |
persistence pediatric disorder | #1 |
highiq youths | #1 |
rs3776512 | #1 |
individuals attention | #1 |
rf041 | #1 |
schizophrenia european samples | #1 |
cohorts age groups | #1 |
smoking wm microstructure | #1 |
adhd functional | #1 |
motorendophenotype | #1 |
adhd cigarette smoking | #1 |
dsm bipolar disorder | #1 |
adhd volumetric reductions | #1 |
adhd context | #1 |
pregnancy adhd | #1 |
prospective datasets | #1 |
predictors adhd | #1 |
adhd slc6a3 genotype | #1 |
adoption studies | #1 |
4q28 | #1 |
adhd social class | #1 |
d15s1012 | #1 |
behaviors substances | #1 |
rs7118422 | #1 |
copy organization | #1 |
schizophrenia code | #1 |
controls adhd children | #1 |
social adjustment inventory | #1 |
relatives pediatric probands | #1 |
daorasd2 | #1 |
adhd genetic studies | #1 |
adhd asthma | #1 |
interviews disease humans | #1 |
fbxo33 | #1 |
bpd hypothesis | #1 |
schizotaxia subjects | #1 |
bpd anx | #1 |
age groups cohorts | #1 |
higher prevalence girls | #1 |
familial evidence | #1 |
symptoms adult | #1 |
adhd pdics | #1 |
genes etiology | #1 |
motor preference asthma | #1 |
female individuals adhd | #1 |
model ermph | #1 |
hyperactivity pdi | #1 |
parents md | #1 |
teenage parents individuals | #1 |
autistic traits youth | #1 |
siblings adhd probands | #1 |
opd add | #1 |
euphoria cardinal symptom | #1 |
gene aggressive behavior | #1 |
adhd studies | #1 |
rs1040399 | #1 |
adhd medications placebo | #1 |
adult adhd diagnosis | #1 |
mothers fam | #1 |
galantamine hydrogen bromide | #1 |
2276tc | #1 |
cdh13 memory performance | #1 |
mwq inattention items | #1 |
tourettes syndrome adhd | #1 |
concurrent adhd | #1 |
greater risk adhd | #1 |
adhd susceptibility genes | #1 |
drugplacebo response curve | #1 |
adolescent outcome adhd | #1 |
sud parents | #1 |
trait impulsivity adhdct | #1 |
mdd pdag mdd | #1 |
git1 association adhd | #1 |
adhd efds | #1 |
neuropsychological impairments relatives | #1 |
cgsq ermph | #1 |
desr subjects | #1 |
autism‐associated brain regions | #1 |
familybased studies association | #1 |
adolescent sud | #1 |
adhd familial | #1 |
consensus combination | #1 |
relatives girls | #1 |
cbcl clinical scales | #1 |
schizophrenia notch4 | #1 |
adhd mini | #1 |
lifetime impairment | #1 |
mph adult adhd | #1 |
persistent adhd symptoms | #1 |
adhd drug dependence | #1 |
drd2 risk gene | #1 |
adhd structural abnormalities | #1 |
iiv hyperactivity behavior | #1 |
children adolescents cohorts | #1 |
evidence stimulant treatment | #1 |
relatives conduct disorder | #1 |
masir | #1 |
expressed emotion children | #1 |
disorders hypothesis | #1 |
schizophrenia families smoking | #1 |
smaller total brain | #1 |
adhd gender | #1 |
schizotaxia negative schizotypy | #1 |
overlapping symptoms | #1 |
rs1799835 | #1 |
tass adhd | #1 |
ermph clinical response | #1 |
paediatric patients adhd | #1 |
nmu nasal nmu | #1 |
female adhd | #1 |
suds neurocognitive functions | #1 |
biased maternal reporting | #1 |
suggestive linkage | #1 |
symptoms versus impairment | #1 |
bipolar disorder girls | #1 |
males overweight obesity | #1 |
remission definition | #1 |
conduct bipolar disorders | #1 |
pediatric bipolari disorder | #1 |
regions age | #1 |
adult adhd differences | #1 |
prescription stimulant nmu | #1 |
bipolar adhd | #1 |
tova api aklt01 | #1 |
etiology disorder | #1 |
validity diagnosis | #1 |
treatment masxr | #1 |
stimulants height | #1 |
neuropsychological performance adhd | #1 |
syp female adhd | #1 |
impulsive drive | #1 |
conduct disorder probands | #1 |
adhd ads | #1 |
increased expression methylation | #1 |
asrs‐v11 | #1 |
genetic variants adhd | #1 |
hyperactive impulsive | #1 |
psychiatric disorders adhd | #1 |
stimulants childhood | #1 |
relatives multiplex | #1 |
oih cpt | #1 |
77e08 | #1 |
clinical controls | #1 |
features adhd | #1 |
pain tolerance oih | #1 |
clinical response orosmph | #1 |
229 families | #1 |
oih fm | #1 |
rs3746544 rs1051312 | #1 |
schizophrenia rs1076560t | #1 |
adhd children | #1 |
rs2279805 | #1 |
motor preference | #1 |
add relatives | #1 |
dust addictive drug | #1 |
2276ct | #1 |
inattentive subtype adhd | #1 |
prsanalyses | #1 |
schizophrenia bipolar psychoses | #1 |
illness adolescent | #1 |
rs6000200 | #1 |
adhd social disability | #1 |
adhdmethodcurves | #1 |
comorbid adult adhd | #1 |
covariates dopamine receptors | #1 |
boys female gender | #1 |
adhd snps | #1 |
adhd sex | #1 |
stress adhd severity | #1 |
matter volumes volumes | #1 |
bipolar disorder bpprss | #1 |
bmi ldx | #1 |
children general psychopathology | #1 |
snps drd4 gene | #1 |
cigarette smoking metaanalysis | #1 |
combination scientific data | #1 |
notch4 polymorphisms schizophrenia | #1 |
nhe inhibitors adhd | #1 |
autistic traits presence | #1 |
parental probands | #1 |
affective symptoms dbds | #1 |
memory adults | #1 |
larger samples | #1 |
model adult samples | #1 |
amses amrs | #1 |
diagnoses relatives | #1 |
downward extension adolescents | #1 |
aklt01 tova api | #1 |
desipraminestimulants | #1 |
prescription stimulant nonmedical | #1 |
trypotphan | #1 |
emotional symptoms adhd | #1 |
schizophrenia hrscz | #1 |
17yearold boys | #1 |
low attention | #1 |
proband youth bpdsud | #1 |
desr adhd | #1 |
relatives multiplex families | #1 |
network‐level assessment | #1 |
cbclbp profile children | #1 |
adhd neuroimage study | #1 |
biological schizophrenia stress | #1 |
studies adhd children | #1 |
lateonset adhd | #1 |
studies depressed children | #1 |
142 combined subtype | #1 |
ermph placebo groups | #1 |
genetics adhd | #1 |
parental panic depression | #1 |
adhd dat1 gene | #1 |
ctcata | #1 |
fhraff | #1 |
p81e06 | #1 |
discipline problem | #1 |
major depression share | #1 |
adhd desr | #1 |
adhd comorbid disorders | #1 |
nonreferred sample | #1 |
cyp2d6 hypothesis | #1 |
c2orf82 | #1 |
variance oppositional symptoms | #1 |
greater risk add | #1 |
severe dysregulation | #1 |
association psychiatric comorbidity | #1 |
adhde | #1 |
adhd sample | #1 |
alphaglx | #1 |
p44e05 | #1 |
bpi disorder sexes | #1 |
tass internal consistency | #1 |
maoa neuropsychological functioning | #1 |
bpdsud bpd | #1 |
smoking adhd | #1 |
antisocial disorders bpd | #1 |
diagnostic continuity | #1 |
evidence sud phenotypes | #1 |
relatives 3 probands | #1 |
adhd stronger connectivity | #1 |
rs2498799 | #1 |
major depression youth | #1 |
based association study | #1 |
dsm5 adult adhd | #1 |
inattentive hyperactive | #1 |
predicted clinical response | #1 |
intelligence additive effects | #1 |
1236a | #1 |
scz palau | #1 |
stimulant treatment profiles | #1 |
sob adhd | #1 |
marijuana smoking metaanalysis | #1 |
schizophrenic probands1portions | #1 |
offspring sud parents | #1 |
norepinephrine transporter gene | #1 |
adhd learning | #1 |
adhd clinical obesity | #1 |
p446e08 | #1 |
adhd psychiatric | #1 |
measurement invariance study | #1 |
bpd firstdegree relatives | #1 |
20183 cases | #1 |
iiv shr | #1 |
multiplex sample | #1 |
adhd france | #1 |
structural differences children | #1 |
interaction adhd | #1 |
metaanalysis controlled study | #1 |
adhd child comorbidity | #1 |
selfreport adhd symptoms | #1 |
subthreshold adhd subjects | #1 |
adherence stimulant medication | #1 |
anxiety disorders relatives | #1 |
lobe mri measures | #1 |
manic children pdd | #1 |
adhd serotonin | #1 |
ats siblings | #1 |
adhd background | #1 |
cadhd aadhd | #1 |
adhd african | #1 |
probands clinical status | #1 |
diagnosis bpi disorder | #1 |
deletioncarrier | #1 |
children teaes | #1 |
association snap25 | #1 |
parental children | #1 |
adhd single nucleotide | #1 |
ldx masir | #1 |
adhd adhd cases | #1 |
higher pdi | #1 |
mr006 | #1 |
school reliability | #1 |
vcfsadhd adhd | #1 |
time qualitative review | #1 |
adverse impact adhd | #1 |
trypotphan hydroxylase | #1 |
neuropsychological probes | #1 |
efficacy medications | #1 |
14 children pdd | #1 |
adhd girls adhd | #1 |
inattentive symptoms adults | #1 |
tic persistence | #1 |
allele adhd | #1 |
nonreferred adults | #1 |
risk substance disorders | #1 |
comt maoa interaction | #1 |
symptom burden adults | #1 |
hypothesis disorders | #1 |
hyperactivity child child | #1 |
adolescents sud treatment | #1 |
metabias | #1 |
large controlled study | #1 |
risk tourette spectrum | #1 |
onset mania | #1 |
nplz | #1 |
molecular genetic studies | #1 |
ld addh children | #1 |
adhd total score | #1 |
neuropsychologic function schizophrenia | #1 |
childhoodonset mania | #1 |
versus disability | #1 |
adhd adult adhd | #1 |
normal sexual dimorphisms | #1 |
unfamiliar challenges | #1 |
bpd probands | #1 |
oral nmu | #1 |
adhd population | #1 |
offspring parental md | #1 |
adhd genetic receptors | #1 |
neurocognitive dysfunctions | #1 |
htf9c | #1 |
comorbid odd adhd | #1 |
motheronly | #1 |
adhd findings | #1 |
anx relatives | #1 |
earlyandmoderate | #1 |
shr iiv | #1 |
dbds adhd | #1 |
aadhd hyperactivity biomarkers | #1 |
association slc6a3 | #1 |
nonpsychotic relatives controls | #1 |
structured interview mania | #1 |
stable behavioral inhibition | #1 |
regions lgi | #1 |
effects lisdexamfetamine dimesylate | #1 |
adhd comorbid | #1 |
sensitive adhd | #1 |
growth outcomes adhd | #1 |
family‐based association test | #1 |
rs3027400 | #1 |
depression offspring variables | #1 |
symptoms aggregation | #1 |
criteria 14 children | #1 |
tidqam | #1 |
adhd linkage | #1 |
diagnoses adhd | #1 |
substantial genetic component | #1 |
repeat allele | #1 |
treating adhd | #1 |
stimulant treatment alcohol | #1 |
sample adhd | #1 |
diagnostic criteria adhd | #1 |
intellectual delays | #1 |
daodisc1 | #1 |
adhd cbcl | #1 |
disability asthma | #1 |
executive functioning adults | #1 |
bipolar disorder parents | #1 |
adolescent response inhibition | #1 |
adhd asm snps | #1 |
sob association adhd | #1 |
conduct disorder aspd | #1 |
interobserver agreement measures | #1 |
adhdtd siblings | #1 |
high‐risk adolescent offspring | #1 |
type adhd | #1 |
adhd bipolar studies | #1 |
adhddbds | #1 |
children antisocial disorders | #1 |
prss adhd | #1 |
adolescent attention | #1 |
lifetime impairment survey | #1 |
nonreferred subjects | #1 |
ermph cgsq | #1 |
adhd probands | #1 |
adhd antisocial disorders | #1 |
anxiety disorders siblings | #1 |
odd disruptive behavior | #1 |
new phenotype definition | #1 |
shared endophenotypes | #1 |
fspds | #1 |
youth bpi disorder | #1 |
european treatment guidelines | #1 |
masir ldx | #1 |
mwq adhd module | #1 |
smd higher rates | #1 |
drd4 association | #1 |
parental suds | #1 |
desr adults | #1 |
arch ger psychiatry | #1 |
hyperactivity child | #1 |
adhd clinical trial | #1 |
teachers cbt intervention | #1 |
schizophrenia fhrs | #1 |
adhd module | #1 |
bpi disorder children | #1 |
age onset criterion | #1 |
bpd relatives | #1 |
disorder | #1 |
adhd vntr | #1 |
aud adhd | #1 |
oros methylphenidate orosmph | #1 |
snpssnpsa | #1 |
asd weaknesses | #1 |
99item cbs | #1 |
patients attentional disorders | #1 |
childhood predictors adhd | #1 |
distribution child | #1 |
p179e06 | #1 |
stimulants comorbidity | #1 |
adhd hyperactivity automobile | #1 |
adhd genetic correlation | #1 |
stimulant treatment adults | #1 |
“schizotypes | #1 |
meaningful anxiety phenotype | #1 |
motorendophenotypes | #1 |
bpd anx relatives | #1 |
sud risk offspring | #1 |
aisrs asrs | #1 |
adhd subjects controls | #1 |
pooleddata | #1 |
children pdag parents | #1 |
deficit hyperactivity | #1 |
controls adhd probands | #1 |
osa genetic heterogeneity | #1 |
stimulant treatment | #1 |
gender familial risk | #1 |
hyperactivity biomarkers aadhd | #1 |
groups girls | #1 |
drd4 7repeat allele | #1 |
schizophrenia current knowledge | #1 |
age stimulant treatment | #1 |
140 adhd | #1 |
15q13 deletions | #1 |
adhdassociated alleles | #1 |
competitivep | #1 |
subsets linkage | #1 |
brain activity flow | #1 |
vall66 | #1 |
sbrv | #1 |
persons rels | #1 |
exposure maternal smoking | #1 |
adults life | #1 |
p20e04 | #1 |
suds relatives | #1 |
prevalence attention | #1 |
unaffected siblings volumes | #1 |
rs1076560t | #1 |
inattention items | #1 |
assess adult adhd | #1 |
starsadhd | #1 |
nonreferred | #1 |
adhd oxidative stress | #1 |
risk disorder | #1 |
adhd adolescent | #1 |
adults ldx sizes | #1 |
neurocognitive marker | #1 |
pdd mania | #1 |
2327ct | #1 |
adhdoddcd | #1 |
adhd highiq youths | #1 |
controls rels | #1 |
sexdifferentiated effects traits | #1 |
odd affective symptoms | #1 |
snp quantitative phenotype | #1 |
risk psud | #1 |
adhd fam | #1 |
adhd symptom counts | #1 |
5q23q31 | #1 |
adhd adoption studies | #1 |
chi25762 | #1 |
snps quantitative phenotypes | #1 |
positive peer affiliation | #1 |
referred parents | #1 |
siblings adhd | #1 |
qms adult adhd | #1 |
non‐random error | #1 |
rs11568324 | #1 |
impaired sensorimotor timing | #1 |
bpi disorder efds | #1 |
slc9a9 | #1 |
report adhd | #1 |
vulnerability indicators schizophrenia | #1 |
adhd maternal smoking | #1 |
schizotypal relatives | #1 |
risk aggressive symptoms | #1 |
medications adult adhd | #1 |
diagnostic continuity adhd | #1 |
sexes bpi disorder | #1 |
hyperactivity comorbidity humans | #1 |
neuropsychological functioning boys | #1 |
risk anxiety disorders | #1 |
a409p | #1 |
european treatment guideline | #1 |
neurocognitive traits | #1 |
transient financial stress | #1 |
disorder versus disability | #1 |
bpi relatives | #1 |
dysfunctional gene | #1 |
rates relatives | #1 |
stimulant nmu | #1 |
teacher combined | #1 |
adhd maternal | #1 |
children idiopathic adhd | #1 |
adhd pattern | #1 |
parental polygenic risk | #1 |
childhood genetic background | #1 |
elevated risk adhd | #1 |
adhd genetic | #1 |
mania pdd subjects | #1 |
morbidity adhd | #1 |
rs1482337–rs2252471 | #1 |
adhd 11 years | #1 |
psychiatric comorbidity girls | #1 |
adhd stimulant treatment | #1 |
future dsm | #1 |
hamshere | #1 |
mspi allele | #1 |
endophenotypic construct | #1 |
subjects lateonset adhd | #1 |
masxr treatment | #1 |
hyperactivity biomarkers | #1 |
placebo cgsq | #1 |
pharmacogenetics predictors | #1 |
female gender boys | #1 |
odd disorders follow | #1 |
analysis adhd | #1 |
phenotype adhd | #1 |
cbcldesr | #1 |
51 genes | #1 |
familial association adhd | #1 |
gene comt | #1 |
adhd asd youth | #1 |
deficits expected growth | #1 |
adhd african children | #1 |
impairments adults | #1 |
self‐reported adhd | #1 |
subtype adhd | #1 |
affs add | #1 |
comorbid problems adhd | #1 |
genes adhd | #1 |
parental sud adhd | #1 |
predictors persistence | #1 |
criteria mania | #1 |
adhdtd | #1 |
visual memory deficit | #1 |
bipolars unipolar relatives | #1 |
asrs | #1 |
children behavioral | #1 |
adhd smoking risk | #1 |
adhd treatment treatment | #1 |
disorder report | #1 |
rutters | #1 |
relatives risk adhd | #1 |
timely renewal | #1 |
key conceptual issues | #1 |
adhd phenotypes | #1 |
bpd bpdsud | #1 |
120 normal controls | #1 |
mddprss | #1 |
adhd outcome | #1 |
prescription stimulant adults | #1 |
dsmiv subtypes adhd | #1 |
context adhd | #1 |
sud phenotypes | #1 |
adhd followup | #1 |
relszs | #1 |
highiq adults | #1 |
treatment stimulants | #1 |
pathways adhd | #1 |
anx bpd | #1 |
healthy cortical development | #1 |
adhd rat | #1 |
adhd maoa | #1 |
adulthood genetic architecture | #1 |
idir aversion | #1 |
stimulant treatment adhd | #1 |
anterior insular lobule | #1 |
adhd screening | #1 |
items 99item cbs | #1 |
nfspd | #1 |
adhd dyscalculia | #1 |
boys social disability | #1 |
hyperactivity | #1 |
pdi hyperactivity | #1 |
slc9a9 disease associations | #1 |
cacng2 gene | #1 |
adhd sample model | #1 |
adhd psychoactive substance | #1 |
siblings adhd children | #1 |
children disorder | #1 |
parental md | #1 |
bipolar mdd | #1 |
loci asd symptoms | #1 |
bpi disorder aspd | #1 |
hyperactive impulsive symptoms | #1 |
ldx sizes | #1 |
10repeats | #1 |
adhd diagnosed | #1 |
comt intelligence | #1 |
adhd | #1 |
compared adhd | #1 |
maoa adhd | #1 |
cbt intervention adolescents | #1 |
methylphenidate efficacy | #1 |
htf9c gene | #1 |
aspd youth | #1 |
drd2 disrupts | #1 |
aud alcohol disorders | #1 |
135–526 | #1 |
adult persistence | #1 |
aklt01 adhd | #1 |
genetic heterogeneity adhd | #1 |
benefit‐risk ratio | #1 |
genetic studies adhd | #1 |
outcome adhd | #1 |
rs2469758–rs2461489 | #1 |
nonreferred adult | #1 |
stimulant misuse | #1 |
shlod | #1 |
adhd mp | #1 |
dopamine d4 gene | #1 |
adhd conduct disorder | #1 |
factors adhd | #2 |
disorder children | #2 |
dsm subtypes | #2 |
probands | #2 |
hyperactivity impulsiveness | #2 |
expanded symptom criteria | #2 |
studies adderall | #2 |
bias child child | #2 |
stimulant therapy | #2 |
parents major depression | #2 |
candidate genetic pathways | #2 |
qtl linkage adhd | #2 |
iii attention | #2 |
pediatrically | #2 |
comorbidity probands | #2 |
oral prescription | #2 |
idiopathic adhd | #2 |
bsfq | #2 |
comorbid conduct | #2 |
stin2vntr | #2 |
neuropsychoanalytic treatment | #2 |
boys maoa | #2 |
comorbidity attention | #2 |
disease humans receptors | #2 |
child comorbidity | #2 |
disorder findings | #2 |
disorder girls | #2 |
scales sex | #2 |
treatment childhood adhd | #2 |
n3199 | #2 |
twin studies adhd | #2 |
psychoactive substance disorders | #2 |
emf impairments | #2 |
adhd risk icv | #2 |
adults adhd | #2 |
hypothalamic abnormalities | #2 |
bpd adhd | #2 |
6‐year longitudinal study | #2 |
target features | #2 |
adhd odd | #2 |
adhd report | #2 |
adhd outcomes | #2 |
rates adhd | #2 |
disorder add | #2 |
nonpsychotic relatives | #2 |
cbcl profile | #2 |
jackknife procedure | #2 |
familial association | #2 |
odd girls | #2 |
ratio081 | #2 |
dsm adhd | #2 |
dsmiv adhd | #2 |
systematized delusions | #2 |
wky nhsd | #2 |
separation attention deficit | #2 |
cbsk | #2 |
adhd bpd | #2 |
cacng2 genes | #2 |
dsmiv subtypes | #2 |
adhd risk factor | #2 |
adhd major depression | #2 |
role adhd | #2 |
eye vergence responses | #2 |
alleles attention | #2 |
ldsc genetic correlations | #2 |
wm deficits | #2 |
schizophrenia genetic studies | #2 |
asrs health organization | #2 |
cbcl clinical | #2 |
default network schizophrenia | #2 |
disorder studies | #2 |
support genetic factors | #2 |
disease humans inhibition | #2 |
structured diagnostic | #2 |
consortium neuroscience | #2 |
screening diagnosis treatment | #2 |
amses | #2 |
scz data | #2 |
adult samples | #2 |
youth attention | #2 |
variance adult | #2 |
sex differences adhd | #2 |
schizotaxia discussion | #2 |
adhd adhd patients | #2 |
anx bipolar disorder | #2 |
adhd psychiatric disorders | #2 |
adhd risk gene | #2 |
life social adjustment | #2 |
disorders findings | #2 |
prior reports | #2 |
cnvs copy variants | #2 |
referred youth | #2 |
pilot adult | #2 |
rs3746544 | #2 |
deficits efds | #2 |
psychiatrically | #2 |
methylphenidate attention | #2 |
conjfdr005 | #2 |
qualitative review | #2 |
dsmiiir adhd | #2 |
conners adult adhd | #2 |
adhd growth | #2 |
female probands | #2 |
symptoms neuropsychological | #2 |
bpd sud | #2 |
snp12snp2ctgn | #2 |
overlap mania | #2 |
siblings youth | #2 |
schizophrenia twin studies | #2 |
comparison probands | #2 |
adhd icv | #2 |
nicotine substance | #2 |
underlying bipolarity | #2 |
age onset distribution | #2 |
status rating scales | #2 |
6p243 | #2 |
7point | #2 |
comorbid aggression | #2 |
youth rates | #2 |
investigator ratings | #2 |
blind raters | #2 |
chromosomes inclusion | #2 |
performancemeasures | #2 |
viloxazine extendedrelease | #2 |
subjects adults | #2 |
d10s1432 | #2 |
genome‐wide association scan | #2 |
background attention | #2 |
acpts | #2 |
disorder inattentive | #2 |
lgi regions | #2 |
current adult adhd | #2 |
consecutively referred children | #2 |
youth selfreports | #2 |
schizophrenia parahippocampal gyrus | #2 |
adhd method | #2 |
juvenile antisocial | #2 |
executive function outcome | #2 |
comorbid conduct disorder | #2 |
proinflammatory expansion | #2 |
developmental subtype | #2 |
qualitative literature review | #2 |
n1934 | #2 |
disorder oppositional | #2 |
disorder background | #2 |
adhd control subjects | #2 |
opioid induced hyperalgesia | #2 |
n2455 | #2 |
method subjects | #2 |
galantamine hbr placebo | #2 |
tourette spectrum | #2 |
diabetes disorders | #2 |
ncrl wky | #2 |
hyperactivity attention deficit | #2 |
function deficits | #2 |
adhd adults | #2 |
n2246 | #2 |
consecutively referred | #2 |
scales adolescent | #2 |
bidirectional overlap | #2 |
expanded versions | #2 |
association meta analysis | #2 |
age onset distributions | #2 |
testretest reliability screener | #2 |
n328917 | #2 |
galantamine hbr | #2 |
schizotypy handedness | #2 |
adhd genes | #2 |
n‐acetylcysteine treatment | #2 |
reward‐related activation | #2 |
multicenter adhd | #2 |
heterogeneity schizophrenia | #2 |
versus controls | #2 |
probands relatives | #2 |
neuroleptic dose reduction | #2 |
iii adhd | #2 |
work needed | #2 |
items screener | #2 |
hypothesis adhd | #2 |
evidence adhd | #2 |
polygenic resilience score | #2 |
rs6938431 | #2 |
schizophrenia calcineurin | #2 |
derived diagnosis | #2 |
case subjects adhd | #2 |
internal distractibility | #2 |
variants adhd | #2 |
bmi adhd symptoms | #2 |
findings children | #2 |
checklist clinical | #2 |
patterns comorbidity | #2 |
adhd bipolar | #2 |
naltrexone adults | #2 |
adhd comorbid problems | #2 |
effects paternal smoking | #2 |
informant source | #2 |
regions studies | #2 |
manic switches | #2 |
cbcljbd children | #2 |
subjects conduct disorder | #2 |
expert clinician | #2 |
spectrum phenotypes | #2 |
risk factor adhd | #2 |
adhd birth | #2 |
genome‐wide association data | #2 |
adhd combined | #2 |
addicted | #2 |
comorbid oppositional defiant | #2 |
youth meaningful | #2 |
association data | #2 |
somatosensory functioning | #2 |
aggressive symptoms | #2 |
unipolar relatives | #2 |
structure adult adhd | #2 |
control subjects adhd | #2 |
2q143 | #2 |
childhoodonset adhd | #2 |
5 loci adhd | #2 |
wky ncrl | #2 |
strong heritability | #2 |
subjects criteria | #2 |
cigarette smoking suds | #2 |
deficits sustained attention | #2 |
multigenic inheritance | #2 |
disorders similarities | #2 |
millennium consortium | #2 |
adhd african americans | #2 |
6 17 | #2 |
comorbidity disorder | #2 |
adhd ldx | #2 |
elusive indicators | #2 |
wiatii | #2 |
childhood adolescent adhd | #2 |
efds adults | #2 |
antisocial disorders | #2 |
relatives add | #2 |
lallele homozygotes | #2 |
selfmedicating | #2 |
immune disorder | #2 |
rates bpd | #2 |
shared genetic background | #2 |
ncrl | #2 |
adhd autism symptoms | #2 |
familial trait | #2 |
adolescents substance disorder | #2 |
cpt oih | #2 |
comparative profile analysis | #2 |
adhd lower | #2 |
deficit hyperactivity disorder | #2 |
major depression findings | #2 |
aklt01 | #2 |
s038 | #2 |
n17666 | #2 |
risk add | #2 |
antisocial disorders relatives | #2 |
psychotic relatives | #2 |
ppv hyperactivity diagnostic | #2 |
preventing schizophrenia | #2 |
deficits adults | #2 |
schizophrenia pedigrees | #2 |
n11221 | #2 |
disorders adhd | #2 |
disorder adults | #2 |
correlates adhd | #2 |
dimesylate treatment | #2 |
hypothetical task | #2 |
activation trigger | #2 |
stimulants adults | #2 |
schizophrenia interactions | #2 |
adhd adhd children | #2 |
chromosomes 6 14 | #2 |
relatives adhd | #2 |
adhd choice | #2 |
ldsc heritability | #2 |
bipolar disorder relatives | #2 |
hyperactivity diagnostic | #2 |
adhdliability | #2 |
clinically referred | #2 |
adhd impact | #2 |
hyperactivity female humans | #2 |
efficacy stimulants | #2 |
adra2a polymorphism | #2 |
adhd height | #2 |
familybased studies | #2 |
psychiatric comorbidity | #2 |
checklist scales | #2 |
disorders suds | #2 |
bipolar disorder sud | #2 |
hantac | #2 |
subjects desr | #2 |
enigma adhd | #2 |
adhd subjects | #2 |
unweighted screener asrs | #2 |
factors attention | #2 |
serum neuroleptic activity | #2 |
ermph children | #2 |
wwwhapmaporg | #2 |
personal satisfaction | #2 |
methodological complexities | #2 |
rs1800955 | #2 |
risk panic disorder | #2 |
adhd mph response | #2 |
adhd physical conditions | #2 |
mood disorders adhd | #2 |
adhd assessed | #2 |
models adhd | #2 |
subsyndromal manifestations | #2 |
adhd genetics | #2 |
disorder impact | #2 |
assessed structured | #2 |
quetiapine monotherapy treatment | #2 |
adhdonly | #2 |
neuropsychological function girls | #2 |
adhd comparison | #2 |
relatives | #2 |
diagnosis attention | #2 |
efds | #2 |
adhd neuropsychological deficits | #2 |
hrscz | #2 |
combinedtype | #2 |
modest evidence | #2 |
postcleavage | #2 |
attention‐deficit hyperactivity | #2 |
clinically referred children | #2 |
adhd relatives | #2 |
rs1801028 | #2 |
617 years | #2 |
dysfunction offspring | #2 |
d2s410 | #2 |
male psychiatric | #2 |
euphorigenic effects | #2 |
juvenile bipolar phenotype | #2 |
bipolar disorder symptomatology | #2 |
weaknesses youth | #2 |
deficit sustained attention | #2 |
eye vergence | #2 |
sud bpd | #2 |
child behavioral inhibition | #2 |
g72 daao | #2 |
comorbid conduct problems | #2 |
cognition youth | #2 |
comorbidity adhd | #2 |
health organization asrs | #2 |
key cognitive phenotypes | #2 |
manic children | #2 |
cbcl desr | #2 |
maoa comt | #2 |
drug abuse dependence | #2 |
trauma adhd | #2 |
girls adhd | #2 |
rates odd | #2 |
pdd overlap | #2 |
adhd families | #2 |
dsmjbd | #2 |
association mtbi | #2 |
morbidity dysfunction | #2 |
adhd suds | #2 |
parental anxiety disorders | #2 |
adverse effects subjects | #2 |
relatives simplex families | #2 |
adhdprss | #2 |
structured diagnostic interviews | #2 |
desr children | #2 |
adhd combined subtype | #2 |
stimulants adhd | #2 |
adhd emotional symptoms | #2 |
d0·18 | #2 |
families schizophrenia patients | #2 |
molecular genetics schizophrenia | #2 |
≥210 | #2 |
initial stimulant | #2 |
add probands | #2 |
attentional control effects | #2 |
problems adhd | #2 |
young adult years | #2 |
allele schizophrenia | #2 |
stress adhd | #2 |
adhd disability | #2 |
morning behavior | #2 |
adhd comparison subjects | #2 |
masxr | #2 |
genetic transmission | #2 |
enigma adventure | #2 |
actively reducing | #2 |
rs40184 | #2 |
treatment sud patients | #2 |
18 dsm | #2 |
adhd case subjects | #2 |
deficits executive | #2 |
small literature | #2 |
parents disorder | #2 |
levels comorbidity | #2 |
mirsky | #2 |
adhd conduct | #2 |
parent rating | #2 |
suggestive linkage loci | #2 |
familial risk analysis | #2 |
adhd objective | #2 |
large controlled | #2 |
comorbidity disorders comorbidity | #2 |
subthreshold diagnoses | #2 |
infancy complications | #2 |
stimulants | #2 |
disorder adolescent | #2 |
persistent attention | #2 |
scale asrs | #2 |
specific haplotype | #2 |
maternal smoking mothers | #2 |
adults attention | #2 |
adhd acc | #2 |
p161e05 | #2 |
adhd surface area | #2 |
derived phenotypes | #2 |
familial adhd | #2 |
6 17 years | #2 |
psychotic mood disorder | #2 |
adhd major | #2 |
risk female cases | #2 |
adhd neuropsychological tests | #2 |
concurrent attention | #2 |
actively reducing severity | #2 |
relatives schizophrenic | #2 |
140 girls | #2 |
adhd lifespan | #2 |
child comorbidity illness | #2 |
adherence stimulants | #2 |
subsequent substance | #2 |
affective probands | #2 |
disorder conclusions | #2 |
10092 | #2 |
intron13 | #3 |
morning school | #3 |
adhd systematic review | #3 |
hyperactivity central | #3 |
nicotine disorders | #3 |
children vcfsadhd | #3 |
response methylphenidate | #3 |
comorbidity panic disorder | #3 |
deficits height | #3 |
neurological polymorphism | #3 |
tsuang | #3 |
psychotic behaviour | #3 |
studies square | #3 |
vcfsadhd | #3 |
pdd adhd | #3 |
adhd ptsd | #3 |
dsmiiir diagnosis | #3 |
weight effects | #3 |
large battery | #3 |
topic adolescent | #3 |
deficient emotional | #3 |
association confounders | #3 |
adhdpi | #3 |
schizophrenia genotype | #3 |
social perception skills | #3 |
predisposition schizophrenia | #3 |
qtl linkage | #3 |
petronis | #3 |
adhd comorbid conditions | #3 |
cgsq | #3 |
children mania | #3 |
gsprs | #3 |
13q222 | #3 |
learning disabilities adhd | #3 |
sirolimus 12 months | #3 |
ermph | #3 |
adhd rare cnvs | #3 |
nonpsychotic relatives persons | #3 |
adult psychiatric outcomes | #3 |
risk factors sud | #3 |
genetic receptors serotonin | #3 |
adhd pairwise correlations | #3 |
ptsd adhd | #3 |
schizophrenia allele | #3 |
relatives bipolar disorder | #3 |
inattentive subtype | #3 |
adhd control | #3 |
htr1e | #3 |
asd ocd groups | #3 |
stimulants treatment | #3 |
bipolar disease | #3 |
familial nature | #3 |
adolescent adhd | #3 |
highly heritable disorder | #3 |
bpd rates | #3 |
atomoxetine response | #3 |
enigma neuroimaging genetics | #3 |
cpt deficits | #3 |
n2271 | #3 |
dose response effects | #3 |
experienced pain | #3 |
networks adhd | #3 |
manic symptoms youth | #3 |
drd5 marker | #3 |
adolescents mania | #3 |
clinically referred adults | #3 |
md adhd | #3 |
relationship adhd | #3 |
comt adhd | #3 |
simulated workplace laboratory | #3 |
major depression comorbidity | #3 |
rs6565113 | #3 |
disease humans interviews | #3 |
adhd metaanalysis | #3 |
adhd mental disorders | #3 |
lbw adhd | #3 |
variance severity | #3 |
risk panic | #3 |
cortical thickness cases | #3 |
adhd bipolar disorder | #3 |
adhd mtbi | #3 |
mania disorders | #3 |
n1777 | #3 |
sud youths | #3 |
adhd emotional | #3 |
growth deficits | #3 |
adhd combined type | #3 |
ocd groups asd | #3 |
dat1 | #3 |
anxiety disorders authors | #3 |
global neuroscience decade | #3 |
hyperactivity bipolar | #3 |
familial risk factors | #3 |
neuropsychiatric disorders similarities | #3 |
syndromatic | #3 |
n2323 | #3 |
relatives proband groups | #3 |
prenatal adversities | #3 |
asthma adhd | #3 |
firstdegree relatives | #3 |
pairwise correlations disorders | #3 |
genetics initiative | #3 |
potential gene | #3 |
naltrexone methylphenidate | #3 |
children adhd | #3 |
sexdifferentiated effects | #3 |
chromosome 10q22 | #3 |
disorders conclusions | #3 |
methylphenidate studies | #3 |
parents panic disorder | #3 |
drug nicotine | #3 |
substances symptoms | #3 |
lambdasib | #3 |
adhd mania | #3 |
disorder conduct | #3 |
adhd mdd | #3 |
defined adhd | #3 |
schizophrenia neurocognitive performance | #3 |
dmi addh | #3 |
structural imaging findings | #3 |
relatives persons | #3 |
schizophrenic outpatients | #3 |
caarsss | #3 |
impact adhd | #3 |
schizotaxia | #3 |
drd4 7 | #3 |
7repeat allele | #3 |
“negativity | #3 |
parents panic | #3 |
smds scz | #3 |
vulnerability indicators | #3 |
longitudinal follow | #3 |
controls 6 disorders | #3 |
emotional dysregulation adhd | #3 |
enigma wgs wgs | #3 |
cognition comorbidity | #3 |
evidence genetic association | #3 |
9rcarriers | #3 |
similarities genetic etiology | #3 |
adhd psud | #3 |
mtbi studies | #3 |
snps haplotype | #3 |
anxiety behavioral inhibition | #3 |
tic disorders adhd | #3 |
disabilities male | #3 |
comorbidity diagnosis | #3 |
remittent | #3 |
desr | #3 |
adhd common | #3 |
reln promoter | #3 |
interactions schizophrenia | #3 |
metadoxine extended release | #3 |
disproportionate impairment | #3 |
international adhd | #3 |
sibling trait | #3 |
adhd risk | #3 |
european‐american | #3 |
adhd psychiatric comorbidity | #3 |
ldx amphetamine | #3 |
67e07 | #3 |
27 risk loci | #3 |
siblings young | #3 |
conduct disorder adhd | #3 |
smoking probands | #3 |
psychiatric comorbidity adhd | #3 |
brain methylation | #3 |
enuresis adhd | #3 |
notch4 schizophrenia | #3 |
adhd polygenic | #3 |
amphetamines attention | #3 |
schizophrenia schizotaxia | #3 |
mania children | #3 |
manic symptoms children | #3 |
impulsivity errors | #3 |
adhd wm deficits | #3 |
adhd implications | #3 |
temperamental correlates | #3 |
impairment adhd | #3 |
adhd presence | #3 |
asrs v11 | #3 |
intra‐individual variability | #3 |
candidate gene studies | #3 |
hyperactivity attention | #3 |
enigma global neuroscience | #3 |
z280 | #3 |
resilience score | #3 |
observed age | #3 |
wonderlic personnel test | #3 |
abstraction verbal memory | #3 |
non500 | #3 |
sud offspring | #3 |
npl scores | #3 |
anxiety disorders parents | #3 |
substance disorders adhd | #3 |
bipolar psychoses | #3 |
comt promoter | #3 |
adhd data | #3 |
subjects sud | #3 |
model adhd | #3 |
probands parental | #3 |
excess transmission | #3 |
teacher reports | #3 |
7 repeat | #3 |
faraone reply | #3 |
morbidity risk | #3 |
md females | #3 |
disorder comorbid | #3 |
common disorders brain | #3 |
508e7 | #3 |
psychopathologic conditions | #3 |
alcohol adhd | #3 |
childhood attention‐deficit | #3 |
schizoaffective bipolar disorder | #3 |
adhd stimulant medication | #3 |
zakzanis | #3 |
checklist cbcl | #3 |
nmu prescription stimulants | #3 |
cigarette smoking children | #3 |
sud children | #3 |
youths ocd | #3 |
educational deficits | #3 |
cbcl scales | #3 |
girls attention | #3 |
nervous stimulants | #3 |
control probands relatives | #3 |
persistence psychiatric disorders | #3 |
comorbidities adhd | #3 |
n5827 | #3 |
parental substance disorders | #3 |
oprm1 variants | #3 |
children adhd diagnosis | #3 |
adolescent outcome | #4 |
disorders neuropsychological | #4 |
receiver operator characteristic | #4 |
familial vulnerability | #4 |
adhd association | #4 |
lifetime dimensions | #4 |
odd adhd | #4 |
adhd adulthood | #4 |
adhd pharmacotherapy | #4 |
motor coordination problems | #4 |
phenotypes adhd | #4 |
adhd participants | #4 |
bipolar disorder linkage | #4 |
suds adolescents | #4 |
growing literature | #4 |
rels | #4 |
relatives controls | #4 |
coordination problems | #4 |
child behavior checklist | #4 |
subsequent substance disorders | #4 |
quantitative phenotype | #4 |
adhd symptom | #4 |
developmental improvement | #4 |
anxiety disorders offspring | #4 |
rutter | #4 |
genetic heterogeneity schizophrenia | #4 |
increased neural responses | #4 |
adhd control children | #4 |
adhd reported | #4 |
attention adhd | #4 |
maoa | #4 |
treatment adhd | #4 |
metaanalyzes | #4 |
hemmings | #4 |
primary substance abuse | #4 |
deficits executive functioning | #4 |
pediatric mania | #4 |
preterm sample | #4 |
strattera | #4 |
parental panic | #4 |
gender children | #4 |
adhd children mph | #4 |
md individuals | #4 |
boys higher prevalence | #4 |
sd133 | #4 |
factors substance | #4 |
report scale | #4 |
rs3916968 | #4 |
comorbid attention | #4 |
adhd md | #4 |
bpd sud bpd | #4 |
disorders comorbidity | #4 |
enrichment adhd | #4 |
homogeneous subtypes | #4 |
risk factors adhd | #4 |
adhd youth | #4 |
enigmaadhd | #4 |
risk gene schizophrenia | #4 |
neuropsychoanalytic | #4 |
rs3916971 | #4 |
adolescent years | #4 |
expected height | #4 |
schizophrenia genetic factors | #4 |
substance disorders suds | #4 |
psc35 | #4 |
presence adhd | #4 |
choice adhd | #4 |
mts growth | #4 |
fmri replication | #4 |
transporter genotypes | #4 |
psychiatric gene discoveries | #4 |
humans lisdexamfetamine | #4 |
adhd substance abuse | #4 |
disease genome humans | #4 |
controls basal ganglia | #4 |
chinese sample | #4 |
anxiety disorders mdd | #4 |
families girls | #4 |
differences adults | #4 |
adhd etiology | #4 |
psychiatric comorbidity risk | #4 |
image sample | #4 |
angerirritability | #4 |
secondary psychotic symptoms | #4 |
female probands relatives | #4 |
onset adhd | #4 |
reward dysfunction | #4 |
comorbidity humans | #4 |
safren | #4 |
rutters indicators | #4 |
nonoral routes administration | #4 |
pavgrnk000417 | #4 |
relatives normal controls | #4 |
roh risk | #4 |
offspring sud | #4 |
gxr adhd | #4 |
treatment stimulant medication | #4 |
psychiatrically referred | #4 |
treatment adult adhd | #4 |
reported findings | #4 |
adhd pdd | #4 |
adhd controls | #4 |
tests psychiatric | #4 |
cbclaps | #4 |
objective studies | #4 |
notch4 locus | #4 |
acting formulations | #4 |
adderall methylphenidate | #4 |
disorders panic | #4 |
jbd | #4 |
disorder objective | #4 |
openlabel studies | #4 |
lgi age | #4 |
rates psychiatric | #4 |
functioning adhd | #4 |
distinct disorder | #4 |
time reproduction | #4 |
psychiatrically referred youth | #4 |
d4s2361 | #4 |
rs140700 | #4 |
cbcl | #4 |
adhd neuropsychological performance | #4 |
vcfs sample | #4 |
health female | #4 |
selenbp1 schizophrenia | #4 |
adhd pharmacogenetic studies | #4 |
neuropsychological performance schizophrenia | #4 |
vulnerability schizophrenia | #4 |
independent transmission | #4 |
impaired intellect | #4 |
maternal smoking alcohol | #4 |
46222 | #4 |
stimulantnaïve | #4 |
reported adhd | #4 |
hypescheme | #4 |
vcfs adhd | #4 |
depression parental depression | #4 |
subthreshold | #4 |
snps intelligence | #4 |
adhd impairments | #4 |
subjects schizotaxia | #4 |
behavior checklist | #4 |
rate switching | #4 |
psud | #4 |
comorbid psychiatric | #4 |
risk factors bpd | #4 |
findings risk | #4 |
4th international meeting | #4 |
remittent adhd | #4 |
shr ncrl | #4 |
comorbid aggression adhd | #4 |
rs1079727 | #4 |
adhd based | #4 |
metadoxine placebo | #4 |
adults | #4 |
global neuroscience | #4 |
adhd subgroups | #4 |
inhibition anxiety | #4 |
height deficits | #4 |
aggregation adhd | #4 |
mhlod | #4 |
disorders attention | #4 |
asd mood disorders | #4 |
poor motor performance | #4 |
support mechanism | #4 |
executive function deficits | #4 |
cbcljbd phenotype | #4 |
panic disorder pregnancy | #4 |
scores adhd | #4 |
4year followup | #4 |
handedness schizotypy | #4 |
quantitative models | #4 |
rs3785143 | #4 |
17q111q12 | #4 |
achievement goal orientation | #4 |
addictive drug | #4 |
bpd sud patients | #4 |
adhd individuals | #4 |
d4s1644 | #4 |
adhd status | #4 |
adhd brain regions | #4 |
parents bpd | #4 |
inattentive adhd | #4 |
sud bpd sud | #4 |
treatment seeking patients | #4 |
total score week | #4 |
pord05 | #4 |
intelligence snps | #4 |
risk variants adhd | #4 |
children comorbid adhd | #4 |
snpbased | #4 |
genetic linkage schizophrenia | #5 |
severe scores | #5 |
xr adults | #5 |
cbcl data | #5 |
familial distribution | #5 |
adhd treated | #5 |
psychosis scale | #5 |
conventional medications | #5 |
etiopathologies | #5 |
risk relatives | #5 |
pdmd | #5 |
youth vcfs | #5 |
large collaborative study | #5 |
bipolar disorder pedigrees | #5 |
function adhd | #5 |
disorder rating | #5 |
interview psychological | #5 |
serum neuroleptic | #5 |
methylphenidate adults | #5 |
puwma | #5 |
referred youths | #5 |
bipolar disorder bpd | #5 |
desistent | #5 |
torture review | #5 |
hyperactivity clinical trials | #5 |
mothers anxiety disorders | #5 |
psychiatric correlates | #5 |
3 probands | #5 |
year prospective | #5 |
growth dysregulation | #5 |
adhd tic disorders | #5 |
panic disorder parents | #5 |
nt5dc1 | #5 |
ncrl rats | #5 |
adhd response | #5 |
ppp3cc schizophrenia | #5 |
sex adhd | #5 |
kiddieschedule | #5 |
adhd ld | #5 |
behavioral inhibition children | #5 |
rs1799836 | #5 |
psychosis velocardiofacial syndrome | #5 |
social disability | #5 |
adhd nonaffected siblings | #5 |
zmynd17 | #5 |
d22s683 | #5 |
neuropsychiatric comorbidity | #5 |
schizophrenia palau | #5 |
resilience project | #5 |
prembr | #5 |
disorders follow | #5 |
intellectually capable adults | #5 |
children dbds | #5 |
referred sample | #5 |
dopamine risk | #5 |
2nd cohort | #5 |
oosterlaan | #5 |
female individuals | #5 |
cardinal symptom | #5 |
adhd comorbid anxiety | #5 |
unipolar mdd | #5 |
combined subtype | #5 |
relatives female probands | #5 |
neuropsychological risk | #5 |
adhd cases | #5 |
psychiatric disorders study | #5 |
proband risk | #5 |
sud | #5 |
hechtman | #5 |
disorder sud | #5 |
desipramine placebo | #5 |
screener | #5 |
lifetime impact | #5 |
highly heritable | #5 |
symptoms hyperactivity | #5 |
checklist child | #5 |
onset criterion | #5 |
sms intervention | #5 |
organization adult | #5 |
inattentive symptoms | #5 |
adhdlike symptoms | #5 |
inhibited children | #5 |
wcst scores | #5 |
parental adhd | #5 |
humans interview | #5 |
criteria schizotaxia | #5 |
risk anxiety | #5 |
maternal reports | #5 |
height weight | #5 |
adolescence adhd | #5 |
report screening | #5 |
adult attention | #5 |
asrs screener | #5 |
adhd inattentive type | #5 |
major depression parents | #5 |
auditory vigilance | #5 |
mania adhd | #5 |
pdd subjects | #5 |
pathways association | #5 |
aagc | #5 |
disorders psychiatric | #5 |
ascertainment source | #5 |
children ldx | #5 |
shared haplotypes | #5 |
impairment survey | #5 |
clinical obesity | #5 |
kuntsi | #5 |
elevated rates | #5 |
adult probands | #5 |
child child behavior | #5 |
adhd adult | #5 |
disorder parents | #5 |
effects adhd | #5 |
palauan | #5 |
familial subtypes | #5 |
anxiety disorders anx | #5 |
disorder genetic | #5 |
iiv adhd | #5 |
multivariate endophenotypes | #5 |
adhd bupropion | #5 |
diagnosis mania | #5 |
familial risk adhd | #5 |
comorbid disorders | #5 |
3q13 | #5 |
nonaffected siblings | #5 |
study genetic factors | #5 |
adults adult | #5 |
parents psychiatric | #5 |
disorder anxiety | #5 |
impaired parents humans | #5 |
adolescent alleles | #5 |
nonmedical nmu | #5 |
scale adhd | #5 |
grubb | #5 |
risk factors schizophrenia | #5 |
dsm age | #5 |
memantine hydrochloride | #5 |
initial responsiveness | #5 |
impairment baseline | #5 |
hyperactivity caregivers | #5 |
pleiotropic effects disorders | #5 |
parental sud | #5 |
mood disorders asd | #5 |
oppositional defiant disorder | #5 |
depression panic disorder | #5 |
boys attention | #5 |
tass | #5 |
referred children | #5 |
adhd youths | #5 |
literature efficacy | #6 |
differences cortical thickness | #6 |
premorbid cognitive ability | #6 |
adhd mental retardation | #6 |
maniclike symptoms | #6 |
schizophrenic probands | #6 |
fspd | #6 |
combined subtypes | #6 |
specific predictor | #6 |
adhd variability | #6 |
parental major depression | #6 |
symptoms disorder | #6 |
pediatric bipolar | #6 |
nhe inhibitors | #6 |
driving simulation | #6 |
groups adults | #6 |
males adhd | #6 |
adhd firstdegree relatives | #6 |
taan | #6 |
irmph | #6 |
oppositional defiant | #6 |
referred children adolescents | #6 |
pseudocontrols | #6 |
life adults | #6 |
females adhd | #6 |
environmental adversity | #6 |
adhd children adults | #6 |
risk attention | #6 |
p1e04 | #6 |
followup studies | #6 |
hyperactivity child chromosomes | #6 |
t518 | #6 |
nonparanoid schizophrenia | #6 |
psychiatric disorders prss | #6 |
individual alleles | #6 |
genome‐wide | #6 |
schizophrenia spectrum schizophrenia | #6 |
criteria adhd | #6 |
adhd genetic factors | #6 |
benefitrisk ratio | #6 |
risk sud | #6 |
relatives probands | #6 |
paternal age schizophrenia | #6 |
total gray matter | #6 |
familial loadings | #6 |
bpdsud | #6 |
unfamiliar situations | #6 |
bpd comorbid | #6 |
pediatric bpd | #6 |
large heterogeneous | #6 |
schizophrenia g72 | #6 |
enigma wgs | #6 |
bpd controls | #6 |
psychiatric | #6 |
disorders adolescent | #6 |
seidman | #6 |
xp114p113 | #6 |
clinical scales | #6 |
disorder combined | #6 |
downward extension | #6 |
adults disorder | #6 |
wm performance patients | #6 |
stimulant prescription | #6 |
tmcq | #6 |
t515 | #6 |
nmu | #6 |
placebo response response | #6 |
children relatives | #6 |
adhd women | #6 |
pavgrnk | #6 |
anxiety disorder relatives | #6 |
ppp3cb | #6 |
stimulant treatment children | #6 |
hyperactivity disease models | #6 |
dnajc9 | #6 |
liability schizophrenia | #6 |
interpreting estimates | #6 |
teenage parenthood | #6 |
parents major | #6 |
value09 | #6 |
vulnerability indicator | #6 |
association studies schizophrenia | #6 |
prevalence adult adhd | #6 |
cpg sites methylation | #6 |
140 children | #6 |
year recall | #6 |
dsm iii | #6 |
chromosome 15 locus | #6 |
adhd mood disorders | #6 |
hierarchical factor model | #6 |
adhd compared | #6 |
psychoactive substance | #6 |
schizophrenia premorbid | #6 |
child delayed | #6 |
druggable genome | #6 |
cbcljbd | #6 |
gxr efficacy | #6 |
dopamine transporter gene | #6 |
referred adults | #6 |
ascertained | #6 |
cognition adults | #6 |
scales psychometrics | #6 |
adhd increased risk | #6 |
depression panic | #6 |
clinical features children | #6 |
male odds | #6 |
mixed amphetamine | #6 |
adhd tic | #6 |
disorders relatives | #6 |
genetic child | #6 |
facial memory | #6 |
4634 | #6 |
adhdia | #6 |
neuropsychological functioning | #6 |
pediatric mood disorders | #6 |
combined condition | #6 |
behavioral inhibition | #6 |
prior stimulant treatment | #6 |
symptoms adhd | #6 |
normal sexual dimorphism | #6 |
objective marker | #6 |
loci autism | #6 |
niacin schizophrenia | #6 |
altered neural connectivity | #6 |
concurrent validation | #6 |
genetic linkage genome | #6 |
oceanic palau | #6 |
adhd life | #6 |
psychopathology children | #6 |
schizophrenia deficit | #6 |
cognitive impairments adhd | #6 |
neuroleptic activity | #6 |
pdag mdd | #7 |
velo‐cardio‐facial | #7 |
boys adhd | #7 |
swedish registry data | #7 |
kgas | #7 |
adhd symptoms association | #7 |
dimensional measures | #7 |
ancestry attention | #7 |
flush response | #7 |
systematic chart review | #7 |
highrisk siblings | #7 |
studies dopamine | #7 |
ldx treatment | #7 |
children bpd | #7 |
coming years | #7 |
pmee | #7 |
children tourettes syndrome | #7 |
childhood disorder | #7 |
controls probands | #7 |
attention task | #7 |
snap25 adhd | #7 |
adhd improvement | #7 |
conduct disorder girls | #7 |
pdqr | #7 |
asd asd youth | #7 |
adhd criteria | #7 |
seeking substance | #7 |
methylomics | #7 |
neurocognitive performances | #7 |
long repeats | #7 |
development adhd | #7 |
idir | #7 |
odd | #7 |
adhd substance disorders | #7 |
drd5 | #7 |
methylphenidate therapy | #7 |
hyperactivity brain | #7 |
polygenic scores adhd | #7 |
asd youth | #7 |
authors goal | #7 |
adhd authors | #7 |
measures adhd | #7 |
adhd asrs | #7 |
combined type adhd | #7 |
adhd persistence | #7 |
adhd boys girls | #7 |
parents prevalence | #7 |
neuroimage study | #7 |
disorders probands | #7 |
parents psychiatric disorders | #7 |
confusability | #7 |
locus haplotypes | #7 |
parent reports | #7 |
members schizophrenia | #7 |
bipolar unipolar disorders | #7 |
myosin5b | #7 |
teachers boys | #7 |
sensorimotor timing | #7 |
hraff | #7 |
genome‐wide association | #7 |
palauans | #7 |
wonderlic | #7 |
markov chain analysis | #7 |
mph adhd | #7 |
nrp104 | #7 |
exon15 | #7 |
adhd symptoms | #7 |
mph adhd adults | #7 |
6 psychiatric disorders | #7 |
adhd sud sud | #7 |
children learning disorders | #7 |
adhdrs | #7 |
qlesqsf | #7 |
pediatric major depression | #7 |
n1031 | #7 |
prevention schizophrenia | #7 |
nmu prescription | #7 |
persistence anxiety disorders | #7 |
exome chip analyses | #7 |
outpatient child | #7 |
spn812 | #7 |
tomoxetine | #7 |
association cdh13 | #7 |
child impaired | #7 |
dependence rates | #7 |
chromosome workshop | #7 |
relatives schizophrenic patients | #7 |
adhdct | #7 |
disorder substance | #7 |
skin flush response | #7 |
implicating | #7 |
nalysis | #7 |
candidate gene schizophrenia | #7 |
relatives risk | #7 |
haplotype schizophrenia | #7 |
statistical measure | #7 |
adhd overweight obesity | #7 |
adhd emotional dysregulation | #7 |
saica | #7 |
mdd pdag | #7 |
volumetric reductions | #8 |
impulsivity adhd | #8 |
adhd adolescence | #8 |
impaired motor performance | #8 |
behavioral inhibition anxiety | #8 |
disorders families | #8 |
adhd boys | #8 |
nonpsychotic | #8 |
male multifactorial inheritance | #8 |
pliszka | #8 |
offspring trios | #8 |
diagnosed adhd | #8 |
pempirical | #8 |
nonverbal social | #8 |
human aggression | #8 |
multigenerational pedigree | #8 |
participants adhd | #8 |
adhd associations | #8 |
presence autistic traits | #8 |
child diagnostic | #8 |
behavior attention | #8 |
avoidant disorder | #8 |
symptoms impairment | #8 |
subjects children | #8 |
rs3916966 | #8 |
childhood mania | #8 |
notch4 | #8 |
adhd manic symptoms | #8 |
autistic traits children | #8 |
behavioral inhibition risk | #8 |
ordered subsets | #8 |
adhd symptom scores | #8 |
metaanalysis schizophrenia | #8 |
affairs cooperative | #8 |
adhdcd | #8 |
adhd stimulant | #8 |
analysis association | #8 |
substantial evidence | #8 |
probands risk | #8 |
cadhd | #8 |
mwq | #8 |
controls relatives | #8 |
crossover comparison | #8 |
onset bpd | #8 |
attention deficit adhd | #8 |
disorder probands | #8 |
n1314 | #8 |
adhd inattentive | #8 |
gender effects | #8 |
mph adults | #8 |
symptoms behaviors | #8 |
dimesylate ldx | #8 |
rs3916965 | #8 |
euphoria | #8 |
differential utility | #8 |
adhd rtv | #8 |
prescription stimulant | #8 |
hemideletion | #8 |
schizophrenia polymorphisms | #8 |
disease humans polymorphism | #8 |
shared familial effects | #8 |
polygenic associations | #8 |
control adhd | #8 |
bpd disorders | #8 |
10q223 | #8 |
sample youth | #8 |
chromosome schizophrenia | #8 |
unaffected siblings adhd | #8 |
aversion adhd | #8 |
treatment sirolimus | #8 |
therapeutic dilemmas | #8 |
negative symptoms scale | #8 |
studies provide | #8 |
adhd remission | #8 |
familybased association study | #8 |
psychiatric genomics | #8 |
adhd unaffected | #8 |
link adhd | #8 |
treatment lead | #8 |
disorders baseline | #8 |
attention | #8 |
biederman | #8 |
schizophrenia members | #8 |
indicators schizophrenia | #8 |
pvalues005 | #8 |
abbreviated questionnaire | #8 |
agreement measures | #8 |
stimulanttreated | #8 |
biological relatives | #8 |
promising directions | #8 |
familial aggregation adhd | #8 |
adhdhi | #8 |
adhd dat1 | #8 |
diagnosis major depression | #8 |
gwas psychiatric disorders | #9 |
nonparanoids | #9 |
rasd2 | #9 |
deficit disruptive | #9 |
serotonin genes | #9 |
hyperactivity automobile | #9 |
stimulant medication | #9 |
addh | #9 |
adhd loci | #9 |
blindly | #9 |
disorders sex interaction | #9 |
taiwanese families | #9 |
sud bipolar disorder | #9 |
haplotype snps | #9 |
25e07 | #9 |
sustained attention schizophrenia | #9 |
schizophrenia resilience | #9 |
adult report | #9 |
hum genet | #9 |
adhd article | #9 |
endophenotypic | #9 |
g×s interaction disorders | #9 |
schizotaxic | #9 |
ecpbhs | #9 |
netherlands twin registry | #9 |
genes risk factors | #9 |
ldps | #9 |
diagnostic efficiency | #9 |
nonreplications | #9 |
hyperactivity humans | #9 |
rs685012 | #9 |
etiologically | #9 |
adhd enuresis | #9 |
substantial risk | #9 |
39 datasets | #9 |
adhd healthy | #9 |
male nuclear | #9 |
dao gene | #9 |
alzheimer disease schizophrenia | #9 |
extendedrelease methylphenidate | #9 |
comorbidity female | #9 |
disruptive behavior disorders | #9 |
snp7 | #9 |
adhdi | #9 |
lag sequential analysis | #9 |
ads individuals | #9 |
nuremberg code | #9 |
moderate sensitivity | #9 |
inattentive | #9 |
neuropsychologic function | #9 |
hhrr | #9 |
proband groups | #9 |
depression offspring | #9 |
subtypes adhd | #9 |
mdd youth | #9 |
comparison girls | #9 |
serotonin gene polymorphisms | #9 |
adult symptoms | #9 |
childhood psychosis | #9 |
children assessed | #9 |
festschrift | #9 |
n41 | #9 |
symptoms mania | #9 |
orosmph irmph | #9 |
adderall | #9 |
aisrs | #9 |
rpdr | #9 |
pregnancy depression | #9 |
childhood adhd symptoms | #10 |
young adult outcome | #10 |
adulthood association | #10 |
slod | #10 |
adhd sud | #10 |
drd4 | #10 |
kruglyak | #10 |
severity adhd | #10 |
adult years | #10 |
systematic qualitative review | #10 |
preteen | #10 |
psychiatric clinic | #10 |
deficits adhd | #10 |
small effects | #10 |
comorbidity | #10 |
genes disorders | #10 |
adhd unaffected siblings | #10 |
aged attention | #10 |
panic depression | #10 |
4th | #10 |
untreated adhd | #10 |
comorbid odd | #10 |
diminished risk | #10 |
genetic vulnerability schizophrenia | #10 |
ascertainment methods | #10 |
adhd difficulties | #10 |
rorb | #10 |
adhd substance disorder | #10 |
genetics network | #10 |
reassessed | #10 |
stimulants child | #10 |
noninhibited | #10 |
comorbidity depressive | #10 |
comorbid bpd | #10 |
irmph orosmph | #10 |
caadid | #10 |
asd tourette syndrome | #10 |
psychiatric genetic studies | #10 |
image project | #10 |
case identification | #10 |
linkage analyses | #10 |
risk md | #10 |
dms1 | #10 |
sexual dimorphisms | #10 |
probands bpd | #10 |
amphetamine salts | #10 |
cbclap | #10 |
conduct disorder | #10 |
parent‐of‐origin effects | #10 |
stimulants humans | #10 |
preschool depressive | #10 |
gwas adhd | #10 |
association death | #10 |
groups boys | #10 |
adhd childhood | #10 |
d4 receptor gene | #10 |
association dat1 | #10 |
rates abuse | #10 |
nonpharmacologic treatments | #10 |
new specialty | #10 |
evidence genetic | #10 |
pthreshold | #10 |
normal sexual | #10 |
disorder age | #10 |
adhd quality | #10 |
anxiety disorders children | #10 |
shared neurobiology | #10 |
sleep problems adhd | #10 |
nephews | #10 |
bipolar disorder probands | #10 |
neuropsychological test scores | #11 |
shr model | #11 |
etiology pathophysiology | #11 |
fbatpc | #11 |
ppp3cc | #11 |
serotonin genetic receptor | #11 |
offspring bipolar parents | #11 |
children addh | #11 |
studies mtbi | #11 |
growth delays | #11 |
remission adhd | #11 |
disorders | #11 |
adhd intellectual disability | #11 |
n136 | #11 |
release methylphenidate | #11 |
adhd substance | #11 |
effects genes | #11 |
disorders mothers | #11 |
pediatric bipolar disorder | #11 |
hydrochloride attention | #11 |
defiant disorder | #11 |
rora rorb | #11 |
shared familial | #11 |
panic disorder comorbidity | #11 |
sample adults | #11 |
deficits schizophrenia patients | #11 |
dimesylate | #11 |
real progress | #11 |
achievement adolescent | #11 |
cutraits | #11 |
study perspective | #11 |
attention deficit disorder | #11 |
dopamine d5 receptors | #11 |
adolescents adhd | #11 |
polymorphism 5 | #11 |
informativeness | #11 |
hyperactivity child cross | #11 |
multiple domains | #11 |
4372 | #11 |
adhd time | #11 |
juvenile mania | #11 |
nosologists | #11 |
disorder pedigrees | #11 |
inhibition adhd | #11 |
adult relatives | #11 |
female relatives | #11 |
diagnosis adults | #11 |
adhd psychopathology | #11 |
gene adhd | #11 |
paternal smoking | #11 |
ldx placebo | #11 |
inattentive type | #11 |
adhd onset | #11 |
rs1137070 | #11 |
psychiatric disorders youth | #11 |
differentiated genetic | #11 |
differences parents | #11 |
youth bpd | #11 |
vcfs | #11 |
nonadhd controls | #11 |
markers adhd | #11 |
major depression adhd | #11 |
comorbidity patterns | #11 |
maternal antenatal anxiety | #11 |
symptom subtype | #11 |
differences adhd | #11 |
lisdexamfetamine ldx | #11 |
disease humans schizophrenia | #11 |
children bipolar | #11 |
familybased association test | #11 |
cardinal symptoms | #11 |
prodromal psychosis | #11 |
agoraphobia anxiety | #11 |
preschool depressive disorder | #11 |
adhd female humans | #11 |
probands siblings | #12 |
variable age | #12 |
psychotic behavior | #12 |
comorbidity diagnostic | #12 |
dat1 polymorphism | #12 |
adhd symptoms adults | #12 |
salts extended | #12 |
defiant | #12 |
sud adhd | #12 |
assessment adhd | #12 |
genes methylation | #12 |
psychotic mood disorders | #12 |
multiplex schizophrenia | #12 |
cbcl children | #12 |
adhd dopamine | #12 |
epilepsy mothers | #12 |
convergent functional | #12 |
onelevel | #12 |
striatal sensitivity | #12 |
functional impairments | #12 |
pleiotropic mechanisms | #12 |
test wcst | #12 |
adhd offspring | #12 |
stimulant medication children | #12 |
rs947267 | #12 |
treatment attention | #12 |
sec23ip | #12 |
obesity adhd | #12 |
neurocognitive measures | #12 |
sample consisted | #12 |
symptom rating | #12 |
unaffected siblings individuals | #12 |
kappa coefficients | #12 |
hawi | #12 |
impulsivity children | #12 |
youths bpd | #12 |
impaired parents child | #12 |
studies relatives | #12 |
psychiatric clinics | #12 |
effects time | #12 |
psychiatric genetics | #12 |
common disorders | #12 |
amfetamine | #12 |
sexually dimorphic effects | #12 |
adhd core symptoms | #12 |
girls relationship | #12 |
adolescent adult age | #12 |
sud patients adhd | #12 |
adult outcome | #12 |
ksadse | #12 |
juvenile bipolar | #12 |
twins humans models | #12 |
metan | #12 |
unaffected sibs | #12 |
rs778293 | #12 |
adhd age | #12 |
response atomoxetine | #12 |
nonoral | #12 |
thalamic activation | #12 |
perceived motor competence | #12 |
deficits attention | #12 |
n1397 | #12 |
40–48 | #12 |
cnvs risk | #12 |
nhe9 | #12 |
treatment paliperidone | #12 |
common psychiatric | #12 |
covid19 restrictions children | #12 |
lossavoidance | #12 |
scales treatment | #12 |
obesity risk alleles | #12 |
comorbid disorder | #12 |
disorder adult | #12 |
disorder subjects | #12 |
impaired parents | #12 |
digital treatment | #12 |
systematized | #12 |
early psychosis study | #12 |
overanxious | #13 |
transdermal methylphenidate | #13 |
bpd offspring | #13 |
ravg | #13 |
taiwanese sample | #13 |
genomewide significance | #13 |
robust effects | #13 |
response inhibition adolescents | #13 |
symptoms attention | #13 |
colorado springs | #13 |
longallele | #13 |
adhd cognitive | #13 |
adverseevents | #13 |
methods subjects | #13 |
humans methylphenidate | #13 |
adderall mph | #13 |
adhd alterations | #13 |
cognitive impulsivity | #13 |
iiv | #13 |
specific hypotheses | #13 |
rates comorbidity | #13 |
psychiatric risk | #13 |
chi12 | #13 |
pkcm | #13 |
velocardiofacial syndrome vcfs | #13 |
disorders child | #13 |
adhd alcohol | #13 |
adhd diagnosis | #13 |
male samples | #13 |
environment adolescent | #13 |
persistence remission | #13 |
diagnostic threshold | #13 |
risk mood | #13 |
permutation testing | #13 |
morbidity risks | #13 |
disorder youth | #13 |
risk parents | #13 |
adhdodd | #13 |
psychotic mood | #13 |
114 years | #13 |
girls | #13 |
late onset | #13 |
studies bipolar | #13 |
label studies | #13 |
scale studies | #13 |
psychometric measure | #13 |
disorder childhood | #13 |
psychometrics reproducibility | #13 |
necrotic death | #13 |
convergent functional genomics | #13 |
weight bmi | #13 |
diagnostic concepts | #13 |
pair 6 chromosomes | #13 |
disorders sud | #13 |
familial risk schizophrenia | #13 |
nonoral routes | #13 |
wraadds | #14 |
worldwide prevalence | #14 |
genetic studies schizophrenia | #14 |
economic psychology | #14 |
factors schizophrenia | #14 |
nimh genetics | #14 |
emotional impulsivity | #14 |
cnvs park2 | #14 |
studies adults | #14 |
cautiously | #14 |
older adults adhd | #14 |
children bipolar disorder | #14 |
n643 | #14 |
early precursors | #14 |
attention executive | #14 |
relatives male probands | #14 |
genes schizophrenia | #14 |
comorbid condition | #14 |
aadhd | #14 |
siblings cases | #14 |
prss mdd | #14 |
diagnosis mdd | #14 |
geschwind | #14 |
subcortical brain volume | #14 |
stimulant abuse | #14 |
adhd brain | #14 |
associations adhd | #14 |
sud patients | #14 |
selfcontained | #14 |
mixed amphetamine salts | #14 |
mph adderall | #14 |
unaffected siblings controls | #14 |
disorders comorbid | #14 |
lphn3 adhd | #14 |
social school | #14 |
familial disorder | #14 |
adhd phenotype | #14 |
bipolar probands | #14 |
common disorder | #14 |
suds | #14 |
hillside | #14 |
symptoms psychiatric disorders | #14 |
disorder child | #14 |
ocd scz | #14 |
lisdexamfetamine dimesylate ldx | #14 |
quetiapine bipolar disorder | #14 |
children criteria | #14 |
teachers reports | #14 |
disorder odd | #14 |
differential heritability | #14 |
children stimulants | #14 |
siblings probands | #14 |
adhd symptoms adulthood | #14 |
risk substance | #15 |
adhd study | #15 |
executive function theory | #15 |
49 children | #15 |
disorder evidence | #15 |
prodromal symptoms psychosis | #15 |
seconddegree relatives | #15 |
symptoms adulthood | #15 |
ocd comorbid adhd | #15 |
nhsd | #15 |
mphmlr | #15 |
chi2 | #15 |
adhd functional connectivity | #15 |
persons schizophrenia | #15 |
study design features | #15 |
male mood | #15 |
zranb2 | #15 |
schizophrenia families | #15 |
cbclpbd | #15 |
agents attention | #15 |
rs2652511 | #15 |
gxr children | #15 |
healthy comparison subjects | #15 |
psychiatric interviews | #15 |
bipolar schizoaffective disorder | #15 |
4669 | #15 |
adhd diagnostic | #15 |
velocardiofacial | #15 |
disord | #15 |
methylation gene expression | #15 |
asd mdd | #15 |
adults substance disorders | #15 |
treatment xr | #15 |
daily living administration | #15 |
sackett | #15 |
metabolic syndrome obesity | #15 |
symptom count | #15 |
diagnostic interviews | #15 |
substance disorder patients | #15 |
wfirsp | #15 |
tests psychomotor | #15 |
paediatric bipolar disorder | #15 |
adhd treatment | #15 |
interaction genotype | #15 |
pregnancy risk factor | #15 |
behavior disorders | #15 |
d10s1423 | #15 |
male relatives | #15 |
snps methylation | #15 |
adhd performance | #15 |
association schizophrenia | #15 |
card sorting | #15 |
adhd disorders | #15 |
genderdifferences | #15 |
poor perception | #15 |
adhd anxiety symptoms | #16 |
familial relationship | #16 |
linkage findings | #16 |
n424 | #16 |
youths adhd | #16 |
control participants participants | #16 |
adhd symptom severity | #16 |
pervasive developmental disorder | #16 |
informant assessment | #16 |
special classes | #16 |
drug disorder | #16 |
ntac | #16 |
onset anticipation | #16 |
geneenvironment interaction | #16 |
hyperkinetic disorders | #16 |
multiple test | #16 |
parents anxiety disorders | #16 |
dexedrine | #16 |
dbds | #16 |
adhd diagnoses | #16 |
risk psychotic disorders | #16 |
adhd obesity | #16 |
“difficulty | #16 |
growth children | #16 |
factual factor analysis | #16 |
scz risk | #16 |
longitudinal assessments | #16 |
brainbody | #16 |
cprsr | #16 |
regional cortical thickness | #16 |
delayed action | #16 |
rdoc framework | #16 |
rbfox1 | #17 |
depression md | #17 |
relation adhd | #17 |
young offspring | #17 |
nonparametric linkage | #17 |
factors siblings | #17 |
prevalence adhd | #17 |
ocd age | #17 |
pediatric disorder | #17 |
schizophrenia psychosis | #17 |
accn2 | #17 |
hyperactivity attitude | #17 |
resultsfirst | #17 |
asd ocd | #17 |
studies psychiatric | #17 |
association markers | #17 |
assessment positive symptoms | #17 |
medication type | #17 |
diagnostic statistical | #17 |
a161t | #17 |
pediatric samples | #17 |
study adhd | #17 |
childhood predictors | #17 |
neuropsychiatric evaluation | #17 |
larger sample | #17 |
persistent adhd | #17 |
samples children | #17 |
multiple anxiety disorders | #17 |
bipolar disorder subjects | #17 |
condfdr | #17 |
psychology schizotypal | #17 |
disability adhd | #17 |
combined type | #17 |
mania | #17 |
5071 | #17 |
random forest regression | #17 |
prospective follow | #17 |
driving behaviors | #17 |
substance disorders sud | #17 |
ldx children | #17 |
association scan | #17 |
adulthood adhd | #17 |
parents adhd | #17 |
method participants | #17 |
considerable overlap | #17 |
response inhibition network | #17 |
children vcfs | #18 |
meet criteria | #18 |
kcnj4 | #18 |
anxiety mdd | #18 |
linkage regions | #18 |
psuds | #18 |
preschool diagnostic | #18 |
fullsiblings | #18 |
unemotionality | #18 |
adhd cannabis | #18 |
transporter gene | #18 |
bipolar major | #18 |
4286 | #18 |
potential contributor | #18 |
single nucleotide severity | #18 |
conduct disorder children | #18 |
schizophrenia dtnbp1 | #18 |
adhd sud patients | #18 |
bipolar choice trial | #18 |
adhd groups | #18 |
hrr 95 | #18 |
marijuana age | #18 |
depression genetic risk | #18 |
schizophrenia patients relatives | #18 |
poor tolerability | #18 |
lisdexamfetamine dimesylate | #18 |
primary substance | #18 |
low dose naltrexone | #18 |
illness twins | #18 |
risk disorders | #18 |
relatives control subjects | #18 |
neuropsychologic | #18 |
childhood traumas | #18 |
symptom overlap | #18 |
minisatellite repeats | #18 |
adhd severity | #18 |
stimulant | #18 |
prolonged therapy | #18 |
unaffected siblings | #18 |
operationalized | #18 |
dcdq | #18 |
behavior scale | #18 |
rs3918342 | #19 |
adolescent age | #19 |
casecontrol sample | #19 |
disorders adults | #19 |
adhd neurodevelopmental | #19 |
disconfirmations | #19 |
lod1 | #19 |
adhd young adults | #19 |
assessing outcome | #19 |
comorbidity rates | #19 |
mental health human | #19 |
adolescent age onset | #19 |
hyperconnectivity | #19 |
verbal memory task | #19 |
nature nurture | #19 |
medication trials | #19 |
scz ocd | #19 |
mcgue | #19 |
psychosocial features | #19 |
symptoms adolescent | #19 |
candidate loci | #19 |
euphoric effects | #19 |
familial transmission | #19 |
addicted patients | #19 |
improvement symptoms | #19 |
substance adhd | #19 |
action preparations | #19 |
deficits children | #20 |
neuropsychologically | #20 |
dicap | #20 |
manual mental | #20 |
mflynn | #20 |
neuroleptic dose | #20 |
biological families | #20 |
rbfox1 gene | #20 |
inhibition children | #20 |
illness female humans | #20 |
pedigree selection | #20 |
depression adhd | #20 |
parent origin | #20 |
controlled pilot study | #20 |
neuropsychological function | #20 |
schizophrenia attention | #20 |
ratings adhd | #20 |
response curve | #20 |
kiddie | #20 |
humanhap550v3 | #20 |
outcome attention | #20 |
human ortholog | #20 |
linkage scans | #20 |
parents risk | #20 |
sibpair | #20 |
disorders polymorphism | #20 |
slc6a2 | #20 |
nonpsychotic siblings | #20 |
prenatal exposure nicotine | #20 |
notch4 gene | #20 |
transmission ratio distortion | #20 |
adolescent | #20 |
gsma | #20 |
schizophrenia taiwan | #21 |
monoamine oxidase maoa | #21 |
schizophrenia disease humans | #21 |
treatment growth | #21 |
gender comparisons | #21 |
psychiatric symptoms patients | #21 |
children pdd | #21 |
bipolar pedigrees | #21 |
palau | #21 |
chronic tics | #21 |
genehunterplus | #21 |
cacng2 | #21 |
childhood conduct disorder | #21 |
life enjoyment | #21 |
prescription stimulants | #21 |
motor problems | #21 |
rs778294 | #21 |
rat shr | #21 |
male probands | #21 |
agler | #21 |
methods age | #21 |
prospective longitudinal | #21 |
schizotypals | #21 |
prevalent cases | #21 |
children comorbid | #21 |
11year followup | #21 |
sodium hydrogen exchanger | #21 |
schizophrenia united | #21 |
risk offspring | #21 |
comorbid adhd | #21 |
humans linkage | #21 |
prenatal exposure alcohol | #21 |
linkage chromosomes | #21 |
ldx | #22 |
association prs | #22 |
children attention | #22 |
schizophrenia pgc | #22 |
stimulants children | #22 |
adhd impulsivity | #22 |
depression treatment patients | #22 |
polygenic overlap | #22 |
bpd subjects | #22 |
adderall xr | #22 |
syndrome vcfs | #22 |
familiality | #22 |
adhd anxiety | #22 |
genetic phenotype | #22 |
pre‐school | #22 |
neurocognitive performance schizophrenia | #22 |
youth bipolar | #22 |
disruptive | #22 |
10p | #22 |
neuropsychological profiles | #22 |
preliminary reliability | #22 |
adhd rating scale | #22 |
rg022 | #22 |
diagnostic interview | #22 |
study methodology | #22 |
adhd susceptibility | #22 |
amygdala structure | #22 |
adhd stimulants | #22 |
amphetamine methylphenidate | #22 |
controls | #22 |
disorders major | #22 |
niacin skin | #22 |
youth mdd | #22 |
6 disorders | #22 |
partial replication | #22 |
overtransmission | #22 |
male individuals | #23 |
comprehensively | #23 |
handful | #23 |
wechsler scales | #23 |
anxious mothers | #23 |
wide linkage | #23 |
twins genetic predisposition | #23 |
n449 | #23 |
metadoxine | #23 |
syp | #23 |
intrinsic curvature | #23 |
rs464049 | #23 |
executive functions efs | #23 |
asd scq | #23 |
risk studies | #23 |
diagnostician | #23 |
snapiv | #23 |
adolescents bpd | #23 |
heterogeneity genetic | #23 |
siblings | #23 |
adhd symptoms childhood | #23 |
phenotype definition | #23 |
kotkin | #23 |
scq asd | #23 |
interview dsm | #23 |
serotonin receptor gene | #23 |
oppositional | #23 |
genetic investigation | #23 |
notch4 receptors | #23 |
propylamines | #23 |
neuroleptic withdrawal | #23 |
disequilibrium male | #23 |
mdd anxiety disorders | #23 |
interacting molecules | #23 |
statistical manual | #24 |
refilled | #24 |
conduct problems adhd | #24 |
amrs | #24 |
expected growth | #24 |
children meeting | #24 |
ocd asd | #24 |
adhd comorbidities | #24 |
deficits | #24 |
nieces | #24 |
nonstimulant | #24 |
neural activation patterns | #24 |
age regions | #24 |
aggression anxiety | #24 |
intelligence schizophrenia | #24 |
stroop task performance | #24 |
snorting | #24 |
0535 | #24 |
adra2a | #24 |
chromosomes 6 | #24 |
receptor d4 | #24 |
mental control | #24 |
adhd characteristics | #24 |
actigraphy studies | #24 |
stress exposure | #24 |
quantitative phenotypes | #24 |
child female humans | #24 |
lithium bipolar disorder | #24 |
genome‐wide linkage scans | #24 |
female humans illness | #24 |
guanfacine extended release | #24 |
dsmiiir criteria | #24 |
symptoms psychosis | #24 |
sassr | #24 |
15q13 | #24 |
–environment interactions | #25 |
psychiatric disorders children | #25 |
clinical interviews | #25 |
d22s283 | #25 |
dapple | #25 |
exposure adhd | #25 |
splicing regulator | #25 |
decreased volume | #25 |
task patients | #25 |
understanding adhd | #25 |
bipolar choice | #25 |
unique profile | #25 |
anticipation schizophrenia | #25 |
screening scale | #25 |
behavioral disinhibition | #25 |
young relatives | #25 |
dyscalculia | #25 |
nudt3 | #25 |
psychometrically | #25 |
maternal criticism | #25 |
or194 | #25 |
neurocognitive predictors | #25 |
biased transmission | #25 |
association snps | #25 |
school failure | #25 |
baseline assessment | #25 |
copy variants schizophrenia | #25 |
major affective disorders | #25 |
slc6a3 gene | #25 |
efficacy atomoxetine | #25 |
conners parent | #25 |
wkht | #25 |
symptom subtypes | #25 |
psychiatric nosology | #25 |
vietnam twin registry | #25 |
liker | #25 |
n81 | #26 |
efpc | #26 |
adults symptoms | #26 |
label study | #26 |
voxel based morphometry | #26 |
agreement raters | #26 |
prenatal health | #26 |
neurodevelopmental genes | #26 |
wm microstructure | #26 |
structured interviews | #26 |
core symptoms adhd | #26 |
add | #26 |
major depression md | #26 |
maob gene | #26 |
inrich | #26 |
selfmonitor | #26 |
gender risk | #26 |
nonmedical prescription stimulants | #26 |
screening diagnosis | #26 |
twins humans | #26 |
behavioral disorder | #26 |
bipolar phenotype | #26 |
social impairment | #26 |
controls adhd | #26 |
htr1d | #26 |
rs3730358 | #26 |
adrenergic uptake | #26 |
association allele | #26 |
orosmethylphenidate | #26 |
alcohol drug abuse | #26 |
affair | #26 |
adhd mothers | #26 |
psychometric measures | #26 |
asherson | #27 |
intelligence male | #27 |
d22s278 | #27 |
potential confounds | #27 |
treatment atomoxetine | #27 |
consecutively | #27 |
bipolar disorder comorbidity | #27 |
association signals | #27 |
t102c polymorphism | #27 |
hyperactivity disorder adhd | #27 |
ptsd adults | #27 |
international meeting | #27 |
aff | #27 |
mdd asd | #27 |
osterrieth | #27 |
disorders executive | #27 |
weaker effects | #27 |
rate remission | #27 |
greater severity | #27 |
genetic susceptibility schizophrenia | #27 |
schizophrenia genetic | #27 |
cnvs adhd | #27 |
childreniv | #27 |
offspring risk | #27 |
based association | #27 |
rest task | #28 |
slc6a3 | #28 |
ocd disorders | #28 |
subjects bpd | #28 |
image study | #28 |
child clinical | #28 |
symptoms inattention | #28 |
dopamine transporter binding | #28 |
raters | #28 |
families schizophrenia | #28 |
adults study | #28 |
maternal adhd | #28 |
emotional dysregulation | #28 |
disorder compared | #28 |
genetic etiology | #28 |
cortical gyrification | #28 |
schizophrenia onset | #28 |
persons bipolar disorder | #28 |
symptom reports | #28 |
genomewide studies | #28 |
parent teacher | #28 |
metaalgorithm | #28 |
vigilance performance | #28 |
clinical correlates | #28 |
new genetics | #28 |
snp18 | #28 |
guze | #28 |
sustained attention deficits | #28 |
assessment negative symptoms | #28 |
6179 | #28 |
dopamine receptor d4 | #28 |
male methylphenidate | #28 |
adhd autism | #28 |
adhd differences | #28 |
polysomnography actigraphy | #28 |
preliminary findings | #28 |
offspring parents | #29 |
psychosocial dysfunction | #29 |
childhood antecedents | #29 |
medication usage | #29 |
shared genetic basis | #29 |
dsmiiir | #29 |
bipolar disorder youth | #29 |
misuse diversion | #29 |
inattention hyperactivity impulsivity | #29 |
african‐american | #29 |
infants weight | #29 |
parents bipolar disorder | #29 |
adhd patients controls | #29 |
kcnn3 | #29 |
comorbidity ptsd | #29 |
studies genes | #29 |
disorder bipolar | #29 |
medication misuse | #29 |
disorders offspring | #29 |
childhood diagnosis | #29 |
etiological heterogeneity | #29 |
attention‐deficit | #29 |
hyperactivity impulsivity | #29 |
male polymorphism | #29 |
hyperactive symptoms | #30 |
comorbid | #30 |
treatment adolescents | #30 |
adhd child | #30 |
caarsinv | #30 |
association paternal age | #30 |
diagnosticians | #30 |
relatives age | #30 |
nimh | #30 |
nicotine pregnancy | #30 |
bmi growth | #30 |
parental predictors | #30 |
growth childhood | #30 |
robust statistical methods | #30 |
juvenile bipolar disorder | #30 |
genetic perspective | #30 |
problems attention | #30 |
individual studies | #30 |
structural brain features | #30 |
antisocial behavior asb | #30 |
specific psychopathology | #30 |
nonaffected | #30 |
methylphenidate | #31 |
depression genetic | #31 |
lodscore | #31 |
95 adhd | #31 |
reanalyzed | #31 |
impulsivity inattention | #31 |
bpd risk | #31 |
discriminates | #31 |
prs adhd | #31 |
twin concordance | #31 |
neuroimage | #31 |
charles river | #31 |
neuropsychologic deficits | #31 |
potential endophenotypes | #31 |
extant literature | #31 |
sex effects | #31 |
genotype haplotypes | #31 |
smoking substance | #31 |
rgs4 schizophrenia | #31 |
kif16b | #31 |
n305 | #31 |
nonadhd | #31 |
variable tandem | #31 |
repeat length | #32 |
studies schizophrenia | #32 |
kremen | #32 |
anxiety disorders | #32 |
gender | #32 |
subfields hippocampus | #32 |
70–80 | #32 |
wiscr | #32 |
slc6a4 | #32 |
10p13 | #32 |
psychiatric disorders | #32 |
parents child | #32 |
aggression attention | #32 |
bipolar disorder bpi | #32 |
psychosis youth | #32 |
schizophrenia affective psychosis | #32 |
psdq | #32 |
anterior insular | #32 |
adhd adolescents | #32 |
psychiatric genetic | #32 |
studies adolescent | #32 |
randomized crossover study | #32 |
child psychiatric | #32 |
asd symptoms children | #32 |
attentiondeficit | #32 |
impulsecontrol | #32 |
rs206936 | #32 |
briefa | #33 |
single snps | #33 |
rs1130214 | #33 |
aspd bpd | #33 |
children risk | #33 |
animal model adhd | #33 |
psychiatric sample | #33 |
autism symptoms | #33 |
qsf | #33 |
mood anxiety | #33 |
frontopolar | #33 |
subcortical brain | #33 |
quetiapine monotherapy | #33 |
maternal smoking pregnancy | #33 |
disorder symptom | #33 |
twins factor analysis | #33 |
current adhd | #33 |
youth bipolar disorder | #33 |
psychiatric status | #33 |
neural reward processing | #33 |
prior findings | #33 |
neuropsychiatric sle | #33 |
association genes | #33 |
adhd patients | #33 |
wfirs | #33 |
adhd evidence | #33 |
val allele | #33 |
10repeat allele | #33 |
pharmacotherapy trials | #33 |
ld adhd | #33 |
comorbidity cross | #33 |
rhobtb3 | #33 |
original study | #33 |
neuropsychological deficits | #33 |
treatment memantine | #34 |
harvard | #34 |
social anxiety children | #34 |
disorders mood | #34 |
gxr | #34 |
md risk | #34 |
grm5 | #34 |
treatment sud | #34 |
pharmacotherapy adhd | #34 |
emerging consensus | #34 |
inattention | #34 |
snp4 | #34 |
linkage studies | #34 |
disorders diagnostic | #34 |
risk psychiatric disorders | #34 |
candidate gene polymorphisms | #34 |
dsm5 dsmiv | #34 |
structural brain asymmetries | #34 |
young adults adhd | #34 |
disorder traits | #34 |
psychological tests | #34 |
cognition interaction | #34 |
lifetime rates | #35 |
complex figure | #35 |
sample description | #35 |
adhd rating | #35 |
familial risk | #35 |
n64 | #35 |
hyperactive disorder | #35 |
adhd sleep problems | #35 |
schizophrenia gene | #35 |
bipolar disorder offspring | #35 |
lithium quetiapine | #35 |
recall patients | #35 |
schizophrenia schizotypy | #35 |
catechol‐o‐methyltransferase | #35 |
n265 | #35 |
schizophrenia relatives | #35 |
participants bpd | #35 |
choice impulsivity | #35 |
plink | #35 |
risk females | #35 |
humans intelligence | #35 |
bipolar spectrum disorders | #35 |
htr1b | #35 |
#35 | |
groups adhd | #36 |
retrospective recall | #36 |
intracranial volume icv | #36 |
n185 | #36 |
siblings controls | #36 |
infant gender | #36 |
adhd drug | #36 |
gypc | #36 |
comorbidity children | #36 |
structure psychopathology | #36 |
neurotransmissions | #36 |
schizophrenia genes | #36 |
adhd control groups | #36 |
95 siblings | #36 |
annett | #36 |
neurocognitive markers | #36 |
d6s274 | #36 |
stimulant medications | #36 |
term neuropsychological | #36 |
overanxious disorder | #36 |
nocebo response | #36 |
young adult females | #36 |
suny | #36 |
disorder bpd | #36 |
adult antisocial | #36 |
orosmph | #36 |
tests schizophrenia | #37 |
combined sample | #37 |
functioning adults | #37 |
symptom criteria | #37 |
parents adhd children | #37 |
odd dimensions | #37 |
offspring association | #37 |
studies comorbidity | #37 |
adhd asd | #37 |
dat1 gene | #37 |
predictive utility | #37 |
disorder severity | #37 |
genetics | #37 |
lisdexamfetamine | #37 |
n278 | #37 |
delayedaction preparations | #37 |
rs5 | #37 |
mapping genomic loci | #37 |
child behavioral | #37 |
slc22a16 | #37 |
methylphenidate treatment | #38 |
dsm criteria | #38 |
polymorphism gene | #38 |
unfamiliar | #38 |
height children | #38 |
kiddie schedule | #38 |
pik4ca | #38 |
school age children | #38 |
16 genes | #38 |
pediatric adhd | #38 |
adhd problems | #38 |
family‐based | #38 |
genome‐wide search | #38 |
d15s1360 | #38 |
familial risk depression | #38 |
genetic risk schizophrenia | #38 |
boys | #38 |
rs2391191 | #38 |
behavioral traits | #39 |
mood stabilization | #39 |
dsm5 criteria | #39 |
markers genetic | #39 |
mdd ocd | #39 |
antisocial traits | #39 |
pharmacologic treatment | #39 |
adhd behavior | #39 |
nonparanoid | #39 |
asthma systematic review | #39 |
suggestive | #39 |
ocd adhd | #39 |
iii personality | #39 |
increased risk adhd | #39 |
structural brain abnormalities | #39 |
washu | #39 |
wisconsin card | #39 |
female cases | #39 |
manic symptoms | #39 |
git1 | #39 |
test association | #39 |
mlod | #39 |
onset children | #39 |
diagnosis bipolar disorder | #40 |
onset | #40 |
genetics schizophrenia | #40 |
genetic studies | #40 |
familial effects | #40 |
brainspan | #40 |
rare copy variants | #40 |
anx | #40 |
heinrichs | #40 |
chromosome 10p | #40 |
reln gene | #40 |
rs2283265 | #40 |
genome scan | #40 |
bipolars | #40 |
dsmiv criteria | #40 |
gxe | #40 |
cardiovascular adverse effects | #40 |
pediatric subjects | #41 |
neuropsychiatr | #41 |
schizophrenia severity illness | #41 |
chromosomes 6q | #41 |
sibpairs | #41 |
parent‐of‐origin | #41 |
fhrs | #41 |
methodological advances | #41 |
methylphenidate response | #41 |
sirolimus patients | #41 |
male parents | #41 |
effects growth | #41 |
psychosocial adversity | #41 |
normal comparison subjects | #41 |
bdnf adhd | #41 |
schizophrenia disorders | #42 |
sorting test | #42 |
n262 | #42 |
serotonergic pathway | #42 |
dtnbp1 schizophrenia | #42 |
disorder social | #42 |
fiveyear followup | #42 |
gwas meta | #42 |
adhd deficits | #42 |
child female | #42 |
diagnostic comorbidity | #42 |
male panic | #42 |
individual items | #42 |
schizophrenia | #42 |
tic disorders | #42 |
massachusetts general | #43 |
n232 | #43 |
youngadult | #43 |
adhd depression | #43 |
p094 | #43 |
disorder prevalence | #43 |
simplex families | #43 |
neuropsychological differences | #43 |
digs | #43 |
candidate endophenotype | #43 |
p023 | #43 |
practitioner review | #43 |
brain scans | #43 |
children enuresis | #43 |
neuropsychological tasks | #43 |
adhd prs | #43 |
n176 | #43 |
n242 | #43 |
snp1 | #43 |
mri study | #43 |
adolescents attention | #44 |
asd adults | #44 |
secondborns | #44 |
n140 | #44 |
odds ratio association | #44 |
multidimensionality | #44 |
immediaterelease | #44 |
nosologic | #44 |
mental disorders diseases | #44 |
prior studies | #44 |
dopamine d5 | #44 |
sidp | #44 |
treatment adult | #44 |
substance disorder | #45 |
illness stress | #45 |
cep85l | #45 |
prevalence psychiatric | #45 |
suggestive associations | #45 |
altered brain activation | #45 |
inflation rate | #45 |
baseline adhd | #45 |
pooled size | #45 |
institute mental | #45 |
volume reductions | #45 |
genetic loading | #45 |
schizophrenia genome | #45 |
uncaring | #45 |
genetic underpinnings | #45 |
wnl | #45 |
snpbased heritability | #45 |
tcerg1l | #45 |
behavior rating | #45 |
risk reduction strategies | #45 |
adhd parents | #45 |
pharmacogenetic studies | #45 |
risk schizophrenia | #45 |
offspring adhd | #45 |
controls subjects | #45 |
stronger connectivity | #46 |
lyons | #46 |
converging evidence | #46 |
neuropsychological performance | #46 |
12 months treatment | #46 |
gender influences | #46 |
cbt intervention | #46 |
10year followup | #46 |
response mph | #46 |
adhd effects | #46 |
machine learning study | #46 |
sex bias | #46 |
previous findings | #46 |
referral bias | #46 |
natural reward | #46 |
n164 | #46 |
nat genet | #46 |
familial coaggregation | #46 |
desipramine dmi | #47 |
childhood disorders | #47 |
genetic study | #47 |
baiap2 | #47 |
oppositional symptoms | #47 |
pooled odds ratio | #47 |
meehl | #47 |
association bipolar disorder | #47 |
schizophrenia alleles | #47 |
velocardiofacial syndrome | #47 |
trauma risk | #47 |
compromised | #47 |
shared polygenic risk | #47 |
or125 | #47 |
ocd mdd | #47 |
psychiatric status rating | #47 |
comt | #47 |
loci chromosomes | #47 |
disorders studies | #47 |
parents depression | #47 |
abstract objective | #47 |
n280 | #47 |
scientific foundation | #48 |
adhd prevalence | #48 |
effects gender | #48 |
nullhypothesis | #48 |
rtv | #48 |
n103 | #48 |
association test | #48 |
shared heritability | #48 |
adhd dyslexia | #48 |
n27 | #48 |
revised | #48 |
mpp3 | #48 |
1711 | #48 |
disorder case | #48 |
anxa7 | #49 |
familial loading | #49 |
disorder cognitive | #49 |
volume differences | #49 |
drug holidays | #49 |
schizophrenia cognition | #49 |
rs2494732 | #49 |
negative schizotypy | #49 |
inbred wky rats | #49 |
nurture | #49 |
snap‐25 | #49 |
hyperactivity autism | #49 |
weak evidence | #49 |
serotonin plasma | #49 |
mental disorders children | #49 |
dsmiv dsm5 | #50 |
caseness | #50 |
parent teacher ratings | #50 |
wiat | #50 |
early onset schizophrenia | #50 |
vdm | #50 |
rocf | #50 |
genomic relationships | #50 |
geneenvironment interactions | #50 |
studies biomarkers | #50 |
pair 6 | #50 |
maoauvntr | #50 |
intergenerational effects | #50 |
impulsivity symptoms | #50 |
extended pedigrees | #50 |
n168 | #50 |
wais | #50 |
life outcomes | #50 |
proteins polymorphism | #50 |
epilepsy adhd | #51 |
male personality | #51 |
peer affiliation | #51 |
adhd knowledge | #51 |
manovas | #51 |
adults ocd | #51 |
disorders children | #51 |
1542 | #51 |
bpd | #51 |
psychology adult | #51 |
compelling | #51 |
substantial role | #51 |
common psychiatric disorders | #51 |
gender association | #51 |
major depression | #52 |
youth asd | #52 |
combined adhd | #52 |
growth height | #52 |
adra1a | #52 |
metaanalysis association | #52 |
schizophrenia controls | #52 |
a218c | #52 |
selenbp1 | #52 |
oros methylphenidate | #52 |
bipolar disorder children | #52 |
asdadhd | #52 |
schizophrenia sex | #52 |
intracranial volume | #52 |
gray matter alterations | #52 |
chronic schizophrenia patients | #52 |
adhdc | #53 |
extended‐release | #53 |
placebo children | #53 |
dopamine plasma | #53 |
parahippocampal gyrus | #53 |
n138 | #53 |
ppm1h | #53 |
tourettes disorder | #53 |
risk analysis | #53 |
risktaking behavior | #53 |
smoking schizophrenia | #53 |
psychopathology | #53 |
mania depression | #53 |
schizophrenia adolescent | #53 |
adoption study | #53 |
scales schizophrenia | #53 |
snps candidate genes | #53 |
alcohol drug | #54 |
risk study | #54 |
unphased | #54 |
schizophrenia psychotic disorders | #54 |
pregnancy time | #54 |
onset bipolar | #54 |
bpd children | #54 |
psychlit | #54 |
jackknife | #54 |
genetic reproducibility | #54 |
chromosome 6p | #54 |
dnms | #54 |
ablim1 | #54 |
sample children | #55 |
neuropsychological studies | #55 |
childhood trauma exposure | #55 |
tova | #55 |
viloxazine | #55 |
mid adolescence | #55 |
disorders risk | #55 |
emotional lability | #55 |
1252 | #55 |
gene interaction | #55 |
disorders prevalence | #55 |
endophenotype | #55 |
flat affect | #55 |
children diagnosis | #55 |
longitudinal case | #55 |
child behavior | #55 |
disorder agoraphobia | #56 |
extendedrelease | #56 |
entry points | #56 |
n43 | #56 |
schizophrenia offspring | #56 |
subfield | #56 |
children siblings | #56 |
hyperactive | #56 |
tics children | #56 |
alcohol substance | #56 |
degree relatives | #56 |
cotwin | #56 |
pair chromosomes | #56 |
model attention | #57 |
rating inventory | #57 |
atomoxetine hydrochloride | #57 |
brain structure function | #57 |
methylphenidate hydrochloride | #57 |
zdhhc8 | #57 |
interregional profiles differences | #57 |
apol | #57 |
shared genetic etiology | #57 |
etdt | #57 |
barkley | #57 |
oddsratio | #57 |
controlled study | #58 |
100 children | #58 |
association comt | #58 |
single snp | #58 |
adhd atomoxetine | #58 |
vntr polymorphisms | #58 |
tests attention | #58 |
analysis schizophrenia | #58 |
compelling evidence | #58 |
repeat alleles | #58 |
childhood young adulthood | #58 |
controls children | #58 |
comorbid psychiatric disorders | #58 |
children | #58 |
function schizophrenia | #58 |
conners | #58 |
dbq | #58 |
heritable receptors | #58 |
risk siblings | #59 |
risk psychiatric | #59 |
comt schizophrenia | #59 |
neuroleptic | #59 |
mdd children | #59 |
mdd adhd | #59 |
schizophrenia smoking | #59 |
rtn4r | #59 |
3 domains | #60 |
duval | #60 |
lphn3 | #60 |
functional remission | #60 |
abuse dependence | #60 |
disruptive behavior disorder | #60 |
inattention hyperactivity | #60 |
generalize | #60 |
reported associations | #60 |
disorders including | #60 |
executive functioning | #60 |
13q32 | #61 |
uninhibited | #61 |
study adherence | #61 |
unipolars | #61 |
disorders asd | #61 |
wide scan | #61 |
homogeneous subgroups | #61 |
oih | #61 |
disruptive behavior | #61 |
comparison subjects | #61 |
dysregulation profile | #61 |
cronbachs alpha | #61 |
uncles | #61 |
study adults | #61 |
polygenic risk schizophrenia | #62 |
4 year | #62 |
substantial heritability | #62 |
factors anxiety | #62 |
symptoms | #62 |
inhibition memory | #62 |
schizophrenia human | #62 |
1537 | #62 |
bipolar youth | #62 |
mph treatment | #62 |
tdts | #62 |
relatives schizophrenia | #62 |
maternal psychopathology | #62 |
stability time | #63 |
accounted | #63 |
risk severity | #63 |
schizophrenia schizophrenic | #63 |
n179 | #63 |
structured interview | #63 |
behavioral dysregulation | #63 |
disorders bipolar | #63 |
neurocognitive | #63 |
ksads | #63 |
treatments adhd | #63 |
childhood onset | #64 |
treatment desipramine | #64 |
children mph | #64 |
risk trauma | #64 |
qlesq | #64 |
phacking | #64 |
adhd 95 | #64 |
prefrontal dysfunction | #64 |
methylation cpg sites | #64 |
linkage | #64 |
rating scales | #64 |
endosomal | #64 |
methylphenidate mph | #64 |
europeanamerican | #64 |
40 countries | #64 |
males association | #64 |
diagnostic utility | #64 |
methylphenidate adhd | #64 |
child | #64 |
prior work | #65 |
emo | #65 |
disorders genetic | #65 |
neuropsychological impairments | #65 |
marry | #65 |
net gene | #65 |
schizophrenic | #65 |
etiology schizophrenia | #65 |
small sample size | #65 |
oxidase gene | #65 |
occurrence adhd | #65 |
zcchc4 | #65 |
male siblings | #65 |
adhd epilepsy | #65 |
temperamental | #65 |
comorbid diagnosis | #65 |
emotional regulation | #65 |
controls siblings | #65 |
function female | #65 |
ci105 | #66 |
tic disorder | #66 |
study studies | #66 |
disorder chromosome | #66 |
behavioral genetic | #66 |
adhd dcd | #66 |
extended release | #66 |
tourettes syndrome | #66 |
simple phobia | #66 |
vswm | #66 |
neuropsychological profile | #66 |
attention hyperactivity | #66 |
afternoons | #66 |
children mental retardation | #66 |
cbcldp | #66 |
global ratings | #66 |
treatment quetiapine | #67 |
findings association | #67 |
variance attention | #67 |
chronic tic disorder | #67 |
parents teachers | #67 |
risk bipolar | #67 |
entire sample | #67 |
label trial | #67 |
subjects | #67 |
questionnaires treatment | #67 |
patients bipolar disorders | #67 |
nonrighthandedness | #67 |
substance disorder sud | #67 |
n217 | #67 |
mental diseases | #67 |
grade retention | #67 |
conceptual issues | #68 |
brain gene | #68 |
delay aversion | #68 |
qms | #68 |
naturalistic | #68 |
hypofrontality | #68 |
offspring | #68 |
snparray | #68 |
low adherence | #69 |
physical anhedonia | #69 |
illicit substances | #69 |
clarifying | #69 |
polymorphism schizophrenia | #69 |
symptom checklist | #69 |
regulatory enzymes | #69 |
impulsivity hyperactivity | #69 |
humans schizophrenia | #69 |
people adhd | #69 |
stress response genes | #69 |
panic disorder | #69 |
ctgn | #69 |
chronological age | #69 |
scale assessment | #69 |
subsequent diagnosis | #70 |
a2bp1 | #70 |
neuropsychological consequences | #70 |
smoking children | #70 |
interactions genes | #70 |
linkage scan | #70 |
latrophilin | #70 |
oros mph | #70 |
core adhd symptoms | #70 |
new diagnoses | #70 |
npl | #70 |
nonrandom mating | #70 |
adhd behaviors | #71 |
genetic | #71 |
objective examine | #71 |
adhd anxiety disorders | #71 |
neuroimaging genetics | #71 |
vergence | #71 |
mspi polymorphism | #71 |
genes role | #71 |
treated children | #71 |
school functioning | #72 |
methodological issues | #72 |
boys age | #72 |
genetic receptors | #72 |
ocd subjects | #72 |
molecular genetic | #72 |
learning disorders | #72 |
digital intervention | #72 |
digital health intervention | #72 |
anxiety adhd | #73 |
candidate endophenotypes | #73 |
cellular models | #73 |
logodds | #73 |
cortical abnormalities | #73 |
etiological | #73 |
3372 | #73 |
adhd medications | #73 |
poison control centers | #73 |
disorders childhood | #73 |
adult | #73 |
youth | #73 |
adhd subtype | #73 |
patients rest | #73 |
schizophrenia genetics | #73 |
kagan | #73 |
relapse depression | #73 |
preferential transmission | #74 |
reaction time variability | #74 |
transmission disequilibrium | #74 |
age schizophrenia | #74 |
pfkfb2 | #74 |
based diagnosis | #74 |
desipramine | #74 |
allele association | #74 |
weight body mass | #75 |
linkage schizophrenia | #75 |
akl | #75 |
onset anxiety | #75 |
hyperactivity adhd | #75 |
child china | #75 |
efficacy outcome | #75 |
risk sample | #75 |
drd4 gene | #75 |
mind wandering | #75 |
adhd traits | #75 |
antisocial | #75 |
neale | #75 |
impairment children | #75 |
slc1a1 | #75 |
referred | #75 |
child humans | #76 |
chronic tic | #76 |
adhd total | #76 |
disorders brain | #76 |
child depressive | #76 |
depression pregnancy | #76 |
nondeficit | #76 |
yates | #76 |
schizophrenia young | #76 |
positive schizotypy | #76 |
centers disease control | #76 |
cortex schizophrenia | #77 |
lod score | #77 |
wcst performance | #77 |
performance adhd | #77 |
psychological male | #77 |
childhood adhd | #77 |
atomoxetine children | #77 |
performance schizophrenia | #77 |
predixcan | #78 |
disorders female | #78 |
adhd impairment | #78 |
pharmacologic treatments | #78 |
local gyrification | #78 |
women antidepressants | #78 |
bipolar disorder adhd | #78 |
rare copy | #78 |
bpi | #78 |
retrospective assessment | #79 |
disorder panic | #79 |
nosological | #79 |
n46 | #79 |
pregnancy mothers | #79 |
anxiety separation | #79 |
additive effects | #79 |
studies relationship | #79 |
age adhd | #79 |
obesity metabolic syndrome | #79 |
cardinal | #79 |
schizophrenic patients | #79 |
genetic linkage studies | #79 |
patients adhd | #79 |
student athletes | #79 |
siblings schizophrenia | #80 |
clinical interview | #80 |
linkage chromosome | #80 |
maternal smoking | #80 |
total brain | #80 |
adhd drugs | #80 |
adhd rats | #80 |
endophenotypes | #81 |
children parents | #81 |
major diagnostic | #81 |
treatment adults | #81 |
body mass diabetes | #81 |
hacking | #81 |
subcortical brain volumes | #81 |
interregional profiles | #81 |
differences age | #81 |
eyhs | #81 |
oral routes | #81 |
pathophysiology adhd | #81 |
disliking | #81 |
bipolar disorder | #81 |
square distribution | #82 |
impaired quality life | #82 |
cumulative evidence | #82 |
genes pathways | #82 |
gene schizophrenia | #82 |
frontopolar cortex | #82 |
behavior assessment | #82 |
association maternal smoking | #82 |
comorbidity disorders | #82 |
comorbidity survey | #82 |
adults asd | #82 |
symptoms diagnosis | #82 |
auditory verbal | #82 |
substance disorders | #83 |
illness | #83 |
paterson | #83 |
multifactorial inheritance | #83 |
disorders anxiety | #83 |
management adhd | #83 |
neurocognitive functioning | #83 |
adult form | #83 |
tests risk | #83 |
unreliability | #83 |
oros | #83 |
21 months | #84 |
complex disorder | #84 |
adhd adhd symptoms | #84 |
15q133 | #84 |
women adhd | #84 |
hyperkinetic disorder | #85 |
linkage loci | #85 |
buprenorphine maintenance | #85 |
recycling endosome | #85 |
brain asymmetry | #85 |
atomoxetine | #85 |
adhd assessment | #85 |
genomics consortium | #85 |
9r | #85 |
wide significance | #85 |
adhd subtypes | #85 |
adhdrsiv | #85 |
humans risk | #85 |
monitoring response | #85 |
european samples | #85 |
child conduct | #86 |
paranoid | #86 |
humans inhibition | #86 |
parents | #86 |
affective psychosis | #86 |
pord | #86 |
findings implications | #86 |
siblings children | #86 |
n203 | #87 |
ptsd trauma | #87 |
synaptosomal protein | #87 |
bipolar spectrum disorder | #87 |
bipolar | #87 |
comparison children | #87 |
3utr | #87 |
putamen volume | #87 |
risk alleles | #87 |
hyperkinetic | #88 |
common risk | #88 |
druggable | #88 |
comorbid psychopathology | #88 |
drug effects | #88 |
bonferroni correction | #88 |
empirically | #89 |
comprehensive identification | #89 |
2455 | #89 |
euphoric | #89 |
prenatal nicotine exposure | #89 |
chrna2 | #89 |
auditory attention | #89 |
metaanalytic review | #89 |
caars | #89 |
nucleotide schizophrenia | #89 |
22 studies | #89 |
machine learning analysis | #89 |
1month | #90 |
linkage genome | #90 |
verbal ability | #90 |
242 | #90 |
antidepressants pregnancy | #90 |
snps haplotypes | #90 |
male neuropsychological | #90 |
association metaanalysis | #90 |
pervasive | #90 |
watt | #90 |
attention deficit hyperactivity | #90 |
complicates | #91 |
assertion | #91 |
adhd males | #91 |
adhd efficacy | #91 |
parental socioeconomic status | #91 |
callousness | #91 |
identified studies | #91 |
naturalistic study | #91 |
cortical brain | #91 |
wcst | #91 |
adhd treatments | #91 |
documenting | #92 |
studies association | #92 |
adults schizophrenia | #92 |
raise | #92 |
studies sex | #92 |
candidate gene | #92 |
treatment mania | #92 |
h2snp | #92 |
standardized differences | #93 |
ymrs | #93 |
lifetime cannabis | #93 |
controls participants | #93 |
narrowly | #93 |
referral consultation | #93 |
rate adult | #93 |
brain case | #94 |
social development | #94 |
adhd measures | #94 |
aldh1l1 | #94 |
cdh13 | #94 |
sustained attention | #94 |
gprc5b | #94 |
hfasd | #94 |
growing body | #94 |
hyperactivity autistic | #94 |
underachievement | #94 |
performance variability | #94 |
gottman | #94 |
adolescents bipolar | #95 |
executive | #95 |
total brain volume | #95 |
minisatellite | #95 |
infa | #95 |
studies differences | #95 |
mdd bip | #95 |
asd study | #95 |
cadps2 | #95 |
scq | #96 |
uvntr | #96 |
nominally | #96 |
nxph1 | #96 |
phenotype polymorphism | #96 |
chromosome 9q34 | #96 |
behavior rating inventory | #96 |
hcadherin | #97 |
children tics | #97 |
7q36 | #97 |
genome‐wide association study | #97 |
low cardiorespiratory fitness | #97 |
adolescent onset | #97 |
studies asthma | #97 |
nonfamilial | #98 |
wdpcp | #98 |
hyperactivity brazil | #98 |
bipolar disorder risk | #98 |
driving behavior | #98 |
massachusetts general hospital | #98 |
linkage study | #98 |
identically | #98 |
syn2 | #98 |
single nucleotide receptor | #98 |
concerta | #98 |
induced hyperalgesia | #98 |
oppositionality | #98 |
nonspecificity | #99 |
psychoactive | #99 |
medication effects | #99 |
metaanalysis trials | #99 |
abuse potential | #99 |
neurodevelopmental processes | #99 |
substrains | #99 |
xp114 | #99 |
disorder diagnosis | #99 |
motor timing | #99 |
chd6 | #99 |
adhd role | #99 |
methodssubjects | #99 |
disease genetics | #99 |
obesity abdominal obesity | #100 |
clinical effects | #100 |
adhd methylphenidate | #100 |
hippocampal subfield volumes | #100 |
pelham | #100 |
12year | #100 |
terror | #100 |
reticence | #100 |
upsit | #101 |
tsls | #101 |
slc6a4 gene | #101 |
schizophrenia psychotic | #101 |
depression pregnant women | #101 |
neurocognitive impairments | #101 |
harlan | #101 |
addictive drugs | #101 |
torture | #101 |
empirical test | #101 |
cosegregation | #101 |
advanced paternal age | #101 |
genetic risk scores | #101 |
genomewide | #101 |
roh | #101 |
diagnostic boundaries | #101 |
sob | #102 |
disorder psychiatric | #102 |
klf13 | #102 |
treatment seeking | #102 |
male neuropsychological tests | #102 |
parents offspring | #102 |
inhibition psychological | #102 |
individuals aud | #102 |
functional pathways | #102 |
schizophrenia mood disorders | #103 |
genome wide association | #103 |
clinical picture | #103 |
ocd children | #103 |
pgc | #103 |
symptom profile | #103 |
genetic pedigree polymorphism | #103 |
touchstone | #103 |
patients 12 months | #103 |
genomic region | #104 |
schizophrenia metaanalysis | #104 |
genetic mechanism | #104 |
controlled studies | #104 |
tourette disorder | #104 |
motor competence | #104 |
individual sites | #104 |
1934 | #104 |
current article | #105 |
drug dyskinesia | #105 |
schizophrenia probands | #105 |
adhd review | #105 |
dsmiv diagnosis | #105 |
academic problems | #105 |
school dropout | #105 |
neuropsychological dysfunction | #105 |
children methylphenidate | #106 |
children odd | #106 |
humans lod | #106 |
cogs | #106 |
growth outcomes | #107 |
consecutive sample | #107 |
disorder female | #107 |
functional correlates | #107 |
lenticular | #107 |
oral methylphenidate | #107 |
matter volumes | #107 |
sequential analysis | #107 |
mothers adhd | #107 |
chronic tic disorders | #107 |
adolescents bipolar disorder | #107 |
ldn | #107 |
λs | #107 |
daao | #107 |
association cigarette smoking | #108 |
afni | #108 |
antimanic agents | #108 |
918 | #108 |
site differences | #108 |
maternal warmth | #108 |
proband | #108 |
nesarc | #108 |
pediatric psychopharmacology | #108 |
n197 | #108 |
symptoms childhood | #108 |
pervasive developmental | #108 |
origin effects | #108 |
aged psychiatric | #108 |
longitudinal trajectories | #109 |
depression bipolar | #109 |
gabra6 | #109 |
total scores | #109 |
risk bipolar disorder | #109 |
psychosis proneness | #109 |
adhd medication | #109 |
irrespective | #109 |
worthy | #109 |
neuroleptic medication | #109 |
enlistment | #110 |
adult adhd symptoms | #110 |
adhd parent | #110 |
markers genome | #110 |
linkage association | #110 |
rat models | #110 |
dao | #111 |
affective symptoms | #111 |
symptom ratings | #111 |
5httlpr genotype | #111 |
selective reporting | #111 |
n107 | #111 |
affective psychoses | #111 |
dimorphisms | #111 |
pediatric obsessive | #112 |
factors social | #112 |
substantial proportion | #112 |
childhood risk factors | #112 |
independent studies | #112 |
unmedicated | #112 |
brain gene expression | #112 |
bipolar parents | #112 |
dopamine d4 receptors | #112 |
impact exposure | #112 |
male prevalence | #113 |
cronbach | #113 |
neuropsychological functions | #113 |
xr | #113 |
analysis statistical | #114 |
omim | #114 |
comorbid anxiety | #114 |
functional neuroanatomy | #114 |
–r | #115 |
nuclear families | #115 |
schizophrenia severity | #115 |
endorsed | #115 |
n34 | #115 |
genet | #115 |
liability | #115 |
wm abnormalities | #116 |
formulating | #116 |
diseases twins | #116 |
schizophrenic psychology | #116 |
neuropsychological | #116 |
quality life outcomes | #117 |
coordinated analysis | #117 |
neurocognitive endophenotypes | #117 |
z29 | #117 |
unipolar | #117 |
prenatal smoking | #117 |
polygenic association | #117 |
trait impulsivity | #117 |
current symptoms | #117 |
genetic receptor serotonin | #118 |
major female | #118 |
large study | #118 |
academic functioning | #118 |
prevention science | #118 |
spm2 | #118 |
satisfaction questionnaire | #118 |
grandfathers | #118 |
grandiosity | #118 |
definitively | #118 |
dopaminergic genes | #119 |
schizophrenia linkage | #119 |
efd | #119 |
midadolescence | #119 |
naa ratio | #119 |
method data | #119 |
differences children | #120 |
misunderstandings | #120 |
t01 | #120 |
neurocognitive deficits | #121 |
disorder autism | #121 |
subfield volumes | #121 |
remittance | #121 |
aunts | #121 |
new avenues | #121 |
cgibp | #121 |
n108 | #121 |
schizoaffective | #122 |
psychopathology symptoms | #122 |
structural brain alterations | #122 |
msit | #122 |
anxious | #122 |
adhd comorbidity | #122 |
levels adhd | #122 |
neuropsychiatric disorders | #122 |
disregard | #122 |
disorder depressive | #122 |
refute | #122 |
pabs | #122 |
male risk | #122 |
brain alterations | #122 |
urvs | #122 |
v11 | #122 |
age initiation | #123 |
wechsler | #123 |
adhd ocd | #123 |
adcy2 | #123 |
chr psychosis | #123 |
clinical status | #123 |
wechsler intelligence scale | #124 |
laboratory observations | #124 |
drug placebo | #124 |
p097 | #124 |
trios | #124 |
twothirds | #124 |
longitudinal sample | #124 |
g×s interaction | #124 |
treatment subjects | #124 |
9q34 | #124 |
maximum lod score | #124 |
attention regulation | #124 |
disorder risk | #125 |
psychosis individuals | #125 |
machine learning prediction | #125 |
segregation analysis | #125 |
patients chronic schizophrenia | #125 |
anxiety problems | #125 |
caregiver strain | #125 |
drug disorders | #126 |
developmental aspects | #126 |
memory adhd | #126 |
odd conduct disorder | #126 |
familial influences | #126 |
biological parents | #126 |
parent version | #126 |
complex genetics | #126 |
positive negative symptoms | #126 |
taiwanese population | #127 |
genes | #127 |
disinhibited | #127 |
drd2 | #127 |
attention child | #127 |
adult alleles | #127 |
stevenson | #127 |
psychiatric diagnoses | #127 |
aged 6 | #128 |
neuropsychological measures | #128 |
intactness | #129 |
behavioral outcome | #129 |
opiate antagonists | #129 |
n102 | #129 |
implicate | #129 |
familial | #129 |
personality assessment | #129 |
retrospective data analysis | #130 |
adhd inattention | #130 |
families | #130 |
1990a | #130 |
moderating effects | #131 |
pair 15 chromosomes | #131 |
differed | #131 |
animals attention | #131 |
snps | #131 |
incapacitation | #131 |
bip mdd | #131 |
kinesthesia | #131 |
mood anxiety disorders | #131 |
adolescents ocd | #131 |
register study | #131 |
strong evidence | #131 |
large european cohort | #132 |
n79 | #132 |
hkd | #132 |
p074 | #132 |
child cognition | #132 |
entire brain | #132 |
linkage humans | #132 |
learning disabilities | #132 |
late adolescents | #132 |
male prospective | #132 |
sodas | #132 |
childhood anxiety disorders | #132 |
onset bipolar disorder | #133 |
mph | #133 |
heroin dependence | #133 |
preliminary examination | #134 |
children adults | #134 |
vntr | #134 |
disorders social | #134 |
male massachusetts | #135 |
social deficits | #135 |
association analyses | #135 |
tspan8 | #136 |
relied | #136 |
firstborns | #136 |
risk factors smoking | #136 |
olfactory identification | #136 |
sorcs3 | #136 |
social environments | #136 |
adolescents young | #136 |
expressed emotion | #137 |
schizophrenia affective disorders | #137 |
psychological male memory | #137 |
memantine treatment | #137 |
adolescent bipolar | #137 |
association asthma | #137 |
studies examined | #137 |
gaming | #137 |
longitudinal evidence | #137 |
asds | #138 |
mtor activation | #138 |
6q | #138 |
biomarkers diagnosis | #138 |
control individuals | #138 |
evidence association | #138 |
fhr | #139 |
mgh | #139 |
neuropsychiatric | #139 |
schizophrenia studies | #139 |
meet | #139 |
symptoms disorders | #139 |
n129 | #139 |
n115 | #140 |
parental anxiety | #140 |
intriguing | #140 |
schizotypal traits | #140 |
prss | #141 |
disorder comorbidity | #141 |
genetic vulnerability | #141 |
emotional symptoms | #141 |
haplotype block | #141 |
5ht1b receptors | #142 |
disorders personality | #142 |
neurotrophic | #142 |
covid19 restrictions | #142 |
disorders psychotic | #142 |
22q112 deletion syndrome | #142 |
molecular genetics | #143 |
peripheral biomarkers | #143 |
hydrogen exchangers | #143 |
conduct | #143 |
risk factors obesity | #143 |
fetal movement | #143 |
rfg | #144 |
elston | #144 |
child psychopathology | #144 |
humans linear | #144 |
statistical female humans | #144 |
blind study | #144 |
g72 | #144 |
diagnosed attention | #144 |
diagnostic procedure | #144 |
agents tricyclic | #144 |
p00018 | #145 |
genome‐wide association studies | #145 |
individual symptoms | #145 |
pcb exposure | #145 |
studies depressive | #145 |
drug alcohol | #145 |
common genetic variants | #145 |
early initiation | #145 |
affs | #145 |
genetic heterogeneity | #145 |
major psychoses | #145 |
n105 | #145 |
oppositional behavior | #146 |
warranted | #146 |
prenatal nicotine | #146 |
intelligence quotient | #146 |
atypicality | #146 |
twin studies | #146 |
genders | #146 |
adult psychopathology | #146 |
histrionic | #147 |
intraindividual variability | #147 |
p0016 | #147 |
lras | #147 |
abbreviated | #147 |
comprising | #147 |
sabp | #148 |
single locus | #148 |
cognitive variables | #148 |
basc | #148 |
adolescent young | #148 |
cdrsr | #149 |
schizotypy | #149 |
brain correlates | #149 |
adhd symptoms children | #149 |
risk mdd | #149 |
parental substance | #149 |
sud treatment | #150 |
chrnb2 | #150 |
categorical | #150 |
highlighting | #150 |
nonmedical | #150 |
impulsive | #150 |
adhd relationship | #150 |
synaptic biology | #151 |
consisted | #151 |
higher burden | #151 |
functional impairment | #152 |
diagnostic systems | #152 |
atxn1 | #152 |
parent report | #152 |
httlpr | #152 |
autistic traits | #152 |
metaanalytic | #152 |
xq21 | #152 |
linkage disequilibrium mapping | #152 |
undegraded | #152 |
implicates | #152 |
schizophrenia diagnosis | #152 |
copy variants cnvs | #152 |
placebo subjects | #152 |
increases risk | #152 |
large sample | #152 |
genomewide linkage | #153 |
caucasian children | #153 |
humans learning | #153 |
demoralization | #153 |
marginally | #153 |
alcohol conditions | #153 |
editions | #153 |
schizophrenia bipolar disorder | #153 |
schizophrenia deficits | #153 |
5 httlpr | #153 |
dsm | #154 |
atomoxetine placebo | #154 |
schizophrenia magnetic resonance | #154 |
disorder phenotype | #154 |
emphasizing | #154 |
wisc | #154 |
exposure maternal | #154 |
clarification | #155 |
year follow | #155 |
snpheritability | #155 |
ncsr | #155 |
humans polymorphism | #155 |
genomewide scan | #155 |
tests male | #156 |
n84 | #156 |
600000 | #156 |
interpersonal functioning | #156 |
genetic risk | #156 |
prospective controlled study | #156 |
dopamine d4 | #157 |
enigma consortium | #157 |
panic disorder agoraphobia | #157 |
new knowledge | #157 |
primary setting | #158 |
drd4 genotype | #158 |
cognitive tempo | #158 |
clinical diagnostic | #158 |
oprm1 | #158 |
greatest | #158 |
ppp2r2b | #158 |
htr2c | #158 |
adolescents | #158 |
sledai | #158 |
myo5b | #158 |
genetic linkage | #158 |
dav | #159 |
quetiapine treatment | #159 |
adult human brain | #159 |
selfratings | #159 |
patients substance | #159 |
teachers parents | #159 |
nonpersistent | #159 |
smds | #160 |
medial temporal | #160 |
age onset | #160 |
separation anxiety disorder | #160 |
humans impulsive | #160 |
genetic component | #161 |
adult adhd patients | #161 |
behavioral difficulties | #161 |
tic symptoms | #161 |
hyperactivity disorders | #161 |
population samples | #161 |
schizophrenia bipolar | #161 |
140 | #162 |
disorder depression | #162 |
cooccurring disorders | #162 |
ksadspl | #162 |
empirical tests | #162 |
rats wky | #162 |
disorder clinical | #162 |
paternal age | #163 |
dsmiv | #163 |
neurobiology | #163 |
sample | #163 |
neuropsychological tests | #163 |
5htt | #163 |
dn cells | #163 |
complex phenotype | #164 |
diagnostic status | #164 |
familial liability | #164 |
anxiety attention | #164 |
impairments | #164 |
illness schizophrenia | #164 |
washington university | #165 |
neurocognitive performance | #165 |
boys girls | #165 |
risk subsequent | #165 |
years children | #165 |
domain criteria | #166 |
earlyonset schizophrenia | #166 |
cotwins | #166 |
12–14 | #166 |
antidepressant therapy | #166 |
linkage genetic | #166 |
symptom reduction | #166 |
alcohol disorders aud | #166 |
genetic influence | #166 |
shared environment | #166 |
receptor gene | #166 |
association obesity | #167 |
moderates | #167 |
ipsych | #167 |
polygenic architecture | #168 |
wisciii | #168 |
children 6 years | #168 |
neurocognitive functions | #168 |
leonard | #168 |
duration illness | #169 |
multifactorial | #169 |
perseverations | #169 |
international congress | #169 |
genetic association analysis | #169 |
n111 | #169 |
matter microstructure | #169 |
risk gene | #170 |
traumas | #170 |
anxiety child | #170 |
single nucleotide schizophrenia | #170 |
cfg | #170 |
disorders young | #170 |
conditional probability | #170 |
arrb2 | #170 |
pharmacodynamic properties | #170 |
lgi | #170 |
child psychiatry | #171 |
n91 | #171 |
genesets | #171 |
functional laterality humans | #171 |
treatment studies | #172 |
inattention impulsivity | #172 |
immune disorders | #172 |
interpersonal sensitivity | #173 |
disorders study | #173 |
enuresis | #173 |
gabbr1 | #174 |
male mental | #174 |
tics | #175 |
subsyndromal | #175 |
large samples | #175 |
mph placebo | #176 |
development schizophrenia | #176 |
confounds | #176 |
hyperactive children | #177 |
independent datasets | #177 |
disorders sex | #177 |
suicide death | #177 |
confounded | #177 |
ascertainment | #177 |
kraepelin | #177 |
patients opioid | #177 |
strong genetic component | #178 |
cortical surface | #178 |
n78 | #178 |
parent rated | #178 |
underpinnings | #179 |
gene interactions | #179 |
strongest evidence | #179 |
pregnancy children | #179 |
atomoxetine atx | #179 |
behaviorally | #179 |
genetic confounding | #179 |
nagelkerke | #180 |
connectivity networks | #180 |
cvlt | #180 |
copy variants | #180 |
unemotional traits | #181 |
mothers pregnancy | #181 |
combinatory | #181 |
perceptual disorders | #181 |
271 | #182 |
scz bip | #182 |
phenocopies | #182 |
control participants | #182 |
htr4 | #182 |
structured | #182 |
genotype humans | #183 |
psychometric testing | #183 |
studies gwas | #183 |
rating | #183 |
mechanistic target | #183 |
reading difficulties | #184 |
wei | #184 |
based morphometry | #184 |
effects atomoxetine | #184 |
n‐acetylcysteine | #185 |
reward sensitivity | #185 |
phenocopy | #185 |
allison | #185 |
long acting | #185 |
pdd | #185 |
genome human | #185 |
hyperactivity symptoms | #186 |
218 | #186 |
biomarker studies | #186 |
statistical female | #186 |
predominately | #186 |
schizophrenia evidence | #187 |
stratifying | #187 |
schizophrenia major depression | #187 |
risperidone placebo | #187 |
autocorrelation | #188 |
parahippocampus | #188 |
blood biomarkers | #188 |
depression treatment | #188 |
3 untranslated region | #188 |
enigma | #188 |
undertreatment | #189 |
bna | #189 |
differential association | #189 |
genetic correlations | #189 |
scwt | #190 |
medication adhd | #190 |
functioning children | #190 |
childhood | #190 |
linkage evidence | #190 |
clarify | #191 |
mph children | #191 |
psychiatric phenotypes | #191 |
greater activation | #191 |
implicated | #191 |
schedule female | #191 |
social dysfunction | #191 |
mood disorder | #191 |
fsiq | #191 |
dopamine genes | #191 |
iasp | #192 |
612 years | #192 |
association response | #192 |
freedman | #194 |
joseph | #194 |
inconsistent findings | #194 |
sza | #195 |
clinical global | #195 |
placebo p001 | #195 |
polymorphisms snps | #195 |
cognitive endophenotypes | #195 |
overactivity | #197 |
wm performance | #197 |
perinatal complications | #197 |
arhgef9 | #197 |
dependence symptoms | #197 |
neural substrates | #197 |
mdd scz | #198 |
g×s | #198 |
ptk2b | #198 |
lifetime diagnosis | #198 |
developmentally | #198 |
snps schizophrenia | #198 |
bsd | #199 |
specific genes | #199 |
childhood symptoms | #199 |
raises | #199 |
male phenotype | #199 |
male | #199 |
asic1a | #199 |
small samples | #200 |
asd adhd | #200 |
neuropsychological battery | #200 |
disruptive disorders | #200 |
mri data | #200 |
childhood attention | #200 |
catecholomethyltransferase | #201 |
parents schizophrenia | #201 |
functional genomics | #201 |
disorder humans | #201 |
pain tolerance | #202 |
cognitive flexibility | #202 |
unaffected | #203 |
neuropsychological correlates | #203 |
control association | #203 |
pdq | #203 |
childhood adulthood | #203 |
genetic liability | #203 |
stopsignal task | #203 |
schizophreniform | #204 |
concurrent validity | #204 |
attentional control | #204 |
microsatellite marker | #204 |
adolescent psychiatry | #204 |
respond | #204 |
extend | #204 |
genes risk | #206 |
selfdirectedness | #206 |
nonshared | #206 |
uptodate | #206 |
sluggish cognitive tempo | #207 |
method drug | #207 |
prkg1 | #208 |
parental alcohol | #208 |
susceptibility schizophrenia | #208 |
prolactin levels | #208 |
clinical benefits | #209 |
baseline follow | #209 |
variable expression | #209 |
60mg | #210 |
acds | #210 |
5year followup | #210 |
n96 | #210 |
correspondence | #210 |
maudsley | #210 |
park2 | #210 |
vntr polymorphism | #211 |
greater risk | #211 |
predisposition disease | #211 |
dimensional models | #212 |
apoe4 allele | #212 |
stroop task | #212 |
grm7 | #212 |
ps005 | #212 |
adult patients adhd | #212 |
hkdc1 | #212 |
sought | #213 |
sampling strategy | #213 |
trauma ptsd | #213 |
replication studies | #213 |
negative outcomes | #213 |
suggestive evidence | #214 |
cvltii | #214 |
continuous performance test | #214 |
rare cnvs | #214 |
disorders models | #214 |
schizophrenia chinese | #214 |
humans neuropsychological | #214 |
bilag | #215 |
lifetime version | #215 |
male mental disorders | #215 |
adult cognition | #215 |
functional mri study | #216 |
vivo correlation | #216 |
glr | #217 |
chromosome 15 | #217 |
antisocial personality | #217 |
male schizophrenia | #217 |
hippocampal subfield | #218 |
gene based | #218 |
trim31 | #218 |
parental | #218 |
panic | #218 |
polygenic | #219 |
study selection | #219 |
misunderstood | #219 |
drug double | #220 |
normal controls | #220 |
snpa | #220 |
irritable mood | #221 |
triangularis | #221 |
parental psychopathology | #221 |
symptoms adults | #221 |
telephone interview | #221 |
studies cognition | #221 |
n76 | #222 |
methyltransferase comt | #222 |
diagnoses | #222 |
patient engagement | #222 |
score male | #222 |
childhoodonset | #222 |
study findings | #223 |
learning disability | #223 |
revisited | #223 |
abnormalities schizophrenia | #224 |
effective treatments | #224 |
adhd sleep | #224 |
sensing ion | #224 |
axis disorders | #224 |
gria2 | #224 |
default network | #225 |
coordination disorder | #225 |
bipolar spectrum | #225 |
children placebo | #226 |
hk3 | #226 |
inattentiveness | #226 |
subfields | #226 |
unemotional | #227 |
disorder study | #227 |
scales psychotic | #227 |
criteria diagnosis | #227 |
subcortical regions | #227 |
individual variability | #227 |
dependent variables | #227 |
male twins | #228 |
atomoxetine treatment | #228 |
control based | #228 |
age subjects | #228 |
comorbid anxiety disorders | #228 |
birth complications | #229 |
structural abnormalities | #229 |
equally | #229 |
overlapped | #229 |
psychiatric outcomes | #230 |
international multicenter | #231 |
commission errors | #231 |
4years | #231 |
heritable | #231 |
risk indicators | #231 |
hyperactivity behavior | #232 |
differences prevalence | #232 |
serotonin transporter gene | #232 |
worse performance | #234 |
candidate genes | #234 |
study sample | #234 |
discriminating | #235 |
disorder medication | #235 |
probabilistic forecasts | #235 |
shr wky rats | #236 |
reliably | #238 |
fifty years | #238 |
placebo response | #238 |
agoraphobia | #238 |
route administration | #238 |
allelic heterogeneity | #239 |
scientific data | #240 |
pdag | #240 |
acid oxidase | #240 |
healthy siblings | #240 |
nosology | #240 |
patients siblings | #240 |
symptoms quality | #241 |
adolescent offspring | #241 |
doubleblind | #241 |
disorder asd | #241 |
adequately | #241 |
joint analysis | #242 |
sodium hydrogen | #242 |
neurodevelopmental model | #242 |
psychiatric comorbidities | #242 |
impulsive choice | #242 |
reward processing | #242 |
patients relatives | #243 |
aggressive behaviors | #243 |
valid | #243 |
onset obsessive | #243 |
female | #243 |
giftedness | #244 |
n74 | #244 |
population differences | #245 |
5ht2a receptor | #245 |
interregional | #245 |
adversity | #245 |
paliperidone | #245 |
disorder ptsd | #245 |
expression genetic | #246 |
dsmivtr | #246 |
cadm2 | #246 |
community controls | #246 |
812 | #247 |
motor performance | #247 |
studies associations | #248 |
cigarette smoking | #248 |
chinese families | #248 |
epigenetic studies | #248 |
developmental disorder | #249 |
behavioral characteristics | #251 |
childs | #251 |
hypoactivation | #252 |
german patients | #252 |
tourette | #253 |
female subjects | #253 |
genomewide association | #253 |
iqs | #253 |
intellect | #253 |
benzodiazepine | #254 |
schizophrenia adult | #254 |
kappas | #254 |
studies metaanalysis | #254 |
cpt performance | #254 |
study schizophrenia | #254 |
conduct problems | #255 |
larsson | #256 |
cacna1c gene | #256 |
shared genetic | #256 |
biochemical studies | #256 |
carlson | #257 |
children adhd symptoms | #257 |
year study | #259 |
endorsement | #259 |
parental depression | #259 |
n61 | #260 |
piq | #260 |
dexamphetamine | #261 |
diagnosis | #261 |
pharmacotherapy | #261 |
anxiety depressive disorders | #261 |
genomewide linkage scan | #263 |
sex factors | #263 |
22q11ds | #263 |
fluid intelligence | #263 |
obsessive compulsive disorder | #263 |
selfreports | #263 |
disorder personality | #264 |
attention problems | #264 |
confirm | #264 |
conceptualized | #264 |
distinct subtypes | #264 |
adverse health | #264 |
long term outcomes | #265 |
ptsd risk | #266 |
schizophrenia cases | #266 |
5090 | #266 |
new models | #266 |
diagnostic validity | #266 |
scz mdd | #267 |
phenotype schizophrenia | #267 |
genetic approaches | #268 |
strong support | #268 |
diagnosis schizophrenia | #268 |
neuropsychological impairment | #268 |
test scores | #269 |
years baseline | #269 |
diagnostic process | #269 |
phlda1 | #270 |
segregate | #270 |
largest | #270 |
age effects | #270 |
withdrawn | #270 |
genetic overlap | #271 |
sibling pairs | #271 |
adult psychiatric | #271 |
circadian genes | #271 |
symptoms assessed | #271 |
social adversity | #271 |
structural brain | #272 |
diagnostic issues | #272 |
rora | #273 |
szs | #273 |
schizophrenia siblings | #273 |
alcohol smoking | #273 |
age | #273 |
statistics topic | #273 |
search terms | #273 |
444 | #273 |
4year | #273 |
22 years | #274 |
sleep behavior | #274 |
underlie | #275 |
surgency | #275 |
reading disability | #275 |
maf1 | #275 |
t102c | #276 |
missingness | #276 |
familial schizophrenia | #276 |
2q | #276 |
mania symptoms | #277 |
adhd healthy controls | #277 |
adolescent risk | #277 |
growing evidence | #277 |
nicotinic schizophrenia | #277 |
synaptosomal | #278 |
nr3c1 | #278 |
manual | #278 |
early psychosis | #278 |
clinical setting | #278 |
silico approach | #279 |
nicotine dependence | #279 |
ocd | #279 |
intelligence scale | #279 |
polygenic risk | #280 |
remitted | #280 |
acting | #280 |
rating scale | #280 |
child parent | #280 |
cognition female | #280 |
n47 | #280 |
abuser | #280 |
brain volumes | #280 |
psychotic bipolar | #281 |
phenotyped | #281 |
premature death | #281 |
disorders adult | #281 |
individuals | #281 |
response inhibition | #282 |
collaborative analysis | #282 |
5ht1b | #282 |
onset ocd | #282 |
reading problems | #282 |
velo | #283 |
titrated | #283 |
antisocial behaviors | #283 |
continue | #283 |
aspd | #284 |
3untranslated region | #285 |
quantitative traits | #285 |
gria3 | #285 |
neuroanatomical | #285 |
normal variation | #285 |
neoffi | #285 |
scale children | #286 |
clues | #286 |
swanson | #286 |
explication | #286 |
siblings patients | #286 |
quantitative analyses | #286 |
effects age | #287 |
schizophrenia abnormalities | #288 |
deficit schizophrenia | #288 |
bmisds | #289 |
postmortem brain | #289 |
psychiatric traits | #290 |
disease haplotypes | #290 |
pediatric ocd | #290 |
22q112 | #290 |
publication bias | #291 |
subcortical volumes | #291 |
low serum levels | #291 |
substrain | #292 |
groups children | #293 |
modest | #293 |
hypertensive rat | #294 |
cognition disorders | #294 |
subjective responses | #294 |
salary | #294 |
interference control | #295 |
risk factors children | #295 |
post‐traumatic stress disorder | #295 |
dtnbp1 | #295 |
european populations | #295 |
psychosis schizophrenia | #295 |
adverse impact | #295 |
executive functions | #296 |
continuous performance | #296 |
ldsc | #296 |
asd traits | #297 |
early onset | #297 |
obesity overweight | #297 |
anxiety disorder | #297 |
discriminated | #298 |
reanalysis | #298 |
diagnostic approach | #298 |
predisposition | #299 |
negative symptom | #299 |
qvalues | #300 |
cortical thickness | #300 |
effects stress | #300 |
psychiatric hospitalization | #301 |
roc analysis | #301 |
cognitive measures | #301 |
intrasubject variability | #302 |
published literature | #302 |
states adolescent | #302 |
emotional problems | #302 |
prefrontal function | #302 |
permuted | #303 |
psychometrics | #303 |
height body | #303 |
psychiatric conditions | #304 |
795 | #304 |
manifest | #305 |
case subjects | #305 |
dsm5 | #305 |
interviewers | #305 |
ats | #305 |
aggressive behavior | #305 |
affective disorders | #305 |
dopamine transporter | #306 |
early morning | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
gene environment | #309 |
membrane transport | #309 |
perseveration | #309 |
omission errors | #309 |
documented | #309 |
myh9 | #309 |
spencer | #309 |
genetic schizophrenia | #310 |
efficacy treatment | #310 |
motor domain | #310 |
adolescent aggression | #310 |
memory wm | #310 |
life social support | #310 |
rdoc | #311 |
gender age | #312 |
stroop test | #312 |
childhood adolescence | #312 |
mainstays | #312 |
mapping female | #313 |
npsr1 | #313 |
genetic analyses | #314 |
underscore | #314 |
risk estimation | #315 |
bedtimes | #315 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
asb | #317 |
demonstrable | #318 |
schizophrenia review | #318 |
n55 | #319 |
5ht2c | #319 |
individual genes | #319 |
adolescent adrenergic | #320 |
intelligence tests | #321 |
shared genetic influences | #321 |
addictive disorders | #321 |
gene | #321 |
127 | #322 |
bipolar type | #322 |
risperidone treatment | #322 |
robins | #322 |
humans longitudinal | #322 |
abusers | #323 |
time variability | #323 |
conceptual models | #324 |
guanfacine | #324 |
nolan | #324 |
manic | #325 |
yielded | #326 |
neonatal abstinence syndrome | #326 |
sex characteristics | #326 |
impaired | #327 |
xq26 | #327 |
status female | #327 |
spurious | #327 |
etiologic | #328 |
comprised | #328 |
disorders pervasive | #329 |
8q | #329 |
overrepresented | #330 |
metaanalyses | #330 |
sexdifferences | #330 |
htr2a | #331 |
scores patients | #331 |
drug response | #331 |
women schizophrenia | #332 |
expression brain | #333 |
familial factors | #333 |
txndc5 | #333 |
naltrexone | #333 |
multiple comparisons | #334 |
cognitive dysfunctions | #334 |
obesity diabetes | #334 |
adler | #335 |
24weeks | #335 |
mood disorders | #335 |
forthcoming | #335 |
persist | #336 |
methylphenidate placebo | #336 |
rey | #336 |
humans mental | #336 |
inferior parietal lobule | #336 |
777 | #337 |
mobp | #337 |
neuropsychological test | #337 |
asd individuals | #337 |
tph2 | #337 |
disentangle | #338 |
evening | #339 |
patients attention | #339 |
replications | #339 |
psychopathological | #339 |
disorder ocd | #340 |
consistently | #340 |
exclusion criteria | #340 |
evidence linkage | #340 |
pnmt | #340 |
intelligence | #341 |
placebo effects | #341 |
encompassing | #341 |
treatment bipolar | #341 |
visual memory | #342 |
phobic | #342 |
multicenter analysis | #342 |
neuroimaging studies | #342 |
maoa genotype | #342 |
bipolarity | #342 |
integrated analysis | #344 |
mood problems | #344 |
comorbid diagnoses | #344 |
schizoaffective disorder | #344 |
tbv | #344 |
frontal pole | #344 |
catechol methyltransferase | #345 |
systematically | #345 |
casecontrol studies | #345 |
864 | #346 |
gifts | #346 |
confused | #347 |
study genotype | #347 |
mdd bpd | #347 |
psychotic | #348 |
tic severity | #348 |
converging | #348 |
collaborative study | #349 |
temporal processing | #349 |
schizotypal personality disorder | #349 |
adolescent anxiety | #350 |
methylphenidate atomoxetine | #350 |
aetiological | #350 |
suspiciousness | #351 |
adults children | #352 |
distractibility | #352 |
disequilibrium | #352 |
receptor genes | #352 |
impairing | #353 |
disease genome | #353 |
executive attention | #354 |
brain atlas | #354 |
disorders middle | #354 |
gabra1 | #354 |
reln | #354 |
genetic environmental | #354 |
child attention | #354 |
substantial | #354 |
maob | #354 |
prodh | #355 |
rgs4 | #355 |
dsmiii | #355 |
male adolescent | #355 |
phobic disorders | #356 |
schizophrenia data | #356 |
heterogeneous disorder | #356 |
measures attention | #357 |
children anxiety disorders | #357 |
chrna7 | #357 |
gottesman | #358 |
deviant | #359 |
persists | #359 |
psychiatric symptoms | #359 |
maternal cigarette smoking | #359 |
disorder patients | #359 |
symptom scores | #360 |
linkage analysis | #360 |
n54 | #361 |
neuroleptic treatment | #361 |
chromosomal regions | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
paralimbic | #365 |
tid | #365 |
confirmation | #366 |
elevated risk | #366 |
core symptoms | #366 |
memory load | #367 |
771 | #367 |
pediatric populations | #367 |
bpd mdd | #368 |
comparison groups | #368 |
study entry | #368 |
risk psychopathology | #368 |
702 | #369 |
young adulthood | #369 |
differential involvement | #369 |
hyperactivityimpulsivity | #369 |
representativeness | #370 |
differential susceptibility | #370 |
nervousness | #370 |
schizophrenia risk | #371 |
current concepts | #371 |
damphetamine | #371 |
prevention strategies | #372 |
endorse | #372 |
replicate | #372 |
comt gene | #372 |
5httlpr | #373 |
genomewide association studies | #373 |
executive function | #373 |
small sample | #374 |
driving performance | #374 |
snp heritability | #374 |
wide analysis | #375 |
dozens | #375 |
scz | #375 |
916 | #375 |
emphases | #376 |
medication children | #376 |
teenage | #376 |
genetic architecture | #377 |
data studies | #377 |
sas | #377 |
children medication | #377 |
memory short | #377 |
child adolescent | #377 |
schizotypal personality | #378 |
children adolescents | #378 |
impression | #378 |
control adults | #379 |
marriages | #379 |
pearson | #380 |
converged | #380 |
youths | #380 |
ht1b | #380 |
opd | #380 |
methylphenidate children | #381 |
invaluable | #381 |
relevant articles | #381 |
culmination | #381 |
overlap | #381 |
disorder diagnostic | #381 |
receptors dopamine | #381 |
general cognitive ability | #381 |
chisquare | #382 |
adolescent patients | #382 |
psychopharmacological treatment | #383 |
antimanic | #383 |
carefully | #383 |
psychopathologies | #383 |
researched | #384 |
summary statistics | #384 |
gad2 | #385 |
7r | #385 |
treatment children | #386 |
18p | #386 |
multigenerational | #386 |
neural activation | #387 |
chinese subjects | #387 |
npas2 | #388 |
contrasted | #388 |
evenings | #388 |
versa | #388 |
adhd symptomatology | #389 |
childhood depression | #389 |
lefthandedness | #390 |
perinatal morbidity | #390 |
handedness | #390 |
studies children | #390 |
disorder symptoms | #390 |
brain circuits | #390 |
interaction genetic | #391 |
genetic predisposition | #391 |
lambert | #392 |
comorbid substance | #392 |
schizophrenia susceptibility | #392 |
p54 | #393 |
substance users | #394 |
genes expression | #394 |
hippocampal subfields | #395 |
function humans | #395 |
dopamine norepinephrine | #395 |
adolescents adults | #396 |
fbat | #397 |
disorders schizophrenia | #397 |
schizophrenia disorder | #397 |
psychometric | #397 |
mental health children | #397 |
3methoxy4hydroxyphenylglycol | #397 |
clinical risk psychosis | #398 |
spm8 | #398 |
earlier onset | #398 |
wandering | #398 |
neuropsychological testing | #400 |
control sample | #401 |
inattention symptoms | #402 |
suffocation | #402 |
core symptom | #402 |
academic outcomes | #402 |
implications findings | #403 |
inconsistencies | #403 |
relations male | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
vntrs | #406 |
n52 | #406 |
neuropsychiatric conditions | #406 |
diagnosis children | #406 |
parahippocampal | #406 |
attending | #407 |
cognitive inhibition | #408 |
childhood risk | #408 |
communitybased | #409 |
behavior genetics | #409 |
0038 | #409 |
substance | #410 |
distinct subsets | #410 |
children studies | #411 |
impulsive behavior | #411 |
dextroamphetamine | #411 |
twin study | #411 |
reading comprehension | #411 |
psychotic disorders | #412 |
neanderthal | #412 |
interview | #412 |
consistent evidence | #412 |
tourette syndrome | #412 |
childhood anxiety | #412 |
apoe4 | #412 |
moderated | #413 |
systematic literature search | #413 |
anticipation | #413 |
151 | #414 |
reviewing | #414 |
performance tests | #414 |
volition | #415 |
polymorphism snp | #415 |
genetic receptor | #416 |
elucidating | #416 |
schizotypal | #416 |
functional effects | #417 |
effects brain | #417 |
adult intelligence | #418 |
adolescent psychiatric | #418 |
conferred | #418 |
genetic association | #419 |
deletion syndrome | #419 |
srsa | #419 |
questionnaires adolescent | #419 |
daily doses | #420 |
dopamine d4 receptor | #420 |
kdm4a | #420 |
antidepressive agents | #420 |
adult subjects | #421 |
sexes | #421 |
modestly | #421 |
operating characteristic | #422 |
cdis | #422 |
iccs | #422 |
drug dependence | #422 |
tricyclic | #423 |
reliability validity | #423 |
medicated | #423 |
characteristic curve | #424 |
gcta | #424 |
transport proteins | #425 |
discovery sample | #425 |
subtests | #425 |
parent ratings | #426 |
cardiff | #426 |
attain | #427 |
hum | #427 |
brain volume | #428 |
diversion | #428 |
spectrum disorders | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
disentangling | #431 |
personality development | #431 |
operating characteristics | #432 |
teacher | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
1433 | #436 |
12q | #436 |
perceptual organization | #436 |
frequency genotype | #436 |
cprs | #436 |
lower scores | #437 |
grin2a | #437 |
disorder brain | #437 |
relatives patients | #437 |
visual learning | #438 |
correlation coefficients | #438 |
srs2 | #438 |
toddlerhood | #438 |
impulsiveness | #438 |
adolescent psychopathology | #438 |
22q112ds | #439 |
risk psychosis | #439 |
digit span | #439 |
genetic genetic predisposition | #439 |
nominal | #439 |
method female | #440 |
aged neuropsychological | #440 |
major risk factor | #440 |
snps association | #440 |
corroborated | #441 |
meaningful | #441 |
post hoc analysis | #441 |
trex | #441 |
allelic association | #441 |
white matter microstructure | #441 |
gmo | #441 |
virtual histology | #442 |
female functional | #442 |
adult analysis | #442 |
logistic regression model | #442 |
disorders autism | #442 |
planum temporale | #442 |
n80 | #443 |
disorders surveys | #444 |
differential female | #444 |
conferring | #444 |
emphasize | #444 |
10 year | #444 |
pcdh10 | #445 |
ntrk3 | #446 |
nucleotide receptors | #446 |
534 | #446 |
statistic | #446 |
862 | #446 |
holland | #447 |
motor coordination | #448 |
behavior child | #448 |
genome wide | #448 |
originally | #448 |
expressiveness | #449 |
earlier age | #449 |
risk variants | #450 |
wistar kyoto | #450 |
early response | #450 |
exceptions | #451 |
sex | #451 |
subsequent risk | #452 |
brain abnormalities | #452 |
clinical expression | #452 |
prevalence correlates | #452 |
children adolescent | #456 |
chat | #456 |
zscores | #457 |
79 | #457 |
psychiatry | #457 |
masse | #458 |
independently | #458 |
structural magnetic | #458 |
preliminary study | #458 |
522 | #460 |
genetic correlation | #460 |
polygenic risk score | #460 |
22q112 deletion | #460 |
lander | #460 |
psychotic disorders schizophrenia | #460 |
hyperkinesis | #461 |
smoking pregnancy | #461 |
jw | #462 |
d4 | #463 |
life treatment | #465 |
affection | #465 |
decrements | #465 |
pregnancy complications | #465 |
neuroanatomy | #465 |
control rates | #466 |
gene sets | #466 |
runs | #466 |
anxiety depressive | #467 |
inbred wky | #467 |
mini | #467 |
bpad | #468 |
subjects patients | #469 |
disorders treatment | #470 |
patient adherence | #470 |
cacna1c | #470 |
genetic effects | #470 |
receiver operating | #471 |
remission relapse | #471 |
psychology adolescent | #472 |
risk allele | #472 |
response remission | #473 |
chrna4 | #473 |
environmental risk factors | #474 |
norepinephrine transporter | #474 |
plp1 | #474 |
developmental coordination | #476 |
cautious | #476 |
opioid addiction | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
multiplex families | #479 |
dysthymia | #479 |
5th | #479 |
humans | #480 |
genetic risk variants | #480 |
adds | #480 |
symptom | #480 |
diagnostic categories | #481 |
semistructured | #481 |
cortex child | #481 |
maternal anxiety | #482 |
data extraction | #482 |
genotyped | #482 |
etiology | #483 |
arithmetic | #483 |
treatment methylphenidate | #484 |
sml | #484 |
conception | #484 |
verbal learning | #484 |
nfil3 | #484 |
adulthood | #485 |
agents bipolar | #485 |
756 | #485 |
outcome variables | #486 |
epidemiologically | #486 |
baseline age | #486 |
symptom dimensions | #487 |
123 | #487 |
evaluates | #487 |
adult anxiety | #487 |
spontaneity | #488 |
female adolescents | #489 |
longterm effects | #489 |
unpublished | #489 |
genetic disorders | #489 |
neuropsychiatric disorder | #490 |
schizophrenia autism | #490 |
shared environmental | #490 |
administration schedule | #490 |
schizophrenia age | #492 |
common variant | #492 |
smoking prevention | #492 |
overlapping | #493 |
pnds | #493 |
antisocial personality disorder | #495 |
frequency genetic | #495 |
late adolescence | #495 |
restlessness | #497 |
psychobiology | #497 |
schizophrenia patients | #497 |
pair human | #497 |
anxiety | #497 |
separation anxiety | #497 |
longitudinal studies | #498 |
bonferroni | #498 |
placebos | #499 |
genetic mechanisms | #499 |
candidate | #499 |
daoa | #499 |
addressed | #499 |
case reports | #500 |
comt val158met polymorphism | #500 |
identifying | #500 |
nocebo | #501 |
d4 receptors | #501 |
rat strains | #501 |
verbal memory | #503 |
additional evidence | #503 |
865 | #503 |
child executive | #505 |
circadian clock genes | #505 |
subscale | #506 |
n26 | #506 |
fallacy | #506 |
cooperativeness | #507 |
continued | #507 |
tobacco disorder | #508 |
reflecting | #508 |
delay discounting | #509 |
developing schizophrenia | #509 |
agg | #510 |
shared | #511 |
educational status | #511 |
dichotomous | #511 |
p80 | #512 |
obsessive compulsive | #512 |
95 death | #512 |
identifiable | #512 |
risk haplotype | #513 |
lod | #513 |
coaggregation | #514 |
disproportionate | #514 |
assessments | #515 |
disorders depression | #515 |
phis | #515 |
morning | #515 |
total sample | #516 |
normal control | #516 |
n39 | #517 |
contributing | #517 |
cognitive traits | #517 |
15q | #518 |
missing link | #519 |
environmental influences | #520 |
pbat | #520 |
fn1 | #520 |
gyrus cinguli | #521 |
specificity ppv | #521 |
dichotic | #521 |
social class | #522 |
polymorphism single | #522 |
selfreport | #522 |
disorder obsessive | #522 |
attention memory | #523 |
dibenzothiazepines | #523 |
assortative | #524 |
adult bipolar | #524 |
dedication | #524 |
dmi | #524 |
phg | #524 |
sciencedirect | #525 |
covariates | #525 |
clinical diagnoses | #525 |
disorder treatment | #525 |
pacific island | #525 |
affiliations | #526 |
functioning | #527 |
persistence | #527 |
criminality | #527 |
symptomatic remission | #528 |
adolescent children | #528 |
depression anxiety disorders | #528 |
adverse life events | #528 |
design study | #528 |
ruled | #529 |
abrupt | #529 |
parental reports | #529 |
compulsive disorder | #529 |
community samples | #529 |
flnc | #529 |
tagsnps | #530 |
control children | #530 |
strongest | #531 |
increased burden | #531 |
medications | #531 |
existing studies | #532 |
autism schizophrenia | #532 |
n40 | #532 |
clinical sample | #533 |
subjects age | #533 |
analyses conducted | #534 |
temperament character | #534 |
selective review | #535 |
asd | #535 |
intercorrelations | #535 |
parsing | #537 |
global impression | #537 |
models genetic | #538 |
child adhd | #538 |
autistic symptoms | #538 |
d4 receptor | #539 |
personality factors | #541 |
milder | #541 |
lobe humans | #542 |
single nucleotide | #543 |
disease genotype | #543 |
taiwanese | #543 |
independent samples | #544 |
complexities | #544 |
severe symptoms | #544 |
ld | #545 |
population sample | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
healthy control subjects | #548 |
functional variant | #548 |
computer program | #548 |
nonclinical sample | #549 |
clash | #549 |
risk children | #549 |
behavior male | #549 |
dichotomized | #549 |
patients schizophrenia | #549 |
oral route | #549 |
schizophrenia study | #549 |
genetic pathways | #550 |
765 | #550 |
fam | #550 |
case control | #551 |
motor inhibition | #551 |
ideally | #551 |
define | #551 |
performance test | #552 |
major diagnosis | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
suggests | #555 |
viewed | #555 |
prs schizophrenia | #555 |
release oral | #555 |
spectrum disorder | #556 |
phenotypic features | #556 |
nogo task | #557 |
neuropsychiatric diseases | #557 |
child anxiety | #557 |
equivocal | #558 |
neurodevelopmental | #558 |
africanamerican | #558 |
justify | #559 |
response variability | #560 |
gray matter volumes | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
risk smoking | #565 |
adolescents risk | #565 |
4th edition | #566 |
twins female | #566 |
risky behaviors | #566 |
patients sud | #566 |
intermediate phenotypes | #566 |
haplotype | #567 |
3050 | #567 |
neurocognitive impairment | #567 |
unaffected relatives | #568 |
replication study | #569 |
onsets | #570 |
10−8 | #570 |
diverging | #570 |
environment interaction | #570 |
keywords | #571 |
risk genes | #571 |
birthday | #571 |
dose reduction | #573 |
irritability | #574 |
obesity body mass | #574 |
white matter abnormalities | #574 |
inbred shr | #575 |
questionnaires adult | #575 |
asd diagnosis | #576 |
spaced | #576 |
gyri | #576 |
schizophrenia sample | #577 |
individually | #577 |
medical genetics | #577 |
chromosomes human | #577 |
parent | #577 |
finetuning | #578 |
impulsivity | #578 |
82 | #578 |
symptoms children | #579 |
subsample | #579 |
development anxiety | #580 |
5httlpr polymorphism | #580 |
preschool age | #580 |
cold pressor test | #580 |
haplotype analysis | #581 |
drd1 | #582 |
rdc | #582 |
psychiatric association | #582 |
apol1 | #582 |
delinquent behavior | #583 |
3rd | #583 |
hk1 | #584 |
new approaches | #584 |
data children | #585 |
fine mapping | #585 |
separately | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
defaultmode network | #588 |
compared controls | #588 |
nback task | #588 |
examine | #588 |
138 | #589 |
haplotypes humans | #590 |
40mg | #591 |
behavior adult | #591 |
estonian | #591 |
patients comorbid | #591 |
criticism | #593 |
concordant | #594 |
2005 | #594 |
brain child | #595 |
overrepresentation | #596 |
cognition schizophrenia | #596 |
discounted | #597 |
nonpharmacologic | #597 |
generalizable | #597 |
snap25 | #597 |
affymetrix | #598 |
new directions | #598 |
899 | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnosing | #604 |
diagnostic specificity | #604 |
clinical settings | #604 |
clinician | #606 |
disorganized | #606 |
performance children | #606 |
cognitive outcomes | #606 |
personality traits | #607 |
social environment | #607 |
sizeable | #608 |
4 6 | #608 |
small fraction | #608 |
antisocial behavior | #609 |
executive dysfunctions | #609 |
gold standard | #609 |
true | #609 |
polygenic risk scores | #610 |
functional outcomes | #610 |
informant | #611 |
complex disorders | #612 |
pleiotropic | #612 |
chromosome 6 | #613 |
educational achievement | #614 |
schizophrenia brain | #614 |
grandmothers | #614 |
behavior disorder | #615 |
curve analysis | #615 |
snp markers | #615 |
disease etiology | #615 |
prevalence severity | #616 |
memory deficits | #616 |
genetic epidemiology | #616 |
genome scans | #617 |
tscores | #617 |
differ | #618 |
genetic associations | #618 |
val158met | #618 |
african children | #618 |
correcting | #619 |
digeorge | #619 |
vigilance | #620 |
genetic markers | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
receptor serotonin | #624 |
juvenile delinquency | #624 |
executive dysfunction | #625 |
misconceptions | #625 |
executive control | #625 |
mood stabilizers | #626 |
hrr | #627 |
attentional deficits | #627 |
seeks | #627 |
fibromyalgia | #629 |
treatment disorder | #629 |
child gender | #629 |
schizophrenia findings | #630 |
reject | #631 |
deficits schizophrenia | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
obsessivecompulsive disorder | #638 |
icv | #638 |
generalisability | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
adult outcomes | #641 |
advertisement | #641 |
ranks | #641 |
illness duration | #642 |
gateway | #643 |
inconsistent | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
treatment effects | #652 |
gene association | #652 |
avoidant | #652 |
128 | #653 |
physical conditions | #653 |
hyperactivity inattention | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
reward anticipation | #656 |
random allocation rats | #656 |
bipolar disorder schizophrenia | #656 |
studies evidence | #657 |
boldness | #658 |
impairment | #658 |
groups compared | #658 |
psychosocial treatment | #658 |
hypomanic | #659 |
volumes | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
peer relations | #662 |
structural alterations | #662 |
referrals | #662 |
permission | #665 |
lowlevel | #665 |
digeorge syndrome | #665 |
dacc | #666 |
subcortical | #666 |
psychiatric illnesses | #667 |
mood | #668 |
prominent | #669 |
swedish population | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
unselected | #678 |
disorders memory | #678 |
sleep difficulties | #679 |
129 | #679 |
mental disorders humans | #680 |
psychopathological symptoms | #680 |
middle childhood | #680 |
neurotic | #681 |
gene frequency | #681 |
soviet union | #682 |
semantic fluency | #682 |
trait | #682 |
quetiapine | #682 |
severe phenotype | #683 |
east asian | #685 |
scales | #685 |
remitting | #685 |
p0019 | #687 |
chromosomal region | #688 |
children groups | #688 |
17q | #688 |
postmortem brains | #689 |
fibromyalgia patients | #689 |
younger children | #689 |
tcas | #694 |
disorder schizophrenia | #694 |
average age | #694 |
testretest reliability | #695 |
parcellation | #696 |
cortical surface area | #696 |
participants | #696 |
5years | #697 |
4–5 | #697 |
pharmacokinetic profile | #697 |
122 | #699 |
relevant studies | #699 |
drug abuse | #699 |
effects methylphenidate | #700 |
adult mental | #701 |
illness surveys | #701 |
nonrandom | #701 |
quota | #701 |
gwa studies | #704 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
follow studies | #705 |
preschool years | #706 |
adaptive functioning | #706 |
pathogenesis schizophrenia | #706 |
autism spectrum | #708 |
school settings | #709 |
p009 | #709 |
children diagnosed | #710 |
chronic schizophrenia | #713 |
informative | #713 |
prs | #714 |
misuse | #714 |
eric | #714 |
maternal report | #714 |
dysphoric | #714 |
728 | #715 |
ethanol consumption | #715 |
stress disorder | #715 |
disorders substance | #715 |
641 | #716 |
3 weeks | #716 |
contradictory | #717 |
groundwork | #719 |
abstraction | #719 |
meta‐analysis | #720 |
multiple genes | #721 |
clinical population | #721 |
recurrence risk | #722 |
household income | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
gender dysphoria | #726 |
male adolescents | #726 |
common snps | #726 |
lateonset | #726 |
attention deficits | #727 |
schizophrenics | #727 |
dizygotic | #728 |
statistical | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
correlates | #733 |
voxel based | #733 |
git | #733 |
finding | #734 |
phenotypic heterogeneity | #734 |
wky | #735 |
life cycle | #737 |
health intervention | #737 |
gyrification | #737 |
substancerelated disorders | #738 |
opioid dependence | #738 |
polygenic score | #739 |
inflation | #739 |
validating | #740 |
rapid cycling | #741 |
refill | #742 |
boston | #742 |
caudate | #742 |
time task | #743 |
comparators | #744 |
amphetamines | #744 |
soviet | #745 |
topic twins | #745 |
bupropion | #745 |
neuropsychological status | #746 |
compulsive | #746 |
manifested | #747 |
child interaction | #748 |
duplications | #748 |
adrb1 | #749 |
934 | #750 |
examining | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
molecular genetic analysis | #754 |
347 | #754 |
comt val158met | #755 |
post hoc | #755 |
recalled | #756 |
neuroleptics | #756 |
mental disorders | #756 |
bipolar depression | #756 |
schizophrenia scz | #757 |
nhe | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
matter abnormalities | #764 |
workday | #764 |
humans logistic | #765 |
likelihoods | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
comt polymorphism | #772 |
emerged | #772 |
performance patients | #774 |
birth rates | #776 |
parent reported | #776 |
human pair | #777 |
behavioral phenotypes | #777 |
depressive | #777 |
phenotypes | #778 |
euthymic | #779 |
deletion polymorphism | #779 |
weaknesses | #780 |
risky behavior | #780 |
schizophrenia relationship | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
questioning | #783 |
combined analysis | #783 |
fourth edition | #783 |
emerging roles | #784 |
mega | #784 |
reformulation | #785 |
teaes | #785 |
faced | #786 |
963 | #787 |
pbd | #787 |
adolescence | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
cgi | #791 |
behavioral | #791 |
spelling | #791 |
subtypes | #792 |
clinical criteria | #793 |
individuals schizophrenia | #793 |
association polymorphisms | #794 |
motivations | #794 |
symptom burden | #794 |
caveats | #796 |
delinquent | #796 |
separate | #797 |
363 | #800 |
additional studies | #800 |
genomic regions | #802 |
prenatal exposure | #803 |
dopamine d1 receptors | #803 |
stimulant drugs | #804 |
randomized clinical trials | #804 |
dysfunction | #805 |
clinically | #805 |
superior frontal | #805 |
male memory | #806 |
novelty seeking | #806 |
latent classes | #806 |
dorsolateral | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
dopamine function | #810 |
ucla | #810 |
adjusting | #811 |
preschool female humans | #811 |
dopamine serotonin | #811 |
phonemic | #811 |
blind | #813 |
coadministration | #815 |
declarative | #816 |
mhpg | #816 |
tryptophan hydroxylase | #817 |
breakthroughs | #817 |
cfb | #817 |
lasting | #817 |
quantitative measures | #817 |
single gene | #818 |
substance dependence | #818 |
epigenetic factors | #818 |
memory attention | #818 |
meeting | #820 |
cortical development | #820 |
rated | #821 |
counties | #821 |
patients psychotic disorders | #821 |
hme | #822 |
switches | #822 |
prefrontal regions | #824 |
parental report | #824 |
transcriptomic analysis | #824 |
rare coding variants | #825 |
common genetic | #825 |
humans models | #827 |
adolescents asd | #827 |
s100a6 | #828 |
treatment interventions | #829 |
multipoint | #830 |
timeframe | #830 |
prevalent | #831 |
lifetime prevalence | #831 |
multiple testing | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
n60 | #837 |
sleep disorder | #837 |
gray | #837 |
inbred shr rats | #838 |
aversion | #838 |
matter humans | #838 |
prescription | #839 |
symptom profiles | #839 |
obstetric complications | #839 |
neurocognition | #841 |
parenthood | #842 |
participants completed | #843 |
sporadic cases | #843 |
consensus statement | #844 |
biological basis | #844 |
facial emotion recognition | #845 |
n35 | #846 |
exception | #847 |
dnm | #847 |
gwas summary | #848 |
dysregulated | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
nonsignificant | #857 |
putative | #857 |
putamen | #858 |
estimated prevalence | #858 |
schizophrenia healthy | #858 |
heightened risk | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
global assessment | #866 |
glossary | #866 |
seventy | #866 |
crosssectional studies | #867 |
hypothesized | #869 |
mental | #869 |
nnt | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
shr rats | #874 |
pediatric | #874 |
perseverative errors | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
positive symptoms | #876 |
manova | #876 |
hypotheses | #876 |
genetic counseling | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
n95 | #893 |
n17 | #893 |
obsessive | #893 |
bonn | #894 |
decade | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
biological psychiatry | #903 |
anterior cingulate | #903 |
reinforcer | #904 |
bipolar illness | #904 |
genetic contribution | #904 |
aptitude | #904 |
sibling | #904 |
weight body | #904 |
visit | #905 |
psychosocial functioning | #906 |
late childhood | #906 |
826 | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
pedigrees | #912 |
psychosocial | #912 |
amygdala reactivity | #912 |
complications pregnancy | #913 |
visuospatial memory | #913 |
versions | #914 |
underlying pathophysiology | #914 |
association age | #916 |
disorder specific | #917 |
school performance | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
pharmacogenetic | #924 |
screening tool | #924 |
vulnerability | #925 |
dysthymic | #925 |
wide | #926 |
dividing | #927 |
developmental trajectories | #927 |
affective disorder | #928 |
cpg sites | #930 |
nucleotide | #930 |
participating | #930 |
permutation | #933 |
heroin addiction | #933 |
194 | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
environment interactions | #936 |
smoking risk | #936 |
3040 | #937 |
study designs | #938 |
female genotype | #938 |
diagnostic | #938 |
irrs | #940 |
robustly | #940 |
critics | #941 |
severe form | #941 |
tdt | #943 |
gwas | #946 |
brain regions | #946 |
sles | #948 |
22q | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
personality disorder | #954 |
relapsers | #954 |
amphetamine | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
clinical assessment | #963 |
female frontal | #963 |
children epilepsy | #963 |
dopamine uptake | #965 |
scores | #965 |
tandem repeat | #965 |
cgis | #965 |
body height | #966 |
scarce | #966 |
heritability estimates | #967 |
splicing factor | #968 |
cuneus | #968 |
freesurfer | #969 |
pharmacological treatment | #970 |
schizophrenia association | #970 |
mtbi | #970 |
examined | #970 |
medication treatment | #971 |
risky sexual behavior | #972 |
aggression | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
resolve | #978 |
psychosis risk | #978 |
vmat2 | #978 |
neurodevelopmental disorder | #980 |
2–4 | #980 |
educational | #982 |
pertaining | #982 |
459 | #982 |
seriousness | #985 |
symptoms age | #986 |
alleles | #986 |
logistic regression models | #986 |
patients sle | #987 |
difficulties | #988 |
ranked | #990 |
tci | #990 |
small proportion | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
diathesis | #999 |
keystone | #999 |
detoxification | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
long‐term outcome | #1007 |
daughter | #1007 |
preschool cohort | #1007 |
confounding factors | #1007 |
0016 | #1007 |
allele | #1007 |
structural mri | #1008 |
norms | #1008 |
multiplex | #1009 |
posttraumatic stress disorder | #1009 |
risk alcohol | #1009 |
qualifications | #1009 |
discriminant | #1010 |
genes environment | #1012 |
7 years | #1014 |
ltc | #1014 |
maturational | #1020 |
metabotropic | #1020 |
conclusive | #1021 |
risk prediction | #1024 |
relates | #1024 |
insufficient | #1026 |
004 | #1027 |
pharmacotherapies | #1027 |
obsessive – | #1028 |
persistent | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
frontostriatal | #1031 |
wwwclinicaltrialsgov | #1031 |
analytic | #1031 |
patients panic disorder | #1032 |
symptoms child | #1032 |
preface | #1034 |
73 | #1034 |
predicted | #1034 |
– compulsive | #1034 |
rodent models | #1035 |
brain disorders | #1035 |
total score | #1035 |
negative symptoms | #1035 |
exploratory analyses | #1037 |
eventual | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
serotonin | #1041 |
general intelligence | #1041 |
twin | #1043 |
mental health treatment | #1044 |
gaf | #1044 |
heightened | #1045 |
relate | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
vice | #1056 |
psychiatric morbidity | #1056 |
major humans | #1058 |
nogo | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
illicit | #1063 |
genes involved | #1063 |
199 | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
childhood trauma | #1068 |
heritability | #1068 |
pooled | #1068 |
awakenings | #1068 |
paranoia | #1068 |
negative impact | #1069 |
emotional | #1069 |
memantine | #1069 |
word reading | #1070 |
memory impairments | #1070 |
human genetics | #1070 |
reading ability | #1071 |
single nucleotide receptors | #1071 |
controlled clinical | #1071 |
risk scores | #1071 |
social problems | #1071 |
genetic model | #1071 |
4q | #1072 |
character inventory | #1072 |
associations | #1073 |
validity | #1073 |
obesity risk | #1074 |
3′utr | #1075 |
studying | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
exposure delayed | #1080 |
transdiagnostic | #1080 |
schizophrenia social | #1082 |
adult antipsychotic | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
autoreceptors | #1086 |
psds | #1086 |
onset psychosis | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
subtype | #1090 |
distinctive | #1090 |
polygenic scores | #1092 |
development disorders | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
irritable | #1096 |
semistructured interview | #1096 |
scientific literature | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
daughters | #1103 |
future work | #1103 |
external validity | #1103 |
cnvs | #1104 |
odds | #1106 |
diagnostic groups | #1107 |
psychosis | #1107 |
10 weeks | #1107 |
emotional behavioral | #1108 |
bip | #1108 |
prioritized | #1110 |
psychoses | #1110 |
experimental test | #1110 |
10−5 | #1111 |
share | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
dysthymic disorder | #1128 |
quantifies | #1128 |
enriched | #1128 |
similarities | #1128 |
investigator | #1129 |
adult alcoholism | #1130 |
weighting | #1130 |
attention performance | #1134 |
n28 | #1134 |
psychiatric diagnosis | #1135 |
independent sample | #1136 |
birth outcomes | #1136 |
blood pressure response | #1138 |
laterality humans | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
cognitive domains | #1145 |
early adolescent | #1145 |
prodromal | #1145 |
demographic factors | #1146 |
normal volunteers | #1147 |
emotionality | #1147 |
measurement invariance | #1147 |
refine | #1149 |
discriminability | #1150 |
children association | #1150 |
humans intellectual | #1150 |
discounting | #1150 |
quick | #1152 |
continents | #1152 |
developmental model | #1152 |
normals | #1153 |
generalizability | #1153 |
refinements | #1153 |
alspac | #1154 |
clinical profiles | #1154 |
sensory gating | #1154 |
ht2c | #1160 |
uncorrected | #1160 |
differential humans | #1160 |
phenotype | #1161 |
review findings | #1163 |
” “ | #1163 |
phobia | #1164 |
studies data | #1164 |
neurocognitive function | #1165 |
affective | #1166 |
deteriorated | #1166 |
clinical groups | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
gwas data | #1176 |
bpd patients | #1176 |
cohen | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
clinical validation | #1178 |
male subjects | #1178 |
study gwas | #1179 |
persisting | #1182 |
childhood exposure | #1182 |
reward | #1182 |
cinguli humans | #1182 |
nonverbal | #1183 |
addressing | #1184 |
paradox | #1184 |
triads | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
onequarter | #1198 |
compulsivity | #1198 |
addictions | #1198 |
wm | #1199 |
placebo | #1199 |
230 | #1200 |
asian continental | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
nationwide cohort study | #1209 |
externalizing symptoms | #1209 |
problems children | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
lbw | #1220 |
underlying | #1220 |
antecedent | #1221 |
prospects | #1222 |
child cognitive | #1222 |
study role | #1224 |
profile | #1226 |
partly | #1227 |
approximated | #1227 |
0011 | #1229 |
refining | #1232 |
subgroup | #1232 |
molecular alterations | #1232 |
poster | #1233 |
health organization | #1234 |
pregnancy prenatal | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
tandem repeats | #1242 |
brain structure | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
kf | #1247 |
risk asthma | #1247 |
avenues | #1247 |
enjoyment | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
delineate | #1251 |
roc | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
summarize | #1256 |
serotonin transporter | #1256 |
risk ratio | #1256 |
dysfunctions | #1257 |
nervous | #1257 |
goal | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
developmental pathways | #1277 |
386 | #1277 |
entire | #1277 |
n24 | #1278 |
04 | #1281 |
study evidence | #1281 |
priori | #1282 |
paternal | #1282 |
behavior adolescent | #1283 |
neuroimaging | #1283 |
hopes | #1283 |
increased rates | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
male nerve | #1288 |
orbitofrontal | #1288 |
somatic complaints | #1288 |
aspect | #1289 |
warmth | #1289 |
posttraumatic | #1291 |
dual psychiatry | #1291 |
1hmrs | #1291 |
unmyelinated | #1291 |
animal conditioning | #1292 |
clomipramine | #1292 |
quantitative trait | #1292 |
misclassification | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
sgas | #1309 |
prediction accuracy | #1309 |
vin | #1310 |
extant | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
class analysis | #1317 |
minds | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
parents adolescents | #1323 |
short | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
measures | #1334 |
polysubstance | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
fronto | #1338 |
obsessive–compulsive disorder | #1338 |
longterm outcome | #1342 |
clinical phenotypes | #1342 |
542 | #1344 |
registry data | #1344 |
explaining | #1345 |
llysine | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
loci genetic | #1356 |
diagnostic tool | #1356 |
flush | #1357 |
simon | #1357 |
variabilities | #1357 |
seekers | #1358 |
antidepressive | #1359 |
gene discovery | #1359 |
broad spectrum | #1361 |
mammalian target | #1362 |
middle frontal gyrus | #1362 |
intergenerational | #1365 |
abcd | #1367 |
unexplored | #1369 |
school teachers | #1369 |
uptake inhibitors | #1369 |
neuronal development | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
thought disorder | #1386 |
highlighted | #1386 |
new onset | #1386 |
dimensional approach | #1389 |
familial aggregation | #1391 |
6 years | #1391 |
treatment depression | #1391 |
prodrome | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
thalamic | #1395 |
satisfying | #1395 |
rats shr | #1395 |
manuscripts | #1395 |
racial | #1398 |
timely | #1399 |
emotional stimuli | #1399 |
lability | #1400 |
suggesting | #1400 |
17 | #1402 |
blinded | #1403 |
sufficient | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
shyness | #1414 |
issue | #1414 |
independent | #1415 |
prepubertal children | #1416 |
impressions | #1416 |
332 | #1417 |
carry | #1419 |
logical | #1419 |
humans memory | #1421 |
parents children | #1422 |
discoveries | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
163 | #1431 |
taps | #1431 |
cognitive profiles | #1432 |
interaction effects | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
443 | #1448 |
psychotic illness | #1448 |
chp | #1449 |
prevalence obesity | #1450 |
hydroxylase | #1450 |
ratings | #1451 |
square | #1453 |
ewas | #1453 |
78 | #1453 |
height | #1453 |
population stratification | #1454 |
hypermethylation | #1454 |
switching | #1455 |
collaborations | #1457 |
dorsal striatum | #1457 |
replicability | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
biological pathways | #1463 |
stronger | #1463 |
treatment duration | #1464 |
discordant | #1467 |
principal | #1467 |
untranslated | #1468 |
partial remission | #1468 |
valuable | #1468 |
hippocampi | #1469 |
groups differences | #1469 |
contrast effects | #1472 |
cognition patients | #1474 |
openlabel | #1474 |
statistically | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
smaller | #1497 |
mri studies | #1497 |
allele carriers | #1497 |
lifespan | #1499 |
small sample sizes | #1499 |
twins monozygotic | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
male mothers | #1505 |
ddc | #1505 |
multisite | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
objectivity | #1511 |
existing literature | #1511 |
attained | #1513 |
reports | #1513 |
emotions female | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
topic | #1523 |
114 | #1523 |
cna | #1523 |
inconsistency | #1526 |
bipolar patients | #1526 |
nacetylaspartate | #1528 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
nucleotide risk | #1541 |
default | #1541 |
poses | #1542 |
adult life | #1542 |
dopamine receptor | #1542 |
stress disorders | #1543 |
gwass | #1544 |
yale | #1545 |
treatment schizophrenia | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
problem behaviors | #1554 |
influenced | #1554 |
automobile | #1556 |
857 | #1556 |
early exposure | #1559 |
failed | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
insular | #1565 |
475 | #1565 |
subscales | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
consortium | #1573 |
swedish | #1573 |
191 | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
life quality | #1579 |
meta | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
findings studies | #1582 |
located | #1582 |
single nucleotide polymorphism | #1582 |
cutoffs | #1583 |
network dmn | #1583 |
models male | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
firstepisode schizophrenia | #1588 |
rs4680 | #1588 |
major depressive | #1588 |
pain patients | #1589 |
genetic data | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
moderators | #1599 |
tpv | #1599 |
statistics nonparametric | #1601 |
psychotropic medications | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
1979 | #1610 |
proneness | #1610 |
monoamine oxidase | #1611 |
emotional faces | #1613 |
alcoholism | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
distinguishing | #1622 |
large body | #1622 |
risk mental | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
snp | #1626 |
paucity | #1626 |
ht2a receptor | #1627 |
spatial organization | #1627 |
dysphoria | #1628 |
louis | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
kyoto | #1630 |
study children | #1630 |
emrs | #1631 |
memory task | #1631 |
ambiguous | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
alpha7 | #1643 |
social communication | #1643 |
tendency | #1643 |
rack1 | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
controlled | #1653 |
rea | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
maximize | #1658 |
detect | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
comorbid depression | #1663 |
presentations | #1663 |
asm | #1664 |
510 | #1665 |
mood symptoms | #1666 |
chronic patients | #1666 |
dlpfc | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
statements | #1675 |
alcohol spectrum | #1675 |
53 | #1677 |
introns | #1678 |
registers | #1678 |
calling | #1678 |
homogeneous | #1679 |
social anxiety | #1679 |
beagle | #1680 |
seat | #1680 |
mathematical models | #1682 |
mildly | #1684 |
46 | #1684 |
prescribed | #1684 |
memory deficit | #1685 |
ancestries | #1685 |
autistic disorder | #1689 |
mdd | #1689 |
github | #1689 |
agenda | #1692 |
psychotropic drugs | #1692 |
impulse control | #1693 |
motor skills | #1698 |
recruited | #1698 |
diagnose | #1699 |
91 | #1702 |
memory consolidation | #1704 |
item | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
health records | #1712 |
neuroscience | #1712 |
rater | #1712 |
personality characteristics | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
inhibitory control | #1731 |
107 | #1731 |
cbs | #1732 |
hindered | #1733 |
highlight | #1735 |
machine | #1735 |
stand | #1736 |
identical | #1736 |
aimed | #1739 |
predictors | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
forum | #1746 |
curated | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
social | #1761 |
genetic models | #1761 |
ventral striatum | #1761 |
bipolar affective | #1763 |
drowsiness | #1763 |
chance | #1765 |
includes | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
treatment implications | #1773 |
dizygotic twins | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
major | #1786 |
higher doses | #1786 |
commonalities | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
frustration | #1791 |
male motor | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
positive association | #1797 |
disabilities | #1797 |
causal variants | #1797 |
autism spectrum disorders | #1800 |
members | #1801 |
reporters | #1801 |
aged models | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
european descent | #1813 |
146 | #1813 |
aetiology | #1813 |
internationality | #1815 |
frequently | #1815 |
brain imaging | #1816 |
purchases | #1816 |
lds | #1819 |
hippocampal volume | #1819 |
cohens | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
binocular | #1833 |
foundation | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
neural activity | #1841 |
patterns | #1841 |
assessment tools | #1842 |
trauma exposure | #1842 |
distinctions | #1845 |
twins | #1845 |
initiative | #1845 |
literacy | #1846 |
pertinent | #1847 |
psychological | #1847 |
environmental risk | #1848 |
warrant | #1848 |
polymorphisms | #1849 |
limited | #1850 |
fearful | #1851 |
individual | #1851 |
vocabulary | #1851 |
nonparametric | #1852 |
brainderived neurotrophic factor | #1853 |
differentiating | #1853 |
young | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
tph | #1859 |
prevalence | #1859 |
incentives | #1860 |
behavioral measures | #1860 |
cnb | #1861 |
affiliation | #1861 |
8p | #1862 |
obstacle | #1864 |
poison | #1865 |
vocalization | #1865 |
switch | #1865 |
multilevel | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
roc curve | #1879 |
histograms | #1879 |
shrs | #1880 |
animal model | #1880 |
delusions | #1881 |
longer duration | #1882 |
afb | #1882 |
common genetic variation | #1883 |
genome | #1885 |
differs | #1888 |
false | #1888 |
metaanalysis studies | #1890 |
substance abuse | #1890 |
spanning | #1894 |
heterogeneous | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
specific symptoms | #1907 |
increasingly | #1907 |
emotion | #1908 |
epidemiologic | #1909 |
majority | #1909 |
ads | #1910 |
disorders mental | #1911 |
support vector machine | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
association maternal | #1923 |
satisfied | #1923 |
liking | #1923 |
child cross | #1926 |
aggregate | #1926 |
overview | #1927 |
advertising | #1928 |
sleep problems | #1928 |
251 | #1928 |
empirical studies | #1929 |
ssri | #1930 |
95 cis | #1934 |
asd children | #1934 |
borderline personality disorder | #1937 |
simulation study | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
depression | #1972 |
clinical implications | #1972 |
correctly | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
child depression | #1977 |
repeats | #1977 |
listing | #1978 |
conflicting | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
common mental disorders | #1984 |
chinese population | #1984 |
pax5 | #1986 |
phase 3 trial | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
formulations | #2005 |
asian continental ancestry | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
muscle function | #2014 |
absence | #2014 |
akt1 | #2014 |
noradrenergic | #2015 |
sms | #2015 |
cognitive deficits | #2016 |
possibility | #2016 |
prescribers | #2021 |
159 | #2023 |
schoolage children | #2023 |
serve | #2026 |
sleep disturbances | #2030 |
phenomenology | #2030 |
brain responses | #2031 |
memory verbal | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
receptors nicotinic | #2037 |
prenatally | #2037 |
retest reliability | #2040 |
diminished | #2040 |
erythematosus systemic | #2041 |
asperger | #2041 |
nicotinic acetylcholine | #2045 |
227 | #2046 |
cognitive processing | #2046 |
informants | #2048 |
erythematosus | #2049 |
cognition | #2050 |
functional | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
insula | #2061 |
common diseases | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
demography | #2066 |
overweight obesity | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
functional mri | #2069 |
massachusetts | #2069 |
0008 | #2071 |
phenotypic | #2072 |
parental education | #2072 |
psychotic symptoms | #2077 |
degree | #2078 |
international consensus | #2078 |
descent | #2079 |
wake disorders | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
latent class | #2090 |
43 | #2090 |
factors child | #2093 |
49 | #2095 |
aud | #2096 |
wky shr | #2096 |
subsets | #2099 |
dopaminergic | #2100 |
69 | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
adult population | #2108 |
ht2a | #2108 |
causation | #2109 |
child relations | #2112 |
specific genetic | #2112 |
nicotinic | #2112 |
brain dysfunction | #2115 |
279 | #2115 |
83 | #2117 |
relative age | #2119 |
monoamine | #2119 |
postpartum period | #2119 |
poorer | #2119 |
84 | #2121 |
career | #2122 |
51 | #2122 |
pgs | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
dbh | #2137 |
episode schizophrenia | #2137 |
psychosocial factors | #2140 |
interpretability | #2141 |
adversities | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
105 | #2147 |
intraclass | #2147 |
receptors adrenergic | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
finemapping | #2150 |
glutamatergic | #2150 |
represents | #2150 |
232 | #2150 |
repositioning | #2151 |
assessing | #2151 |
mao | #2153 |
rrr | #2153 |
psychiatric patients | #2155 |
abdominal obesity | #2164 |
differentiated | #2164 |
clinical assessments | #2166 |
shr wky | #2167 |
declarative memory | #2167 |
differing | #2168 |
genetic association studies | #2168 |
differential diagnostic | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
mb | #2171 |
adversely | #2171 |
prevalences | #2171 |
tardive dyskinesia | #2172 |
severity | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
computerassisted imaging | #2188 |
thought | #2188 |
processing speed | #2189 |
differential expression | #2189 |
generalized anxiety disorder | #2192 |
regular | #2192 |
scale | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
conceptual | #2197 |
lifecycle | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
confounding | #2201 |
ages | #2201 |
double | #2205 |
developing brain | #2206 |
brain mapping | #2206 |
abstract background | #2207 |
ottawa | #2209 |
remained | #2209 |
169 | #2209 |
accidents | #2210 |
surveys questionnaires | #2210 |
homozygosity | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
complex diseases | #2220 |
biologically | #2220 |
hippocampal formation | #2220 |
completed | #2220 |
autism | #2221 |
val66met | #2222 |
visuospatial | #2225 |
cognitive task | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
novo mutations | #2263 |
cognitive deficit | #2263 |
earlier | #2264 |
cigarette | #2264 |
criterion | #2265 |
pathways | #2266 |
bds | #2266 |
rewards | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
gray matter volume | #2275 |
remain | #2275 |
axis | #2275 |
cognitive development | #2275 |
tend | #2276 |
random allocation | #2277 |
imaging male | #2277 |
mtl | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
lithium | #2283 |
moderation | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
regions | #2294 |
diverse populations | #2294 |
physical health | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
biology | #2304 |
239 | #2304 |
clinic | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
lupus | #2310 |
difficult | #2310 |
enormous | #2311 |
pregnancy | #2313 |
brain anatomy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
organ size | #2332 |
questionnaires | #2332 |
subset | #2333 |
mind | #2334 |
covariate | #2335 |
archives | #2335 |
disorganization | #2335 |
early risk | #2336 |
depression female | #2340 |
lesser extent | #2342 |
utility | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
time perception | #2353 |
providing | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
concurrently | #2368 |
limited evidence | #2368 |
symptoms schizophrenia | #2369 |
smallest | #2369 |
efforts | #2376 |
social cognitive | #2377 |
catecholamine | #2379 |
antipsychotic agents | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
essence | #2401 |
gray matter | #2401 |
frontal | #2403 |
pubmed | #2406 |
sirolimus | #2407 |
addictive | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
alternative | #2418 |
statistical significance | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
bdnf | #2429 |
term outcome | #2429 |
fmri data | #2431 |
confounders | #2431 |
clinical trial | #2433 |
protein interactions | #2433 |
241 | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
dimorphism | #2448 |
timepoints | #2448 |
items | #2449 |
multiple studies | #2450 |
mvr | #2452 |
deconvolution | #2452 |
systemic lupus erythematosus | #2456 |
overweight children | #2456 |
prefrontal cortical | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
brain maturation | #2460 |
anxiety symptoms | #2460 |
traumatic stress | #2461 |
logistic | #2461 |
concordance | #2461 |
autosomes | #2462 |
sex distribution | #2464 |
crossover study | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unique | #2473 |
unclear | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
180 | #2496 |
hoc analysis | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
establish | #2504 |
original | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
quotient | #2515 |
thresholds | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
risky | #2553 |
psychotic features | #2553 |
depressive disorders | #2554 |
exploratory study | #2555 |
neural responses | #2555 |
quantitative | #2555 |
bipolar affective disorder | #2557 |
memory tasks | #2557 |
chronological | #2560 |
income | #2560 |
risk loci | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
30 years | #2573 |
numerous | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
elucidate | #2585 |
correction | #2585 |
problems | #2586 |
brothers | #2586 |
pvalues | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
disrupted | #2595 |
exist | #2595 |
229 | #2596 |
internalizing externalizing | #2598 |
brain response | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
increased activation | #2611 |
advances | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
evidence role | #2624 |
multiple levels | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
bdnf gene | #2633 |
imaging studies | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
global functioning | #2642 |
fetal alcohol | #2642 |
behavior | #2644 |
preschool female | #2644 |
genetic variants | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
periodicals | #2665 |
puzzle | #2665 |
n14 | #2666 |
089 | #2669 |
health disorders | #2669 |
88 | #2670 |
chromosome | #2670 |
genetic evidence | #2670 |
polysomnography | #2671 |
spectrum | #2675 |
pcps | #2675 |
partially | #2676 |
inconclusive | #2676 |
mediating | #2676 |
adolescent development | #2678 |
memory tests | #2678 |
physiotherapy | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
conditional | #2689 |
triad | #2689 |
age range | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
immaturity | #2698 |
evidenced | #2698 |
extended | #2700 |
chr | #2701 |
interrogation | #2702 |
neurite | #2702 |
attenuate | #2702 |
flares | #2703 |
ext | #2707 |
delinquency | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
occurring | #2714 |
aggressive | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
teens | #2731 |
curve | #2731 |
awakening | #2732 |
doubt | #2733 |
systematic literature review | #2733 |
thicker | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
naa | #2760 |
collaboration | #2760 |
patients bipolar disorder | #2760 |
gt | #2761 |
manifestations | #2762 |
4 years | #2765 |
unadjusted | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
25 | #2777 |
preventive measures | #2777 |
mechanisms underlying | #2783 |
clinical heterogeneity | #2783 |
children symptoms | #2784 |
bivariate | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
dna copy | #2791 |
411 | #2791 |
dyslexia | #2792 |
overt | #2794 |
neurotrophic factor | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
recognition visual | #2808 |
clinical experience | #2808 |
misdiagnosis | #2809 |
397 | #2809 |
monetary | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
circuitry | #2823 |
indexes | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
discriminant validity | #2839 |
early recognition | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
continental ancestry | #2863 |
depression scale | #2863 |
parenting parents | #2865 |
screened | #2866 |
addresses | #2866 |
mothers children | #2867 |
internal external | #2867 |
discordance | #2868 |
cognition humans | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
appeared | #2884 |
measure | #2884 |
citations | #2885 |
shifting | #2885 |
age differences | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
amph | #2916 |
cognitive control | #2916 |
institutes | #2919 |
variability | #2919 |
biological mechanisms | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
disorders sleep | #2942 |
causal relationship | #2942 |
disorders patients | #2946 |
distinct | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
overlaps | #2971 |
markers | #2971 |
models neurological | #2976 |
stratification | #2981 |
725 | #2983 |
qtl | #2983 |
weight height | #2988 |
investigators | #2989 |
imaging mri | #2991 |
attempts | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
centres | #3006 |
196 | #3006 |
377 | #3007 |
19th century | #3010 |
remission | #3011 |
genetic variation | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
difficulties questionnaire | #3039 |
symptoms patients | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
treatment adherence | #3054 |
developmental | #3054 |
protective factor | #3057 |
improvement | #3058 |
pilot | #3061 |
280 | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
driving | #3078 |
cortical | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
stressful life | #3098 |
predictable | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
076 | #3107 |
brain health | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
amygdala hippocampus | #3123 |
articles | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
ptsd symptoms | #3127 |
383 | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
nation | #3146 |
european countries | #3146 |
99 | #3150 |
exploratory | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
explanations | #3165 |
spd | #3165 |
functional consequences | #3166 |
biological processes | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
caution | #3171 |
status humans | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
methyltransferase | #3187 |
adolescents young adults | #3187 |
imaging study | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
attempt | #3202 |
initial treatment | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
situation | #3229 |
scanner | #3229 |
discontinuity | #3229 |
65 | #3235 |
depression study | #3236 |
htt | #3237 |
mediation analysis | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
correlated | #3257 |
211 | #3257 |
publicly | #3265 |
caudate nucleus | #3265 |
interactive effects | #3266 |
humans magnetic | #3266 |
17p | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
increased likelihood | #3282 |
longitudinal cohort | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
clinical severity | #3306 |
synaptic function | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
clock gene | #3336 |
metropolitan | #3336 |
ambiguity | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
glycolysis | #3371 |
battery | #3371 |
frontal regions | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
impaired performance | #3386 |
typically developing | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
depression symptoms | #3405 |
traumatic brain | #3405 |
desirability | #3406 |
oxidase | #3411 |
performing | #3413 |
pool | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
definition | #3439 |
experiencing | #3439 |
exert | #3441 |
fluency | #3446 |
showing | #3448 |
children mothers | #3448 |
lca | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
psychotropic medication | #3455 |
supports | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
hallucinations | #3466 |
genomewide association study | #3466 |
cognitive behavioral | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
remaining | #3477 |
methylation | #3477 |
behavioral response | #3478 |
irr | #3480 |
transmission | #3482 |
postmortem | #3482 |
slower | #3488 |
convergent | #3489 |
exposure pregnancy | #3489 |
lesser | #3489 |
applying | #3492 |
epidemiological study | #3492 |
aged polymorphism | #3497 |
alpha2 | #3497 |
083 | #3497 |
social behaviors | #3497 |
short stature | #3497 |
matched healthy | #3502 |
brain function | #3506 |
p002 | #3506 |
identifier | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
specificity | #3519 |
104 | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
pediatricians | #3527 |
constitutes | #3527 |
basis | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
preferentially | #3536 |
reliable | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
sleep wake | #3544 |
fact | #3544 |
cognitive behavioral therapy | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
neuronal function | #3558 |
preventive interventions | #3558 |
ecgs | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
cardio | #3606 |
major gene | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
methylation status | #3618 |
questions | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
prior | #3640 |
posttraumatic stress | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
depressed mood | #3737 |
hapmap | #3737 |
population | #3738 |
therapy cbt | #3744 |
international | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
333 | #3758 |
neurophysiological | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
promoter polymorphism | #3787 |
peers | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
male marijuana | #3844 |
exchanger | #3844 |
developmental disorders | #3850 |
children aged | #3850 |
disease genes | #3850 |
elevations | #3851 |
risk development | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
74 | #3876 |
influences | #3876 |
208 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
plasma membrane | #3898 |
neurology | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
preexisting | #3937 |
specific factors | #3937 |
frontal gyrus | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
preliminary evidence | #4000 |
categorization | #4000 |
factorial | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
diabetes risk | #4047 |
common variants | #4047 |
modeled | #4051 |
discussion | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
contextual factors | #4058 |
jointly | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
cag | #4068 |
magnetic resonance | #4068 |
serotonin uptake | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
lobe | #4098 |
temporal lobe | #4098 |
genetic variations | #4100 |
maternal depression | #4100 |
limbic | #4102 |
psychologists | #4103 |
age matched | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
comprises | #4121 |
plausible | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
german | #4145 |
dosing | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
helpful | #4216 |
route | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
predict | #4253 |
gpcr | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
trajectory | #4263 |
representative | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
adequacy | #4315 |
potential targets | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
exists | #4375 |
relation | #4375 |
mediate | #4378 |
intolerance | #4378 |
066 | #4382 |
clarity | #4383 |
psychological adolescent | #4383 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
solving | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
striatal dopamine | #4449 |
human studies | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
visits | #4516 |
disorders cognitive | #4516 |
valuation | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
postnatal day | #4540 |
considerable | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
higher level | #4553 |
employment | #4553 |
preschool children | #4564 |
birth | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
neuronal differentiation | #4587 |
psd | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
trouble | #4651 |
unmet | #4651 |
regression model | #4652 |
marriage | #4658 |
microsatellite | #4660 |
centers | #4660 |
deliveries | #4660 |
anterior cingulate cortex | #4661 |
trajectories | #4662 |
243 | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
vector machine | #4715 |
hazards models | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
conflict | #4760 |
77 | #4760 |
tasks | #4762 |
heavily | #4763 |
portions | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
samples | #4791 |
noncarriers | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
modafinil | #4825 |
cognitive tests | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
wave | #4880 |
deterioration | #4880 |
subsamples | #4881 |
cigarettes | #4881 |
young age | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
early adolescence | #4923 |
achievements | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
pooled analysis | #4951 |
powerful | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
selective attention | #5021 |
caucasians | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
probabilistic | #5039 |
discuss | #5039 |
correct | #5040 |
distinguish | #5040 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
auc | #5047 |
sga | #5050 |
convergent validity | #5051 |
marital | #5051 |
early | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
reached | #5101 |
09 | #5101 |
103 | #5104 |
screening | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
mediation | #5132 |
single nucleotide polymorphisms | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
inherent | #5146 |
difference | #5146 |
pharmacogenomics | #5147 |
involves | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
238 | #5193 |
disability | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
molecular biology | #5215 |
remains | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
billion | #5295 |
trend | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
social interactions | #5345 |
individual level | #5345 |
predictive tests | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
penetrance | #5380 |
higher frequency | #5380 |
lost | #5382 |
suicide attempts | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
37 | #5403 |
label | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
york | #5468 |
risk individuals | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
modulate | #5547 |
155 | #5547 |
closely | #5549 |
elevated | #5549 |
prevention | #5551 |
flanking | #5552 |
restraint | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
baseline treatment | #5565 |
frontal cortex | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
mediators | #5579 |
240 | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
lower risk | #5663 |
perinatal | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
40 years | #5686 |
1999 | #5686 |
gene variants | #5687 |
markov | #5688 |
vbm | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
normal | #5696 |
databases | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
focused | #5728 |
thirty | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
98 | #5827 |
nerve net | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
imputation | #5910 |
council | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
region | #5928 |
linked | #5928 |
statement | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
rois | #6005 |
moderating role | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Bericht ausführen | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Bekannt für Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Bekannt für Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Bekannt für Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Bekannt für Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Bekannt für Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Bekannt für Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Bekannt für Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Bekannt für Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Bekannt für Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Bekannt für Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Bekannt für Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Bekannt für Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Bekannt für Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Bekannt für Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Schlüsselpersonen für Hyperactivity Disorder
Stephen V Faraone∗:Expertenwirkung
Konzepte für welcheStephen V Faraone∗hat direkten Einfluss:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:KOL -Auswirkungen
Konzepte im Zusammenhang mit der Arbeit anderer Autoren, für diefor which Stephen V Faraone∗ hat Einfluss:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
Ist das dein Profil? Fordern Sie Ihr Profil an URL kopieren Einbetten Sie den Link zu Ihrem Profil ein |